Applications of silicon dosimeters and Monte Carlo simulations for physical and biological dose quality assurance in particle therapy by Debrot, Emily
University of Wollongong 
Research Online 
University of Wollongong Thesis Collection 
2017+ University of Wollongong Thesis Collections 
2020 
Applications of silicon dosimeters and Monte Carlo simulations 
for physical and biological dose quality assurance in particle 
therapy 
Emily Debrot 
Follow this and additional works at: https://ro.uow.edu.au/theses1 
University of Wollongong 
Copyright Warning 
You may print or download ONE copy of this document for the purpose of your own research or study. The University 
does not authorise you to copy, communicate or otherwise make available electronically to any other person any 
copyright material contained on this site. 
You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 
1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, 
without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe 
their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court 
may impose penalties and award damages in relation to offences and infringements relating to copyright material. 
Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the 
conversion of material into digital or electronic form. 
Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily 
represent the views of the University of Wollongong. 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Applications of silicon dosimeters and Monte Carlo
simulations for physical and biological dose quality
assurance in particle therapy
Emily Debrot
This thesis is presented as required for the conferral of the degree:
Doctor of Philosophy
Supervisors:
Dist. Prof. A. B. Rosenfeld & Assoc. Prof. S. Guatelli
The University of Wollongong
School of Physics, Faculty of Engineering and Information Sciences
April 2020
This work © copyright by Emily Debrot, 2020. All Rights Reserved.
No part of this work may be reproduced, stored in a retrieval system, transmitted, in any form or by any
means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the
author or the University of Wollongong.
This research has been conducted with the support of an Australian Government Research Training
Program Scholarship.
Abstract
Radiation therapy with charged particles, protons and carbon ions in particular, is a modal-
ity used for cancer treatment that has expanded dramatically in recent times. This trend
can be explained by a number of favourable characteristics of charged particles includ-
ing a well defined range, reduced lateral scattering and a heightened relative biological
effectiveness (RBE) at the treatment site. Particle therapy sees a substantial reduction in
the integral dose received by the patient, better dose conformity to the target and reduced
likelihood of normal tissue complication.
The highly conformal dose distributions observed with particle therapy also comes with
tighter tolerances for uncertainties such as those from patient setup, imaging, dose calcu-
lations and delivery system components. That is, more stringent Quality Assurance (QA)
protocols for particle therapy are required. This necessitates high spatial resolution detec-
tors to be used for QA in particle therapy in order to avoid dose averaging effects and to
clearly resolve features in the delivered dose distributions. Furthermore, there is a need
to characterise the complex radiation fields produced in terms of varying radiation quality
which results in fluctuations in the biological response. The production of secondary ra-
diation such as neutrons and fragmentation particles that have the potential to contribute
to high LET out-of-field dose should also be assessed.
This thesis investigates the suitability of silicon diode array detectors and silicon micro-
dosimeters developed at the Centre for Medical Radiation Physics (CMRP), University of
Wollongong, for particle therapy QA. These novel devices allow for sub-millimetre sen-
sitive volumes to be produced and for real-time, high spatial resolution measurement of
particle beam characteristics. The work presented includes both experimental and com-
putational results to extensively characterise these detectors in particle therapy fields. The
Monte Carlo toolkit Geant4 was used for the simulations presented.
The silicon “dose magnifying glass” (DMG) and Duo array detectors are assessed for
range verification and beam energy measurements, and for spot size and position checks
for dosimetry QA, respectively. The proposed system addresses some shortcomings of
many commercially available systems as it is compact, relatively inexpensive, easy to
iv
vsetup, and has sub-millimetre spatial resolution with real-time readout. These devices
were shown to be accurate and reproducible for experiments conducted with proton and
carbon ion beams.
The silicon-on-insulator Bridge microdosimeter was used to measure radiation quality
both within and outside of a passively scattered proton field and in a carbon ion minibeam
radiation field. As it consists of many micron sized sensitive volumes in series, this detec-
tor is capable of high spatial resolution measurements in highly variable fields, such as in
the Bragg peak region, in a configuration indicative of the response of multiple cells. The
spectra measured with the detector was used to determine out-of-field dose equivalents,
to predict RBE and to quantitatively characterise the differences in radiation quality for
carbon ion broad beams to those highly collimated to produce minibeams. The out-of-
field radiation quality was found to be largely dependent on the position and highlights
the importance of assessing secondary and scatter radiation that may be delivered dur-
ing treatment. RBE predicted with the SOI-microdosimetry-MKM method applied were
found to show good agreement with values measured in-vitro. Microdosimetry is impor-
tant to investigate potential benefits of novel treatment techniques in particle therapy. A
carbon ion minibeam treatment field was investigated and it was shown that the mean lin-
eal energy and RBE increases with the introduction of a minibeam collimator, particularly
in the valley regions, and the extreme sensitivity of the collimator setup was assessed. For
correct collimator alignment the peak to valley dose ratio was maintained in the entrance
despite elevated RBE in the valley regions.
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As a disease group cancer is the second leading cause of death globally [1] and is the
greatest cause of disease burden in Australia [2, 3]. Despite this, survival rates for some
indicators such as 5 year survival are increasing [2, 3]. Early detection due to better
screening and diagnostic imaging, as well as improved precision of treatment, play an
important role in this trend. Radiation therapy makes up a large part of cancer treatment
with 48% of patients indicated to external beam radiation therapy.
With better prognosis and longer survival for patients treated with external beam radiation
therapy, the long term effects of healthy tissue exposure and the increased risk of radiation
induced secondary malignancies becomes of increasing concern. Radiation therapy with
charged particles has the potential to increase dose conformity and boost the therapeutic
ratio in external beam radiotherapy for cancer patients. The advantageous dose charac-
teristics and finite range of charged particles allow for significant sparing of surrounding
healthy tissue, preventing the “low dose bath” that is inherent in even the most advanced
photon therapies. The precision of particle therapy modalities are hindered by two pri-
mary sources of uncertainty; those relating to the particle range in the patient and those
due to an ill-defined understanding of the relative biological effectiveness (RBE) arising
from variable radiation quality throughout irradiated tissues.
Range uncertainties arise due to incorrect CT conversion (resulting in inaccurate descrip-
tion of tissue stopping power and density), setup errors, beam delivery, biological effects
[4, 5] and dose calculation [6]. As a result the inclusion of safety margins are generally
on the order of 3.5% of the range plus up to 3 mm [6] in the incident beam direction.
With such sources of range uncertainty it becomes critical that quality assurance (QA)
practises are in place to ensure that the particle energy and range in a given material can
1
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be precisely measured.
Unlike conventional therapy using photons, particle therapy fields have varying ionisa-
tion density along their track resulting in an increase in the linear energy transfer (LET)
with penetration depth. The biological response to radiation is rather elusive and is de-
pendent on a number of factors including but not limited to: dose, dose-rate, tissue type,
biological endpoint, oxygenation and linear energy transfer [7, 8]. In order to translate
the physical dose delivered with ions to a known biological response with a photon refer-
ence radiation, numerous mechanism-inspired models have been developed to predict the
RBE and a subset of these have been implemented in commercially available treatment
planning systems [8]. These parametrised models, often implemented with Monte Carlo
techniques, rely on the LET characteristics of the radiation. Verification and benchmark-
ing of these codes and the radiation quality characteristics of a clinical particle beam is
imperative.
This thesis is concentrated on the application of high resolution silicon diode array de-
tectors and microdosimeters in clinical proton and carbon ion fields. The silicon detectors
investigated were designed at the Centre for Medical Radiation Physics (CMRP), based
at the University of Wollongong, Australia. Two generations of a 1D silicon array de-
tector are assessed for suitability to fast and accurate range measurement for routine QA
practises in clinics. Their high spatial resolution, large dynamic range and instantaneous
readout make them well suited to this application and further, their size and cost make
them an economical alternative to the various detector systems implemented in clinics. A
silicon-on-insulator microdosimeter was investigated for in-field and out-of-field micro-
dosimetric measurements of particle beams. The design of this detector addresses many
of the shortcomings of tissue equivalent proportional counters (TEPCs). The applications
of this microdosimeter for measuring lineal energy for calculation of RBE and for radi-
ation quality and dose equivalents are presented. The Monte Carlo toolkit Geant4 was
used to simulate experimental detector setups and help characterise their response and the
radiation fields in which they were placed.
1.2 Aims and Objectives
The aims of this thesis are to:
Aim 1: Assess the feasibility of using high resolution 1D silicon detector arrays for
carbon ion energy reconstruction for quality assurance.
Research question: Can silicon diode array detectors be used to accurately reconstruct
incident ion energies by measuring particle range in silicon within an accuracy of ±0.5
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mm?
This research question in addressed in chapter 3 where an experimental investigation of
the serial Dose Magnifying Glass Detector (sDMG) was conducted in a passively scat-
tered monoenergetic carbon ion beam. The detector was embedded in a perspex phantom
with its 1D axis of detection parallel to the incident beam direction. The range in silicon
is determined from the Bragg peak position and used to reconstruct the beam energy in-
cident on the phantom. A Geant4 application was developed to mimic the experimental
setup and was used to characterise the detector response.
Aim 2: Use a Monte Carlo model to evaluate the relationship between the Bragg
peak physical depth-dose curve and common proton range definitions in different
media.
Research question: Which point on the physical dose curve shows the best correlation
to mean range and calculated range from commonly used range databases? Does this
depend on the target medium?
This research question was addressed using a Geant4 Monte Carlo toolkit application.
Proton depth-fluence and depth-dose distributions were scored in water, perspex and sili-
con phantoms over a number of clinically applicable energies to determine the mean range
and ranges for the Bragg peak maximum and percentage falloff doses. Both a purely mo-
noenergetic source and a clinical pencil beam phase-space model were considered. The
results are presented in chapter 4.
Aim 3: Assess the accuracy and reproducibility of a revised 1D silicon diode ar-
ray detector for proton range measurements.
Research question: Is the DMG dosimeter suitable for routine QA for range and energy
consistency measurement for pencil beam scanning systems?
The DMG detector was assessed for accuracy and reproducibility for measuring the range
of a clinical proton scanning pencil beam. Two primary configurations were assessed
for measuring proton range in silicon and in perspex, the results of which are presented
in chapters 5 and 6 respectively. The DMG dosimeter was modelled and phase-space
information of the clinical scanning beam was validated for a Geant4 application to char-
acterise the response of the DMG detector for range measurements and compare to mea-
sured data. The sensitivity of the small volume detector to setup errors and the robustness
of the measured range was investigated using the Monte Carlo application. The range
measurement system from chapter 6 was adapted in a combined detector system to simul-
taneously measure pencil beam spot size and position using the 2D silicon diode array,
Duo. The feasibility of using this combined setup as an all-in-one daily QA devise is
presented in chapter 7.
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Aim 4: Explore the applications of silicon microdosimetry in particle therapy for
radiation protection purposes, calculation of relative biological effectiveness and in
novel particle therapy applications.
Research question: Can silicon microdosimeters bridge the gap between RBE weighted
treatment planning systems, Monte Carlo codes and QA of radiation quality and its af-
fects?
The silicon-on-insulator 3D Bridge microdosimeter was investigated for radiation quality
measurements both within and outside the primary proton radiation field. The micro-
dosimetric spectra measured with the microdosimeter was used to calculate mean lineal
energy used to determine the radiation quality factor and effective dose, H, as an indicator
for the risk of radiation induced secondary malignancies in healthy tissues surrounding
the target and to calculate RBE in the primary field according to the modified MKM. The
modified MKM was used here as the microdosimetric spectra measured with the Bridge
microdosimeter is used as an input for this model. This work is presented in chapters
8 and 9 respectively. Finally chapter 10 presents the first experimental microdosimetric
measurements within a 12C minibeam field. The microdosimetric spectra measured with
the detector was used to calculate the mean RBE in the field and complimentary Geant4
simulations of the detector and collimator setup provided insight into the response. The
simulation application was also used to calculate the RBE as a function of position in the
minibeam field.
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2.1.1 Rationale, status & prospectives
The application of protons and heavier ions for therapy was first proposed by R.R. Wilson
in 1946 [9]. Wilson realised their potential for radiotherapy treatment stating that “preci-
sion exposures of well-defined small volumes within the body will soon be feasible” [9,
10]. Investigations of proton beam dose and radiological characteristics were conducted
in the following years at the Lawrence Berkeley Laboratory (LBL) with patient treatments
beginning in 1954 [10]. The first particle therapy treatments began with protons and then
helium ions. After the Bevalac facility became available for use in 1975 treatments with
heavier ions, primarily with helium and neon (some patients also received C, N, O, Si
and Ar ions) were performed until 1992 [11–13]. From the 60’s onwards proton therapy
activity began to grow, primarily within physics research facilities around the globe [14].
In 1994 particle therapy with carbon ions began at the National Institute of Radiological
Sciences (NIRS) in Japan with the Heavy Ion Medical Accelerator (HIMAC). Shortly fol-
lowing, treatment with active beam scanning techniques were developed and employed
at PSI in Switzerland and GSI in Germany starting in 1996 and 1997 respectively. The
majority of clinical experience with carbon ions comes from NIRS with over 20 years
experience treating more than 8,000 patients and conducting trails to determine which
tumours are effectively treated with carbon ions, what dose-fractionation scheme is best
suited to various tumour types and advancing delivery and dose verification techniques
[15].
At the present moment there are 95 particle therapy facilities in operation around the
world (83 proton and 12 carbon) and more than 50 currently in construction or plan-
ning stages [16]. To date, over 220,000 patients have been treated with ions primarily
with protons (~190,000) and carbon ions (~28,000) [16]. The increasing number of pa-
6
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tients treated with ions for radiotherapy can be attributed to the shift from treatments
in researched based laboratories to dedicated hospital-based particle therapy centres [17].
Despite the success reported with proton therapy and the clinical experience in Japan with
carbon ions, there is still a lack of level 1 evidence to support the use of charged particles
for clinical benefit over MV x-ray therapy [15, 18]. Further, the greater initial and running
costs of particle therapy modalities calls into question their cost effectiveness [19] and is
the largest inhibitor to the growth of particle therapy [15].
The rationale for charged particles for radiation therapy is due to both their physical and
biological characteristics. Charged particles deposit the majority of their energy at the
distal end of their range - a depth-dose profile coined the Bragg peak. Ions also exhibit re-
duced lateral scattering compared to photons. These attributes allow for shaper penumbra
in delivered treatment fields, greater localisation and conformation of dose to the target
and sparing of surrounding tissues. In addition to the advantageous dose profile, the ion-
isation density of charged particles is elevated compared with photons and this increases
with depth and decreasing ion energy according to the Bethe-Bloch formula. As such, the
distal end of the charged particle range, which is used to treat the target volume, has a
higher linear energy transfer (LET) than in the entrance channel where healthy tissue is
exposed. The relative biological effectiveness (RBE) is defined as the ratio of dose for a
reference radiation (often photons from a Co60 or kV x-ray source) to that from a radi-
ation type of interest (ie. charged particles) which results in the same biological effect.
LET is closely correlated with RBE as densely ionising radiation leads to greater locali-
sation of DNA damage and results in reduced cellular repair; RBE is discussed in greater
detail in section 2.1.4. While protons exhibit slightly higher LET than photons, with a
larger difference at the end of range, they are still considered to be sparsely ionising radi-
ation and as a result have only a small increase in the RBE. Therein lies the motivation for
the use of heavier ions, such as carbon, which have a greater RBE in the Bragg peak re-
gion, reduced oxygen enhancement ratio (OER) and elicit favourable antiangiogenic and
immune responses [18].
With increased use of charged particle therapy, continued optimisation of its delivery
and ongoing randomised phase II/III clinical trials, the efficacy of particle therapy and its
superiority over x-ray radiotherapy for suitable tumour types is likely to be supported in
coming years. While only protons and carbon ions are currently used for clinical practise,
other ions are being investigated for future use such as helium and oxygen. The former is
of interest due to the reduced RBE in the entrance channel and a smaller fragmentation tail
beyond the Bragg peak compared with carbon ions, which is more conservative for paedi-
atric patients where late morbidity is a concern. Slightly heavier ions than those currently
used, like oxygen, which have greater LET could be advantageous for radioresistant or
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hypoxic tumours. Much heavier ions such as those used at the Bevelac aren’t viable due to
too greater fragmentation and potential risk to healthy tissue [18]. The physical character-
istics of particles indicate their promise for a better therapeutic ratio however more work
into effectively reporting clinical outcomes and understanding of the underlying biology
is needed.
2.1.2 Quality assurance (QA) in particle therapy
The International Commission on Radiation Units and Measurement (ICRU) recommend
that the dose delivered to a target volume in the patient should fall within ±5% of the
prescribed dose for effective treatment [20–22]. This forms the basis on which qual-
ity assurance guidelines are developed. A number of task groups have established such
guidelines and recommendations for photon and brachy therapies however until recently
there has been a lack of established standard protocols for QA in particle therapy. This
is likely due to the presence of fewer particle therapy treatment facilities and to the great
variation in the technology and beam-delivery methods employed. The AAPM task group
224 [23] was assembled to develop comprehensive quality assurance guidelines and rec-
ommendations for proton therapy, with only a handful of clinical facilities treating with
carbon ions, no such standardised protocol has been established. As with many proton
therapy facilities, carbon ion treatment facilities have created site specific QA protocols,
some of which have been published in the literature [24–28].
QA protocols are put in place to ensure radiotherapy equipment is performing within
specifications and adhering to commissioning standards so that treatments are delivered
in an accurate and safe manner. There are three key categories that make-up QA; those
relating to machine specifics (such as dosimetry), patient-specific QA and treatment plan-
ning system QA [23]. Machine QA includes dosimetry, both for absolute absorbed dose
and relative dose distributions, as well as mechanical, safety and imaging system checks
[23]. This review will address the machine QA related to dosimetry only as it is a focus
of this thesis.
The frequency at which specific QA measurements need to be performed is dependent
on the likelihood and severity of deviation of a given QA parameter. That is, not all pa-
rameters need to be checked with the same frequency and as such QA practises are often
divided into daily, weekly, monthly and annual procedures. Table 2.1 summarises the
recommended measurements and their tolerances for daily, monthly and annual dosime-
try QA for proton therapy with double scattering/passive scattering (DS/PS) and Pencil
Beam Scanning (PBS) delivery systems from the AAPM task group 224 [23].
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Table 2.1: Recommended daily, monthly and annual dosimetry QA procedures and tol-
erances for proton therapy. The information presented here is combined from tables were
taken from AAPM Task Group 224 report [23].
Tolerances for delivery method
DS/PS PBS Comments
Daily
Output consistency ±3% ±3% Measured for different ranges on different days with
one consistent field
Depth verification:
Distal ±2 mm ±1 mm Difference from baseline at distal 90%∗ depth dose
Proximal ±2 mm - Difference from baseline at proximal 90%∗ depth dose
SOBP width ±2%/±2 mm - Width between proximal and distal 90%∗ depth dose
Spot position - ±2/±1 mm Absolute/relative - If dose pattern is used, the dose
uniformity and homogeneity should reflect the
same accuracy from baseline.
Monthly
Output consistency ±2% ±2% Measured at different gantry angles (relative to baseline)
Field symmetry ±1% ±1% Measured at different gantry angles (relative to baseline)
Field flatness ±2% ±2% Measured at different gantry angles (relative to baseline)
Range ±1 mm ±1 mm For several clinically relevant energies
Spot size ±10% At different gantry angles
Annual
Output consistency ±2% ±2% Measured at different gantry angles (relative to baseline)
Field symmetry ±1% ±1% Measured at different gantry angles (relative to baseline)
Field flatness ±2% ±2% Measured at different gantry angles (relative to baseline)
Range ±1 mm ±1 mm For several clinically relevant energies
Spot size ±10% At different gantry angles
DS/PS = Double Scattering/Passive Scattering; PBS = Pencil Beam Scanning.
∗Distal and proximal depth dose may also be defined as 80%, 95% or 98% depending on the centre.
Dose per monitor unit (D/MU) measurements are in place to ensure that monitor unit
chambers in the treatment nozzle of the beamline are responding appropriately. This is
an important check as the MU chambers ultimately track the dose that is delivered during
treatment. Parallel plate ionisation chambers are primarily used for D/MU measurements
as accurate and absolute dosimetry is required for this purpose and the response of an IC
is well characterised and is independent of LET and dose. D/MU measurements should
be performed at stable, low dose gradient positions within the delivered field fr example at
the centre of the modulated field for passively scattered fields and for PBS in the entrance
region before the build-up towards the Bragg peak [23].
Spot delivery consistency for PBS treatment is also recommended for daily QA. Many
centres have developed daily QA systems that incorporate multiple or in some cases all
required checks. As such a number of the range measurement systems discussed below
are simultaneously used to check spot delivery consistency. This check can be performed
either by evaluating the reproducibility of individual spot positions and shapes or by as-
sessing the uniformity and penumbra for a scanned field made-up of superimposed spots.
Detectors used for either method require high spatial resolution in 2 dimensions such as
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film, ion chamber arrays or CCD detectors (eg. Lynx, IBA Dosimetry, Schwarzenbruck,
Germany).
Dosimetry dominates regular QA checks and the range measurement is a core compo-
nent of these checks. The AAPM guidelines suggest a tolerance of ±1 mm in the distal
range for proton PBS and similar tolerances have been reported throughout the literature
for carbon ion PBS [25, 27]. To meet this criteria, detector systems used for range mea-
surements for QA require very high, preferably sub-millimetre, spatial resolution. The
following subsection addresses a number of range verification systems investigated or
used for clinical QA.
Range verification systems
It is critical that the ion beam energy and range is well characterised and its consistency
is checked routinely as part of daily QA. An unmonitored reduction in the beam energy,
and hence penetrating range, could result in a lack of target coverage leading to reduced
tumour control probability. Alternatively, an increase in ion energy that is unaccounted
for can cause increased exposure of critical structures distal to the target and greaten the
risk of normal tissue complication.
Annual QA dosimetry is often carried out in a water phantom using calibrated ionisa-
tion chambers (IC). Commercial, particle therapy specific devices are available for this
purpose such as the Bragg peak chamber (PTW, Freiburg, Germany) used in conjunction
with the PEAKFINDER system (PTW) which allows the detector to move in 10 µm steps.
Another example is the Stingray chamber (IBA dosimetry, Schwarzenbruck, Germany)
used in the Blue Phantom 2 (IBA dosimetry) water phantom with 0.1 mm resolution.
While these devices allow for high spatial resolution, absolute depth-dose measurements,
the setup and acquisition time for these systems are too long and are impractical for daily
range measurements.
A number of Multi Layer Ionisation Chambers (MLIC) have been developed in-house at
various particle therapy facilities to combat this problem and allow more efficient range
measurements. A MLIC detector was designed at the GSI [29] with 32 ICs, this QA de-
vice had a spatial resolution of 0.6 mm in depth and was shown to have between -1%
and +3% error in the measured dose and <1% error in the water equivalent depth mea-
surement positions. Nichiporov et al [30] at the Indiana University Cyclotron Facility
developed a 122 IC MLIC device with 1.82 mm water-equivalent resolution and claim
a 0.1 mm precision in range measurements compared to reference data using an IC in a
water tank. Yajima et al [31] also reported on a 64 channel PMMA MLIC designed to
improve measured depth-dose distributions from their previous FR4 layered MLIC design
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for heavy-ion range measurements at NIRS; they showed excellent agreement with refer-
ence data. Commercial MLIC devices such as the Giraffe and Zebra (IBA dosimetry) are
now available for range measurements of pencil beams and in the latter case scattered ion
beams also; the use of these have been reported by Dhanesar et al [32] and Tesfamicael et
al [33]. Both these IBA MLIC devices have a 2 mm depth resolution and use a Bortfield
fit [34] to interpolate the data. The Bortfield fit however, this fit is known to consistently
underestimate the dose at around three-quarters of the maximum range [35], despite this
range measurements with these devises are reported to have an accuracy of±0.5 mm [32,
33].
Beyond the use of ionisation chambers in water or MLIC detectors a number of other
devices and systems have been re-purposed or developed in attempts to optimise the time
needed for routine range measurements while not sacrificing the accuracy of the measure-
ments taken. This often involves calibrating the range measurement method to commis-
sioning values measured ICs in water and determining shifts from that baseline data. A
number of strategies implemented in proton and carbon ion treatment facilities have been
reported in the literature and are summarised following.
Ding et al [36] designed a home-made QA system using the rf-Daily QA-3 (Sun Nu-
clear Corporation, Melbourne, FL) device, used widely for QA applications in photon
therapy, in conjunction with a custom range compensator. This devices uses the electron
ionisation chambers of the rf-Daily QA-3, that are positioned at varying WET depths, to
measure range stability from the ratio of charge collected in the proximal and distal two
detectors. Lambert et al [37] further adapted this system to for an all-in-one daily QA
device that can be used to for all daily QA measurements including dose per monitor unit
and imaging system checks.
The use of a commercial multi-layer Faraday cup (MLFC) the Pyramid MLFC (Pyra-
mid Technical Consultants, Inc, Lexington, MA, USA) for daily range verification at the
McLaren Proton Therapy center was reported by Tesfamicael et al [33]. The MLFC has
128 high pure copper plates and the plate in which the maximum charge is collected (cen-
troid channel) was converted to depth in water and to the range corresponding to the depth
of the 80% dose falloff of the IDD.
Placidi et al [38] proposed coupling the commercially available Sphinx (IBA Dosime-
try) wedge phantom and Lynx CCD camera (IBA Dosimetry) for range verification by
delivering line of pencil beams along a wedge and assigning each pixel the correspond-
ing depth. The Miami Cancer Institute also implemented a similar Sphinx/Lynx setup for
daily QA that was reported on by Rana et al [39].
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The use of Gafchromic EBT2 film (International Speciality Products,Wayne, NJ) for high
spatial resolution quality assurance measurements for carbon ion therapy was investi-
gated by Hara et al [26]. While they showed a strong LET and dose dependence, the peak
position from depth-dose profiles measured with the film placed parallel to the incident
beam direction, was found to be independent of these factors and the measured range
showed variation within 0.6 mm from prescribed data. Mirandola et al [27] describes the
daily range QA measurements at CNAO where EBT3 film (International Speciality Prod-
ucts,Wayne, NJ) is used. For proton beams, the range consistency is checked by placing
EBT3 film in a solid water phantom and parallel to the incident beam. For carbon ions
however, the film LET dependence resulting in quenching at the end of range was found
to result in inaccurate range determination. Instead EBT3 film is placed normal to the
incident beam in a PTW All-in-one phantom (PTW, Freiburg, Germany) behind a double-
wedge and irradiated with a monoenergetic rectangular field. The relationship between
measured field size and change ion range was determined during commissioning and used
to detect range shift from baseline measured during commissioning.
2.1.3 Definitions of proton range
The range of a charged particle is defined as the path length, p, travelled in a medium
before coming to rest and is determined by the particle type, energy and the medium being
traversed [40, 41]. This can be calculated in the continuous slowing down approximation,
named the CSDA range, and is related to the particles initial kinetic energy T0 and the
stopping power as shown in equation 2.1. Two databases commonly used for CSDA









Here dT/ρdx is the mass stopping power in MeV.cm2/g, T is in MeV and hence RCSDA
is given in g/cm2. Due to multiple scattering particle trajectories in matter are not straight
and thus the pathlength/CSDA range do not necessarily describe the penetration depth in
a medium.
The mean range is defined as the thickness of absorber material required to reduce the
particle fluence to half [44][45]. Similarly, Attix defines projected range as the expec-
tation value of the farthest penetration depth in the initial particle direction. The SRIM
(Stopping and Range of Ions in Matter) program developed by J.F. Ziegler and J.P. Bier-
sack [46, 47] implements the Projected Range ALgorithm (PRAL) equations [48] to cal-
culate projected range and is widely used. The algorithm accounts for directional spread
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in ion trajectories, due to multiple scattering, to calculate the mean projected range (x)
from in the summation/integration of mean projected path-length elements along the ion
track [48]. PRAL uses iterations of the difference equation, derived from the relation be-
tween angular spread and nuclear energy loss; the first order expansion of the difference










Here µ = M2/M1, where M1 and M2 are the masses of the ion and target respectively,
E0 is the initial ion energy and Sn and St denote the nuclear and total stopping powers
respectively. The initial condition x(0) = 0 is used.
Perhaps a more clinically relevant definition for particle range is to consider a prede-
termined position on the Bragg peak physical dose profile. While the depth of the Bragg
peak is closely correlated to the mean and projected range, increasing linear energy trans-
fer (LET) at the distal end of the track competes with the reduction in particle fluence.
Several particle therapy facilities have quoted the depth of 80% dose falloff as their stan-
dard for measuring particle range. In chapter 4 different definitions of proton range are
analysed using the Monte Carlo toolkit Geant4 with the setup described in section 4.2.2
and for a generic monoenergeic proton beam.
2.1.4 Relative Biological Effectiveness
Ionising radiation absorbed by living tissue can result in damage of the critical target of
the cell, the DNA. Radiation induced DNA damage can result from either direct or indi-
rect action and the mechanism is heavily dependent on the type of radiation [49]. Photons
deposit energy within the body by exciting or liberating electrons in tissue. Liberated
electrons can cause direct action by damaging the DNA directly. Alternatively liberated
electrons can interact with other cell matter, often water, and produce a free radical. This
is an highly reactive molecule with an unpaired electron that is able to diffuse a greater
distance to reach, interact with and damage the DNA. The latter process, indirect action,
is the most common cause of DNA damage from photon exposure.Higher LET particles
are referred to as directly ionising radiation and evoke damage primarily through direct
interaction with sensitive cell matter. The means by which different radiation types inter-
act with tissue within the body and the resultant distribution of energy depositions dictates
the amount and the localisation of DNA damage that ultimately leads to cell death. As
such high LET radiations are seen to invoke greater damage and have a stronger cell
killing per unit dose. From conventional therapy with photons a wealth of information
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on radiotherapy has been accrued such as an understanding of varying tissue tolerances,
suitable fractionation regimes and more. In order to relate the dose delivered in particle
therapy to that with photons the phenomenon of relative biological effectiveness (RBE)
was conceived.
RBE is defined as the ratio of dose from a reference radiation (Dref) to that from a ra-
diation quality of interest that render the same biological effect (see equation 2.3). The
reference radiation is generally a photon source, Co60 γ rays or kVp x-ray spectra have
been used historically, however megavoltage x-ray sources such as 6 MV beams typically
used in photon radiotherapy linacs are beginning to used more. In this context the radi-
ation modality of interest are charged particles used for particle therapy (hence denoted





While the definition of RBE is well defined, no one value can be used for a given modality.
The RBE is dependent on a wide range of factors including but not limited to biological
endpoint assessed, dose, particle type, particle energy, temporal delivery, tissue type, oxy-
genation, cell phase and so on [10, 50]. The dramatic change in ion LET with penetration
depth alone is a large source of variation in RBE and as such the biological effectiveness
will varies as a function of position in the treatment field and needs to be accounted for in
the treatment planning process. A number of RBE models have been developed in order
to mechanistically describe the biological effectiveness of mixed radiation fields produced
by charged particle therapy beams so that homogeneous biologically weighted doses can
be delivered to a target volume. Two models, most commonly used for RBE calculation
were developed out of the HIMAC and GSI carbon ion therapy projects called the MKM
[51–53] and LEM [54–57] models respectively. These are briefly described below.
Local Effect Model (LEM)
The LEM model was developed for treatment planning to exploit the potential of the
elevated RBE observed with carbon ions and optimise plans to deliver homogeneous bio-
logical dose coverage of the target. This model assumes the biological effect of radiation
is dependent only on the local spatial dose distribution. A track structure model is used
to describe the radial dose distribution of individual particle tracks and the sum of the
dose in a local region from ion irradiation is translated to the biological damage an equiv-
alent local photon dose. The number of lethal lesions within the cell nucleus if found by
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The cell survival following ion irradiation is given by Sion = exp(−Nion) where Nion is
the number of lethal lesions from ion irradiation, Sx is the cell survival from local photon
dose d(x,y,z) integrated over cell nuclear volume, V . The local dose distribution for
an ion track is calculated using the radial dose distribution for each particle species and
energy is defined according to equation 2.5, where λ is a normalisation parameter, rmin
and rmax are cutoff parameters with 10 nm used for the former and the latter calculated
from the maximum δ electron range.
d(r) =

λLET/r2min r < rmin
λLET/r2 rmin ≤ r ≤ rmax
0 r > rmax
(2.5)
The photon cell survival curves are calculated according to equation 2.6 where the linear
quadratic model is used for low doses however beyond a particular transition dose, Dt ,
the cell survival curve transitions to a linear shape at high doses.
S =
{
exp(αxD+βxD2) D < Dt
exp(αxDt +βxD2t + smax(D−Dt)) D≥ Dt
(2.6)
Where smax = αx+2βxDt is the maximum slope at dose Dt , αx and βx are the linear and
quadratic fit parameters respectfully for the cell-specific survival curve. The described
LEM (LEM I) has been incorporated into treatment planning systems to optimise biolog-
ically weighted plans in clinical carbon ion facilities [50, 58–60]. The LEM model was
further developed to address systematic discrepancies between model predictions and ex-
perimental data. The LEM II described in further detail by Elsa¨sser and Scholz [61]
included an updated the radial dose distribution in addition to the inclusion of clustering
effects of DNA damage. This revised version assumes that DNA double-strand breaks
(DSB) as the primary indicator for cell survival and by considering multiple single-strand
breaks SSB within 25 base pair of the DNA as clustered damage and in addition to double
strand breaks are used to determine cell survival. This method improved on the original
LEM which underestimated biological effects ate hight doses. A further revision to the
track structure model to was included for LEM III with a velocity-dependent parameter
used to calculate dose at the centre of the track [62]. The most recent version, LEM
IV, equates the local distribution of DBS after ion irradiation to those from photon ex-
posure to determine the cell survival rather than local dose [63]. Recent extensions to
the treatment planning system using the LEM allow forward and inverse biological dose
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optimised treatment planning that also account for tissue oxygenation [64] working with
helium ions [65] and oxygen ions [66] and for multi-ion plan optimisation [67].
Microdosimetric-Kinetic Model (MKM)
The Microdosimetric-Kinetic model (MKM) was first proposed by Hawkins [51] as a
means to calculate cell survival following ion irradiation based on the LET characteristics
of the ion beams. This model proposed that the number of lethal lesions in a micron-scale
volume, termed a “domain”, is given by the LQ equation with fit coefficients dependent
on the specific energy, z, deposited within the domain. From this Hawkins’ MK model
the number of lethal lesions in generated in a nucleus, Ln, assuming a Poisson disruption
throughout the irradiated cells and surviving fraction, S, is given by equation 2.7.
Ln =− ln(S) = (α0+β z1D)D+βD2 (2.7)
Where D is the abosrbed dose, Z1D is the dose-mean specific energy deposited during a
single event, α0 is the slope of the survival curve as LET → 0 and β is the quadratic pa-
rameter in the LQ model and is independent of radiation type and given by the photon cell
survival curve. Kase et al [53] further developed this model, referred to as the modified
MKM, to account for an overkill effect observed for high LET particles. Equation 2.8 can
be used to relate the dose-mean specific energy to the dose-mean lineal energy yD with





Where the ρ and Rn are the density and radius of the nucleus respectively. Kase et al
introduced a saturation parameter, y0, to account for the saturation effect by correcting yD
for each lineal energy value and subsequently replacing yD with the saturation-corrected
dose-mean lineal energy, y∗. Equations 2.9 and 2.10 are used to determine y0 and y∗











[1− exp(−y2/y20)] f (y) dy∫
y f (y) dy
(2.10)
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The cell survival is then computed with the modified MKM according to 2.7 by replacing









On first application the modified MKM Kase et al [53] performed microdosimetric mea-
surements with a tissue equivalent proportional counter in proton, helium-, carbon-, neon-
, silicon-, and iron-ion beams was a number of water-equivalent depths of plastic. In-vitro
irradiations were performed with human salivary gland (HSG) tumour cells and healthy
human fibroblast cell line, GM05389, to obtain experimental cell survival curves at the
corresponding water-equivalent positions. The parameters for α0 and rd were derived
from the relationship between the α value from the LQ fit of in-vitro data and the cor-
responding yD as yD→ 0. These parameters were later optimised by Inaniwa et al [52]
using LQ data reported by Furusawa et al [68] for HSG tumour cell survival curves af-
ter irradiation with various ions. The revised parameters for the modified MKM are:
α0 = 0.172 Gy−1, β = 0.0615 Gy−1, Rn = 3.9 µm and rd = 0.32 µm [52]. While the
modified MKM parameters are based on data for HSG cells only, they were shown to
agree with in-vitro cell survival for GM05389 cells and a number of other human cell
lines by adjusting only the α0 value [53]. The modified MKM was incorporated into a
biologically optimised treatment planning system implemented using a Monte Carlo code
and a Kiefer-Chatterjee track structure model to produce at z∗1D library for a relevant ion
ion species, their fragments and respective energies [52]. The accuracy of the TPS was
confirmed through in-vitro survival curves measured in biologically optimised plans and
a clinic RBE evaluation presented [52, 69]. Recent developments in the modified MKM
have included modelling the variable RBE due to oxygenation conditions [70, 71] and in
a stochastic MKM to correct for a systematic underestimation of cell survival for high
LET and dose radiation fields [72].
Repair-Misrepair-Fixation (RMF) Model
The repair-misrepair-fixation model [73] calculates the estimated cell survival, not from
the distribution and complexity of the initial induction of DNA damage, but rather ac-
counts for biological repair processes such as unpreparable, misrepaired or fixed DNA
damage.
The RMF treats DSB induction as a compound Poisson process, which is a better ap-
proximation for initial DNA damage induction from intermediate and high LET radiation
compared with previous models [74, 75] which consider only simple Poisson distribu-
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tions. The model uses a system of differential equations to simulate the time-dependent
kinetics of DNA damage and repair by employing first- and second-order terms to de-
scribe exponential rejoining kinetics for the majority of DSB and pairwise DSB interac-
tions, respectively. The entire cell nucleus is considered the maximum volume in which
DSB induction can occur. As DSB pairwise interactions created from both intertrack and
intratrack damage are assessed, sub-volumes or domains within the nucleus needn’t be
studied.
An approximation of the LQ parameters for cell survival, αion and βion for high LET radi-
ation from the RMF model are shown in equation 2.12 where the αR and βR are reference
radiation LQ parameters, zF is the frequency-mean specific energy in a spherical target
with diameter, d, approximated by equation 2.13. The biological parameter RBEDSB is
largely independent of cell type but heavily reliant on particle type and LET. This param-
eter is generally computed as a function of particle type, energy and tissue oxygenation
using the Monte Carlo Damage Simulation (MCDS) software [76]. The frequency-mean
specific energy is additionally computed by MCDS so the only adjustable input parame-
ters for the RMF model are the LQ parameters for the cell type of interest for a reference
radiation and the tissue partial oxygenation concentration. The cell nucleus diameter is
generally assumed to be 4-5 µm.
αion = αR ·RBEDSB
(
1+ 2zF RBEDSB(α/β )R
)










In the case of low dose rates and low doses on the order of, or less than α/β the LQ model
for cell survival is a good estimate of the survival predicted by the RMF model.
2.2 Microdosimetry
Microdosimetry is the study of the energy deposited by ionising radiation to micron sized
volumes [77]. As biological cells are on the order of this size, microdosimetry was pro-
posed by Keller and Rossi [78] as a means to quantify the biological effects of densely
ionising radiation. This theory assumes the micron-sized nucleus of the cell to be the sen-
sitive structure and is based on the total distribution of energies deposited within that vol-
ume. The energy imparted to a micron-sized medium by a particle traversal is a stochastic
quantity [79] and is termed the lineal energy, y. As shown in equation 2.14, the lineal en-
ergy is the quotient of the deposited energy ε and the mean chord length of particles
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A similar quantity is the specific energy z, given by dividing the energy deposited by
the mass of the volume and its mean is analogous to absorbed dose. The probability
distribution function, f (y), associated with a lineal energy can be used to define useful
microdosimetry quantities, such as the frequency-mean, yF , and dose-mean, yD, lineal en-
ergies. The probability distribution is determined by measuring a spectrum of the energy
depositions with a microdosimeter and a multi-channel analyser (MCA) device, dividing
this spectra by 〈l〉 and normalising this distribution to 1. The frequency-mean and dose-
mean lineal energies are given by the first moment and the ratio of the second and first
moments of f (y), given in equations 2.15 and 2.17, respectively.
yF =
∫
y f (y) dy (2.15)
The distribution f (y) is conventionally weighted by the frequency-mean lineal energy as







y2 f (y) dy∫
y f (y) dy
=
∫





As lineal energy is a stochastic quantity and large fluctuations in imparted energy to a vol-
ume often over several orders of magnitude are observed. As such microdosimetric data is
most commonly represented in a semi-log fashion where the horizontal axis showing the
lineal energy is binned with logarithmic spacing and presented with a logarithmic scale.
The conversion of linear to logarithmic bins of y results in the y-axes changing from f (y)
to y f (y) or from d(y) to yd(y) as described in equation 2.18 [79].
d(y) dy = yd(y) d(lny) = (ln10)yd(y) d(logy) (2.18)
Microdosimetry is suited to describing the biological effectiveness of incident radiation
as it accounts for spatial variation in energy deposition events independent of the type or
species of particle incident. As such microdosimetry is well suited to complex and mixed
radiation fields like those delivered during particle radiotherapy treatments. Radiation
protection also uses microdosimetry to quantify radiation quality.
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2.3 Silicon dosimeters
Silicon semi-conductor detectors have a wide range of applications in radiation dosimetry
and exhibit some favourable characteristics such as an ability to generate a high signal-
to-noise ratio with very small and well defined volumes. The mean energy to create an
electron-hole pair in silicon is much lower than for gases such as those used in ionisation
chambers, WSi = 3.6 eV compared to Wair = 33.97 eV. This, in combination with a density
of 2.33 g/cm3, results in a sensitivity of silicon approximately 18,000 times that of an air
filled ionisation chamber of the same volume [80]. Silicon detectors have a short carrier
lifetime which allows for fast response times, they can operate at room temperature and
require little or no external bias voltage to be applied for operation.
The principle of operation of silicon dosimeters relies on the diode, formed by a p-n junc-
tion. Semi-conductor detectors have an inherent band-gap between the conduction and
valence bands making pure semi-conductors poor conductors. Doping is the term used
to describe the introduction of impurities to the material either from groups III or V of
the periodic table to introduce an excess of positive (acceptor) or negative (donor) charge
carriers resulting in so-called p- and n-type semiconductors respectively. As the dopant
concentration is increased, the intrinsic resistivity of the substrate is reduced and the con-
ductive properties become more like that of a metal, due to the introduction of free charge
carriers to the lattice. Heavily doped semi-conductors (with one impurity to ~1011 sili-
con atoms) can be denoted as p+ or n+. The abutment of p- and n-type semi-conductor
materials results in a diffusion of charge carriers between the two substrates to form the
‘depletion region’, free of excess charge carriers with an intrinsic electric field across
the junction. Radiation incident on the junction results in the creation of electron-hole
pairs and the minority carriers within the diffusion region will move towards the junction
thereby creating a current. The charge created is proportional to the dose deposited and
can be measured using an electrometer. Diode detectors may be operated with a reverse
bias applied which increases the size and thus sensitivity of the junction in addition to a
faster response time however this can also result in leakage current and temperature sensi-
tivity. Semi-conductor detectors are most often operated in passive mode without external
bias for dosimetry purposes.
P-type silicon has been demonstrated to show less sensitivity to pre-irradiation and their
response stabilises at lower pre-irradiation doses; they have a better linearity in dose-
rate response and dose-per-pulse dependence than n-type substrates [81]. As such p-type
silicon wafers are more commonly used for radiation dosimeters. Substrate defects are
formed from radiation damage such as atomic displacement and lead to indirect recombi-
nation of charge carriers and a reduce the collection efficiency and hence sensitivity. As
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a result a reduction in detector sensitivity is observed with accumulated dose, particularly
during initial use. It is therefore recommended that new diodes are pre-irradiated before
use so that a saturation of defects is reached and further doses have minimal effect on the
sensitivity over time. Degradation of detector sensitivity is a function of radiation quality
[81] as higher radiation quality results in greater radiation damage. For high LET parti-
cle irradiation it is necessary for silicon diode devices to be calibrated more frequently
to account for this [82]. Substrate defects also increase leakage noise however using the
detector in passive mode can mitigate this effect. Silicon has greater sensitivity to low
energy (keV range) photons compared to water/tissue due to a larger interaction cross-
section for the photoelectric effect. For low energy photon measurements with silicon
diodes this variation in the sensitivity compared to a tissue equivalent material needs to
be assessed. For particle therapy applications, however, the stopping power ratio of sili-
con to water for clinically relevant ions and their fragments at is relatively constant over
the energy range used for treatment so the relative tissue-equivalence and sensitivity is
stable.
Owing to their small size diode detectors can be arranged into arrays with many indi-
vidual volumes allowing for high resolution dosimetry. Further they have minimal dose
averaging effects due to their size unlike many alternate detectors such as ionisation cham-
bers. As such they demonstrate suitability for applications in small fields and high dose
gradients; both of which feature in particle radiotherapy, particularly for PBS delivery.
2.4 CMRP detectors for particle therapy applications
This section describes the silicon array detectors and the silicon-on-insulator microdosime-




The serial Dose Magnifying Glass (sDMG) detector, depicted in figure 2.1, is the prede-
cessor of the previous generations of the dose magnifying glass (DMG) which were first
introduced for quality assurance for a number of photon therapy modalities and was ex-
tensively characterised by Wong et al [83–86]. The sDMG consists of two linear arrays of
sensors wire bonded end-to-end on a flexible printed circuit board (PCB). Each linear ar-
ray consists of 128 n+ silicon strips implanted on a p-type silicon substrate with a 200 µm
pitch. Each wafer has dimensions of 0.4×4×28 mm3 and the combined 256 diodes mea-
sure over a length of 50.8 mm. The sensitive strip area of each diode is 20× 2000 µm2.
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Figure 2.1: sDMG dosimeter
The PCB is 0.5 mm thick and provides the fan-out for connection to the data acquisition
system.
Wong et al [83] characterised a prototype version of the single wafer DMG with 128
channels each with a sensitive area of 20× 5000 µm2 at a pitch of 200 µm and was
mounted on a ceramic substrate. The detector was shown to have a linear dose response
for clinically relevant x-ray doses, negligible stem effects and was able to accurately re-
produce percentage depth dose profiles (PDDs) measured with an ionisation chamber and
penumbral lateral profiles measured with Gafchromic EBT film. The detector was seen to
have a slight dose per pulse dependence however primarily at doses < 0.1 cGy/pulse for
gun pulses delivered at 360 Hz. This prototype was shown to have an angular dependence
of up to 28.1 % ± 0.1 % for a parallel incident beam at 90◦.
The 2nd generation of the DMG detector featured an active strip area of 20× 2000 µm2
and was mounted on a 0.12 µm thick Kapton carrier [85]. Wong et al [85] compared low
and high resistivity (10 Ohm·cm and 5 kOhm·cm respectively) DMG devices for radiation
hardness and dose per pulse dependence for both preirradiated and unirradiated devices.
The preirradiated, low resistivity device showed a maximum variation of 1.1% variation
to an ionisation chamber response. The second generation device showed a greatly im-
proved angular response (within 15.3% ± 0.5%) due to the mounting base being much
thinner and having a density and effective Z closer to tissue and the surround phantom
material resulting in less beam perturbation in the substrate. The second generation de-
tector used for stereotatic radiotherapy profile measurement and was shown to have good
agreement with film measurements [86].
Another 128 channel single wafer DMG prototype with similar specifications to those
in the second generation detector but with a 100 µm sensitive volume pitch and a 380 µm
substrate thickness was tested for measuring depth dose profiles in monoenergetic and
modulated passively scattered proton therapy fields [87] and for lateral beam profiling.
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The small sensitive volume of the detector allows accurate point measurements and mea-
surements of small fields without partial volume averaging [87]. Depth dose profiles
measured with the DMG showed strong agreement with Geant4 simulations, point diode
and Markus chamber measurements and showed no evidence of LET dependence. The
DMG was shown to accurately reproduce MC and film measured lateral beam profiles
with high resolution and in real-time. It was concluded that the DMG is a useful clinical
tool for QA measurements in proton therapy [87].
The sDMG detector was investigated for a range verification quality assurance in pro-
ton therapy in an edge-on configuration with the axis of detection placed parallel to the
incident beam direction by Merchant et al [88]. The setup was able to accurately repro-
duce proton range measurements at varying detector depths within a surrounding perspex
phantom for a monoenergetic 60 MeV proton beam with different beam diameters.
All of the DMG generations described above were designed to be readout using a TERA
chip data acquisition (DAQ) system. This system uses a very large scale integration ap-
plication specific integration circuit (VLSI ASIC) [83] called the TERA chip which was
designed by Istituto Nazionale di Fisica Nucleare (INFN) - Torino Division and Univer-
sity of Torino microelectronics group. The chip is made up of a current-to-frequency
converter paired with a digital counter and has 64 independent channels. The TERA chip
uses a charge subtraction method to eliminate dead time and has a dynamic range greater
than 105 with non-linearity <1%. The single wafer 128 channel DMG systems use a 2
TERA chip front end DAQ while the sDMG uses a 4 chip system to read out all 256
channels simultaneously. The CMRP TERA DAQ is discussed in further detail by Wong
[83] and Fuduli [89].
DMG256
The dose magnifying glass (DMG256) detector is a monolithic 1D diode array consisting
of a p-type silicon substrate mounted on a flexible kapton carrier. This detector proceeds
the sDMG detector and allows continuous profiles to be measured over the 256 channels.
The DMG256 silicon wafer has dimensions 0.47× 4.0× 51.4 mm3 and consists of 256
individual sensitive volumes with a 200 µm pitch. The sensitive volumes are produced by
n+ implants 20 µm × 2000 µm surrounded by a p+ implant to isolate pixels and polarise
the substrate. The kapton carrier provides a fan-out from the sensitive volume array for
connection to the data acquisition system described in the following section (DAQ). The
DMG256 detector is shown in figure 2.2.
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Figure 2.2: DMG256 dosimeter
Figure 2.3: Duo dosimeter
Duo
The Duo detector consists of 512 pixels in two orthogonal linear arrays each with 256
active silicon sensitive volumes at a pitch of 200 µm on a p-type silicon wafer with active
area 52 × 52 mm2 and a thickness of 350 µm. The sensitive volumes on each “arm” are
defined by n+ implants with dimensions 800 µm × 40 µm surrounded by a p+ region.
The 5 central pixels’ dimensions vary in either array to facilitate the intersection of the
orthogonal arrays while maintaining spatial separation between pixels. The n+ implanted
area is consistent between all pixels with the exception of the central pixel shared by both
arrays with ~1% larger area. Figure 2.3 shows the Duo detector and the arrangement and
respective sizes of the central pixels.
The Duo detector has previously been characterised [90, 91] for photon beam QA and
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was shown to have excellent dose linearity and was accurate for measurement of output
factors, PDDs and lateral dose profiles for clinical 6MV linac fields. Porumb et al [91]
performed radiation damage studies showing that the Duo dose response stabilises after
preirradiaiton. They also showed that the detector exhibits no charge sharing between
adjacent volumes and that the charge collection efficiency is 66% when the detector is
operated in passive mode (no external bias applied) from a ion beam induced charge col-
lection (IBICC) study.
Data Acquisition System
The Data Acquisition System (DAQ) used for both the DMG and Duo detectors was de-
veloped at CMRP and has a modular design capable of simultaneous readout from 256
or 512 individual channels and is described in detail by Fuduli [89, 92]. The front end of
the DAQ uses AFE0064 multichannel electrometer chips produced by Texas Instruments
(TI). A purpose built “AFE board” consists of a 16 bit quad channel analogue-to-digital
converter (ADC) from TI that reads out two mounted 64 channel AFE0064 chips in par-
allel. A custom designed field-programmable gate array master board (FPGA MB) drives
the two or four AFE boards (for DMG and Duo dosimeters respectively). The DAQ is
setup in sequential mode so that the analogue outputs from the chips are available alter-
natively in each clock cycle; this results in a system dead time of 70 µ s allowing for data
transfer and integral capacitors to be reset. The FPGA communicates with a Graphic User
Interface (GUI), designed in-house for PC, via USB2.0 link.
The GUI is used to control data acquisition settings such as the gain range, the integration
and total acquisition times, the frequency and buffer size of data transfer sent from tempo-
rary FIFO storage at the FPGA to the GUI, as well as trigger settings. Two trigger settings
are available for acquisition: synchronised by an external trigger or asynchronised using
an internal trigger. The external trigger is particularly useful for acquisitions on modern
LINACs that use pulsed radiation by synchronising detector integration times with beam
pulses in order to reduce dark current and electrical noise contributions to the final signal.
The detector dead time then occur in the time between been pluses. For particle therapy
facilities with an external trigged synchronised with the spill of ions the external trigger
can also be used.
The GUI allows frame-by-frame and integral counts over all channels to be visualised
in real time or post acquisition and for the time response profile of an individual chan-
nel to be visualised. The GUI and also be used to apply an equalisation matrix to data
obtained to account of variation individual pixel response.
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2.4.2 Bridge Microdosimeter
The bridge microdosimeter is a fully 3D silicon-on-insulator (SOI) microdosimeter that
was developed at CMRP based on advancements in silicon microdosimetry in previous
generation designs, a review of this work is given by Rosenfeld [93]. The microdosime-
ter consists of a total of 4248 individual sensitive volumes distributed among 3 segments
each with an “odd” and “even” array that are read out individually in order to reduce
detector noise. Each sensitive volume has a 3D parallelpiped shape with dimensions
30×30×10 µm3 connected by a bridging volume. The silicon surrounding the sensitive
volumes was removed using plasma etching techniques so that charge is not shared be-
tween volumes. Figure 2.4 shows an inset scanning electron microscope (SEM) image of
the bridge microdosimeter sensitive volumes and the microdosimetric dual in line (DIL)
package mounted on the microdosimetric probe, called the Micro Plus probe. The Micro
Plus probe consists of a low noise spectroscopy readout circuit which is located 10 cm
from the detector so that the electronics are outside the primary field reducing the poten-
tial for radiation damage. The probe and detector and inserted into a watertight PMMA
sheath with a thin window above the bridge sensitive volumes.
The small sensitive volume design of the bridge microdosimeter addresses the short com-
ings of the gold standard in microdosimetry, the tissue equivalent proportional counter
(TEPC), such as the limited spatial resolution, high operating voltages and inability to
simulate the response of multiple cells. Particle therapy fields not only feature steep dose
gradients but also have highly variable LET in the end of range region. In order to avoid
blurring of the microdosimetric properties measured in such fields, microdosimeters with
exceptionally high spatial resolution are required and the bridge microdoisimeter with
10 µm thickness lends itself to this.
The bridge microdosimeter has been well characterised [94, 95] and benchmarked against
TEPC measurements in clinical carbon ion fields. The bridge microdosimeter has been
investigated for microdosimetric measurements and RBE calculation both in-field and
out-of-field in passive and active scanning beam delivery techniques for proton therapy
[96, 97], for clinical carbon ion fields [94, 98, 99], with heavier ions such as nitrogen and
oxygen [98] and in boron neutron capture therapy [100].
2.5 Monte Carlo in particle therapy
The Monte Carlo (MC) method is a class of numerical and analytical methods that utilise
the generation of random numbers to solve problems whose outcomes are based on sta-
tistical probabilities. The Monte Carlo method is a well suited approach to describe and
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Figure 2.4: Micro Plus probe and SEM image of bridge microdosimeter sensitive vol-
umes
track particles in matter. Simulations of particle interactions using the MC method are
readily used in medical physics and are advantageous in that they can model the outcome
of measurements that are very difficult or impossible to perform in experiments and are
relatively inexpensive. Monte Carlo simulations are considered the gold standard for dose
calculation in radiotherapy and are widely used for verification of treatment plans based
on analytical beam models. In particle therapy, delivered radiation fields are complex and
contain a mixture of particle types and species due to fragmentation of both the primary
beam and the target. As such, many analytical track structure models can oversimplify
the processes undergone during partcile irradiation leading to miscalculation of the dose
distribution.
In this thesis the Monte Carlo toolkit Geant4 is used to help characterise detector re-
sponses in particle therapy fields and to analyse field composition and quality. The Geant4
toolkit is briefly described below.
2.5.1 Geant4
Geant4 (GEometry ANd Tracking) [101–103] is a powerful MC toolkit developed and
maintained by an international collaboration based at CERN. It allows tracking of parti-
cles traversing a medium and has a variety of applications including high energy, nuclear
and accelerator physics [104]. Geant4 uses c++ frameworks to allow users to define all
aspects of the simulation through source files including the physics models used, tracking
information, geometry, materials etc. Users are required to develop specific applications
built of the Geant4 kernel. Geant4 has three mandatory user initialisation classes that
need to be defined in order for an application to function and are based on the abstract
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base classes; they are discussed below. Optional classes are also available to help cus-
tomise and control the simulation, such as to score and save data.
Detector Construction - The detector construction class defines all the volumes involved
in the simulation including their geometry, material and positioning. The detector con-
struction defines a ‘World Volume’ that sets the boundaries of the simulation and encapsu-
lates all its geometries; it also defines the coordinate system of the setup. The geometries
of an experiment are initially defined as a solid with specified dimensions based on an
extensive library of shapes. A logical volume is set for the solid that contains information
regarding its material, sensitive volume elements and magnetic field. The placement of a
volume including its mother volume (volume in which it is placed), its position and orien-
tation relative to the coordinate system of its mother volume is declaration as the physical
volume.
Primary Generator Action - The primary generation action class defines the primary
particles to be tracked in the simulation. This class defines the radiation source type,
whether it be a radioactive substance such as a brachytherapy seed, modelling a space
environment or most commonly in radiation therapy, to define a beam. The particle type,
starting position, energy and momentum direction can be prescribed or alternatively read-
in from a phase-space source containing beam parameters for a specific source such as a
commercial linac or for a given treatment nozzle of a specific particle therapy centre, for
example.
Physics List - Particle interactions with matter are governed by the user physics list
class. Interactions of particles that can be modelled within Geant4 include electromag-
netic, hadronic, transportation, decay, photolepton-hadron and parametrisation processes
[105]. Physics interactions can be modelled for a wide range of energies from the eV
range up to TeV. Furthermore, the extent of particle tracking can also be set by the user by
defining cut values such as the minimum range and the energy to which secondary parti-
cles are tracked. These parameters can be used to optimise the run time of a simulation
and meet the required accuracy of the run.
Chapter 3
A silicon strip detector array for energy
verification and quality assurance in
heavy ion therapy
The results presented in this chapter have been published in the journal Medical Physics:
E. Debrot, M. Newall, S. Guatelli, M. Petasecca, N. Matsufuji and A. B. Rosenfeld,
“A silicon strip detector array for energy verification and quality assurance in heavy ion
therapy”, Medical Physics, 2018, 45, 953-962.
3.1 Overview
Heavy ion therapy is a modality of growing interest in the field of radiotherapy [106]
with several advantages over conventional photon beam treatments. These advantages are
due to the physical energy deposition characteristics of charged particle beams as well
as their increased biological effectiveness resulting from a high LET. Range and energy
verification of heavy ion beams is an important aspect of quality assurance procedures for
heavy ion therapy facilities. The depth at which the Bragg peak occurs depends heavily on
the medium being traversed, the heavy charged particle type and energy upon incidence.
Hence, the dose delivered and its distribution within a patient due to heavy ion beams,
used clinically in radiotherapy, is heavily dependent on the energy of the beam.
In order to verify beam characteristics for quality assurance in heavy ion therapy, a
detector with high spatial resolution, that is capable of resolving steep dose gradients
and suitable for beam entrance energy verification, is necessary. The silicon strip serial
Dose Magnifying Glass (sDMG) detector, developed at the Centre for Medical Radia-
tion Physics (CMRP), University of Wollongong, is capable of measuring dose with sub-
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millimetre spatial resolution. The sDMG detector consists of two linear arrays of 128
silicon sensitive volumes on a p-type substrate at a pitch of 200 µm along a single axis of
detection.
In this chapter the sDMG detector is characterised as an independent ion beam energy
and range verification system used for quality assurance conducted for ion beams used in
heavy ion therapy. The detector response to a 290 MeV/u 12C ion broad beam incident
along the single axis of the detector embedded in a PMMA phantom. The energy of the
12C ion beam incident on the detector and the residual energy of an ion beam incident
on the phantom was determined from the measured Bragg peak position in the sDMG. A
Monte Carlo simulation based investigation of the sDMG detector was conducted in order
to characterise the detector as a novel tool for verification of residual beam energy and
ion range. A method to reconstruct the incident beam energy on the detector is presented
and analysed.
3.2 Materials and Methods
3.2.1 sDMG detector and data acquisition system
The Serial Dose Magnifying Glass, (Figure 3.1, sDMG) is a multistrip silicon detector
consisting of 256 channels formed from two linear arrays of sensors wire bonded end-
to-end on a flexible printed circuit board (PCB). The linear arrays are each comprised of
128 n+ silicon strips implanted in a thin p-type silicon substrate. The diodes present a
sensitive strip area of 0.05 × 2 mm2 with pitch 200 µm and measure along a single axis
of length 50.8 mm. The total size of each silicon strip detector is 0.4 × 4 × 28 mm3.
The PCB is 0.5 mm thick and provides the fan-out for connection to the data acquisition
system. The PCB and detector are contained within specifically recessed slabs of solid
water providing suitable scattering conditions and mechanical rigidity.
Four TERA 64 channel chips were used to read out each of the 256 sensitive volumes of
the sDMG detector. The TERA chip is an application specific integration circuit (ASIC)
based on a current to frequency converter and digital counter. Each chip has a zero dead
time readout with a high temporal resolution and large dynamic range. This DAQ system
has been used in conjunction with previous generations of the sDMG detector and more
information on the system specifics can be found in work by Wong [83] and Fuduli [89].
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Figure 3.1: Schematics of the serial Dose Magnifying Glass (sDMG) comprised of two
linear arrays detectors is wire bonded to a thin printed circuit board (PCB), the single
axis of detection is indicated by the arrow.
3.2.2 Experimental setup
The results presented here are from experiments conducted at the Heavy Ion Medical Ac-
celerator in Chiba (HIMAC), Japan. The beam line is shown schematically in Figure 8.3
and consisted of an aluminium scattering filter, several meters of air, a brass collimator
with a 10 × 10 cm2 square opening (defining the field boundary) and PMMA phantom
in which the sDMG detector was placed with the axis of detection aligned parallel to the
incident beam direction. The sDMG is mounted on PCB and was surrounded by a small
air recess within the PMMA phantom (see Figures 3.1 and 3.3). The sensitive volumes
of the detector were positioned in the center of the radiation field. Accurate alignment of
the sDMG was achieved using laser beams and reference markers on top of the PMMA
detector package which are aligned with the single axis of the sDMG detector. For the
acquisitions the sDMG detector was operated in passive mode, with no external bias ap-
plied and was irradiated by a 12C ion beam with an energy (E ′) of 290 MeV/u emerging
from the vacuum head of the beamline.
The relative depth dose profiles of the beam were measured in the silicon detector with the
front edge of the first detector at depths of 54, 89, and 102 mm in the PMMA phantom.
The depth of the Bragg peak in silicon was determined from the position of the channel
with the maximum response following equalisation and was used to determine the beam
energy incident on the detector (E1) and the residual beam energy incident on the phantom
(E0).
3.2.3 Uniformity/Equalisation
The response of the individual channels of the sDMG detector varies with the sensitivity
and the corresponding preamplifier gain [107]. This can result in variations in the re-
sponse of detector channels. As such, a uniformity test was performed by exposing the
detector to a uniform field and measuring the response of each individual channel (Xi).
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(a) (b)
Figure 3.2: (a) sDMG detector embedded in PMMA phantom and with data acquisition
system placed in experimental beamline, (b) schematic visualisation of beamline from
Geant4 [101–103] simulation.
An equalisation factor (Fi) was obtained for each channel and used to obtain an equalised
channel response (Xeq−i) as given in equation 3.1, where X is the average response over
all 256 channels. The detector response to a uniform field was obtained by orientating the




→ Xeq−i = XiFi (3.1)
3.2.4 Energy reconstruction method
The energy of the ion beam emerging from the vacuum (E ′) of the beam nozzle was 290
MeV/u in both experiment and simulation. The beam passes through several meters of air
and a scattering filter resulting in a residual energy, E0 at the face of the phantom. The
energy of the beam incident on the detector after traversing the PMMA phantom, thick-
ness s, is E1. This is depicted in Figure 3.3.
The energy of the beam incident on the detector E1 was derived from the depth of
the Bragg peak in the silicon detector and NIST data on the CSDA range [108] in silicon
as a function of particle energy.
R(E0) = s+R(E1) (3.2)
The range of ions with residual energy E0 incident on the PMMA phantom was calcu-
lated by noting the thickness of PMMA traversed s and R(E1), the range of the ions with
energy E1 in PMMA as given in Equation 3.2, where R is the CSDA range for carbon
ions of a given energy. The beam energy, E0 incident on the PMMA phantom was then
reconstructed from R(E0) again using the CSDA range data.
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Figure 3.3: Detailed geometry of the sDMG in PMMA phantom for measurement of
pristine Bragg peak (PBP) depth profile. The air void has an area 19 × 205 mm relative
to the beams eye view; 6 mm of air is between the phantom wall and first silicon wafer
of the detector and the physical gap between to two wafers is 0.6 mm.
3.2.5 Geant4 simulation application
The experimental investigation of the sDMG response at the HIMAC facility in Japan was
modelled using the Geant4 Monte Carlo Toolkit (version 10.1). As in the experimental
setup the sDMG detector was placed with the common axis of detection parallel to the
incident beam direction and in a PMMA phantom at depths of 54, 89 and 102 mm. The
relative depth dose profile of the Bragg peak for a 290 MeV/u 12C ion beam was calcu-
lated by scoring the total energy deposition in each of the 256 sensitive volumes of the
sDMG detector.
The physics models set in the Geant4 simulation Physics List are shown in Table 8.2. The
alternative hadronic physics models Binary Ion Cascade Model (BIC), INCL++, QMD
and QMD with frag option turned on, were compared in a first study. The results are
shown in Section 3.3.1. The NIST material database was used to define the materials of
the detector, phantom and beam line.
Particles were tracked from the point at which they emerge from the vacuum in the beam
line. Beyond this point all elements of the experimental beam-line were modelled: over
6 m of air, an aluminium scattering filter and a brass collimator positioned before the
PMMA phantom (see Figure 8.3). The material G4 PLEXIGLASS, from the Geant4 NIST
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Table 3.1: Geant4 Physics models used in the simulation physics list.
Physics processes Geant4 models
Electromagnetic physics G4EmStandardPhysics option3
Decay physics G4DecayPhysics
Radioactive decay physics G4RadioactiveDecayPhysics




Hadronic Ion Physics Model (BIC, INCL++,
QMD and QMD with frag option on)
Table 3.2: sDMG Dimensions
sDMG contacts Simulated sDMG collection regions
Channels 256 256
Pitch 200 µm 200 µm
Strip area 20 × 200 µm2 100 × 200 µm2
Strip depth 0.6 - 0.8 µm 50 µm
materials database, was used to define the PMMA phantom and the default density of
1.19 g/cm3 was used. This material coincides with that used in the experimental setup
and the NIST range data used to reconstruct the beam energy incident on the phantom.
With the exception of the PCB board, that was excluded due to uncertainty in its material
composition, the detector construction was consistent with the experimental setup.
The internal potential difference established between each n+ electrode and the p-type
silicon substrate of the detector results in a depletion region around the electrode. The
size of this depletion region represents the sensitive volume of each diode in the sDMG
array. The effective size of the sensitive volumes was determined using an ion beam in-
duced charge (IBIC) collection study technique based on scanning the unbiased detector
with a 1 µm diameter 8 MeV proton or 5.5 MeV 4He ion beam. These studies revealed
laterally diffused charge collection within 50 µm of the electrode. The size of the scoring
volumes defined for the simulation were adjusted to replicate this charge collection region
- the depth of each sensitive volume was defined to be 50 µm and the width 100 µm (ac-
counting for diffused charge from either side of the electrode). While this diffusion region
affects the size of each sensitive volume it does not directly reflect the spatial resolution
of the sDMG since the position of each n+ contact is well-defined. The dimensions of the
contacts and sensitive volume size used in the simulation are given in Table 3.2.
A total of 3× 107 primaries were tracked for each simulation with their starting posi-
tion randomly generated on the downstream face of the vacuum window within an area
of 5× 5 cm2 centered on the beam axis. The initial kinetic energy of each primary was
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290 MeV/u. No angular or energy dispersion was modelled in the generation of primary
ions as each ion undergoes multiple scattering events over its trajectory in the beam-
line thus providing some variation in the angular dispersion of primaries incident on the
phantom and detector. Furthermore, this multiple scattering, particularly when particles
traverse the scattering filter, results in an increasing field size with distance along the
beam-line. The field size at the point of primary generation was reduced for the simula-
tion component of this study in order to optimise the simulation and increase statistics for
the interaction of particles within the detector. Prior to this an investigation on the effects
of the generated field size on the depth of the Bragg peak in the silicon detector was per-
formed and showed no field size dependence on the relative peak position. The results of
this investigation are presented in Section 3.3.1. The simulation was further optimised in
terms of execution times by appropriately using the Geant4 Cuts Per Region.
The simulation was also used to investigate the effect of the air gap surrounding the sDMG
detector on its response as well as to characterise the potential advantages of the proposed
next generation of single axis silicon strip detector. The findings are presented in Section
3.3.3.
3.3 Results and Discussion
3.3.1 Geant4 simulation optimisation: investigating detector response
for alternate hadronic physics models and variable field size
Figure 3.4a shows the simulated profiles obtained using the hadronic ion physics models
INCL++, BIC, QMD, and QMD with the frag option turned on for the detector at a depth
of 54 mm in the PMMA phantom. The primary difference between the models is seen in
the fragmentation tail distal to the Bragg peak as the species and yield of the fragments
produced are dictated by the hadronic physics model used. Given the similar energy de-
position profiles with alternate Geant4 fragmentation models, the INCL++ model was
chosen as it was found to have a quicker execution time.
The effect of varying the initial field size of the beam on the sDMG response is de-
picted in Figure 3.4b. Here, the particle flux was held constant for the three field sizes
shown. The relative energy deposition in the buildup to and downstream of the Bragg
peak is seen to increase slightly with the field size. This variation in the relative pro-
file shape is attributed to increased scatter contribution of primaries and fragment ions
scattering from the surrounding phantom into the detector. With greater generated field
sizes a secondary Bragg peak (discussed in Section 3.3.3) still cannot be clearly resolved.
Furthermore, the application of the sDMG detector for 12C ion range measurement and
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Figure 3.4: Comparison of resulting pristine Bragg peak calculated in the sDMG detec-
tor for (a) alternate Geant4 ion hadronic physics models and (b) different generated field
sizes. The sDMG is set at a depth of 54 mm in PMMA. The discontinuity in the centre of
the plot (and in Figures 3.5 - 3.9) is due to the physical separation in sensitive volumes
between the end of the first and the start of the second silicon strip detectors compris-
ing the sDMG (see Figure 3.3). Profiles are normalised to the pixel with the maximum
energy deposition.
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Figure 3.5: Resulting pristine Bragg peak measured experimentally with the sDMG
detector and calculated in the Geant4 simulation at a depth of 54 mm in PMMA.
energy reconstruction relies only on the depth of the Bragg peak in the silicon detector to
be accurately determined and does not concern the shape of the profile. As such, the field
size was reduced to 5 × 5 mm2 in order to increase statistics in the sensitive volumes of
the detector whilst reducing computational time.
The relatively high energy deposition beyond the Bragg peak is due to ions traversing
the surrounding PMMA and scattering into the detector; this effect is further discussed in
Section 3.3.3.
3.3.2 Comparison of experimental and simulation results
The pristine Bragg peak profiles measured in the silicon detector with different thick-
nesses of PMMA phantom placed in front are shown in Figures 3.5-3.7. The measured
positions of the Bragg peak in silicon, the reconstructed energy, E1, of the beam incident
upon the detector and the residual energy, E0, of the beam incident on the phantom are
shown in Table 3.3.
The range of 12C ions in silicon, which is indicated by the position of the Bragg peak,
is shown to have excellent agreement between experiment and simulation with no more
than ±0.2 mm difference in the position.
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Figure 3.6: Resulting pristine Bragg peak measured experimentally with the sDMG
detector and calculated in the Geant4 simulation at a depth of 89 mm in PMMA.
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Figure 3.7: Resulting pristine Bragg peak measured experimentally with the sDMG
detector and calculated in the Geant4 simulation at a depth of 102 mm in PMMA.
Table 3.3: Experimentally measured and calculated position of Bragg Peak in silicon de-
tector for varying thicknesses of PMMA at the entrance of the detector, the reconstructed
energy, E1, of the beam leaving the PMMA incident on the detector and reconstructed
energy, E0, of the beam incident on the PMMA phantom.
PMMA phantom Depth of Bragg peak Reconstructed energy Reconstructed residual
thickness (mm) in silicon (mm) E1 (MeV/u) energy E0 (MeV/u)
(± 1) Exp (±0.4) Sim (±0.2) Exp (±3.0) Sim (±3.0) Exp (±3.0) Sim (±3.0)
54 48.7 48.8 206.0 206.3 280.7 280.9
89 27.2 27.2 146.5 146.5 280.7 280.7
102 19.4 19.2 121.0 120.0 281.4 280.8
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While there is strong agreement in the peak positions, several differences arise in the
shape of the experimental and simulated dose profiles in silicon. These differences are
largely attributed to the non-linear variations in the response of individual sensitive vol-
umes to 12C ions due to their variable LET and to radiation damage (defects) along the
sDMG detector while the applied equalisation factor was based on the response of the de-
tector in a 6 MV x ray field from a linac with uniform, low LET from Compton electrons.
The local peaks observed at depths of approximately 13, 21 and 27 mm in silicon for the
experimental profiles are an example of this where defects were induced from previous
irradiations with varying entrance energies and Bragg peaks at these depths.
The detector response for the experimental profiles with 89 and 102 mm of PMMA placed
at the entrance of the sDMG (Figures 3.6 and 3.7, respectively) are seen to lack the typical
“flat” plateau region proximal to the buildup to the Bragg peak. The increasing detector
signal with depth in the silicon detector highlights the non-linear response of the sili-
con sensitive volumes to changes in particle LET. The simulation presents the ideal case
where the charge collection efficiency in pixels is 100% and cross-talk or charge sharing
between sensitive volumes as well as LET dependent recombination of charge carriers
does not occur.
The distal falloff of the experimental Bragg peak profiles are not as sharp as the simu-
lated profiles. This is because the PCB board is not modelled in the simulation. Since the
stopping power of 12C ions in PCB is less than in silicon, ions that travel through the PCB
and undergo lateral scattering into the silicon detector will have a range exceeding that of
ions travelling in silicon only. The result is energy deposition beyond the Bragg peak and
a broadening of the distal falloff, particularly in Figure 3.5 where the particle range in the
detector (and potentially in the PCB) is greatest.
The average residual energy of the beam incident on the phantom, E0, was calculated
for experiment and simulation to be (280.0 ± 0.8) MeV/u and (280.0 ± 0.2) MeV/u, re-
spectively (uncertainty stated to 2σ); these values agree within experimental error. The
290 MeV/u beam traverses an aluminium scatterer and several meters of air before inci-
dence on the phantom. The energy of the beam entering the phantom was estimated to
be approximately 281 MeV/u by considering the combined water equivalent thicknesses
of the scattering material and air and the range in water of the ions emerging from the
vacuum of the beam head (again employing the method using Equation 3.2). A Geant4
simulation calculating the energy of the beam at the end of the beamline used in the ex-
periment also revealed an average particle energy of 282 MeV/u.
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Figure 3.8: Calculated pristine Bragg peak in the sDMG with a surrounding aid void
with heights of 0.5, 1.0 and 1.5 mm using the Geant4 simulation and the detector placed
at 54 mm in PMMA.
3.3.3 Optimisation of the DMG design: Simulation study of the effect
of air gaps in the DMG response
The dependence of the detector response on the size of the air gap surrounding the de-
tector inside its PMMA casing was investigated using the Geant4 application discussed
previously by varying the height of the air gap above the plane of the silicon sDMG. The
physics list used for the simulation here is the same as in Table 8.2. The actual height of
the air void was measured to be 2.5 mm and this value was used in the profiles simulated
in Figures 3.5 - 3.7. Figure 3.8 shows the profiles obtained with the sDMG placed at a
depth of 54 mm in the phantom for an air void 0.5, 1, and 2.5 mm in height.
An obvious increase in energy deposited downstream of the Bragg peak is observed
for a 0.5 mm air gap only. Energy deposition beyond the Bragg peak is attributed to
carbon ions and fragments scattering from the surrounding phantom into the detector as
particles traversing the phantom have a greater range than those travelling through the
silicon detector due to the greater stopping power of the latter. As high energy carbon ion
beams primarily undergo small angle Coulomb scattering they are likely to traverse the
airgap without entering the sDMG for the cases with a 1 and 2.5 mm airgap. Particles that
traverse the phantom and scatter into the detector contribute to a secondary Bragg peak in
the detector beyond that produced by carbon ions in silicon provided the detector is long
enough to accommodate both Bragg peaks.
The position of this secondary Bragg peak corresponds to the particle range in the PMMA
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Figure 3.9: Calculated pristine Bragg peak in sDMG detector and new proposed single
wafer DMG for air void heights of 0.5 and 2.5 mm and without an air void, at a depth
of 102 mm in PMMA. The vertical line indicates the expected range of carbon ions in
PMMA relative to the detector position.
phantom. The secondary Bragg peak is not observed in Figure 3.8 as the range of the 12C
ions in PMMA is beyond the length of the sDMG placed at this depth.
Figure 3.9 shows the effect of changing the size of the air gap on sDMG response with the
sDMG entrance placed at a depth of 102 mm in the phantom. This plot shows the detector
response for two air void sizes for both the sDMG design described previously and for the
proposed next generation single monolithic DMG that will be approximately 60 mm long
with 256 sensitive volumes. It should be noted that the dose deposition profiles in silicon
for the sDMG and the next generation single monolithic DMG are near identical for the
same size surrounding air void only the response of the new DMG design allows a contin-
uous profile to be observed compared to the gap associated with the spacing between the
sensitive volumes of the two wafers in the sDMG design. The simulated secondary Bragg
peak is clearly observed for the 0.5 mm airgap. This secondary Bragg peak however has
no distinct falloff and lies beyond the expected range of the primary 12C ions in PMMA
(indicated by the red line). Ions contributing to this peak will have traversed the small
air gap between the phantom and the detector and (due to the comparatively low stopping
power of the air) their range will be perpetuated further.
Figure 3.9 also presents the response of the new DMG detector design for an optimum
setup with no air gap between the phantom and silicon of the detector. For this case, the
falloff of the secondary Bragg peak can be clearly seen and is aligned (at approximately
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the 60% falloff mark) with the expected range of the 12C ions in the PMMA phantom
only. With this optimised design of the DMG detector a second method of range verifica-
tion becomes possible where the range of an ion beam in the phantom is determined from
the absolute position of the secondary Bragg peak measured in the detector.
Due to these findings, future DMG designs will adopt the single wafer design and endeav-
our to be closely fitted with a PMMA sheath/carrier in order to increase scatter conditions
and thus detector response.
In summary, two modes of QA operation are possible for the current device and method:
(a) verification of 12C ion beam energy after traversal of homogeneous or heterogeneous
media and (b) energy reconstruction of ions incident on a PMMA phantom of known
density and thickness (or other known homogeneous material) in front of sDMG. The
simulation component of the study indicates that the future DMG design may be used to
directly measure the absolute range of an ion beam in a homogeneous or heterogeneous
phantom from the secondary Bragg peak observed.
Moreover, the sDMG is proposed as a tool for validation of treatment planning systems or
Monte Carlo simulations by reconstructing the energy loss of ions in materials upstream
of the sDMG and, for future generations of the detector, using direct measurement of the
particle range.
While in most silicon diodes the response is effected by the LET of charged particles,
the proposed sDMG or single monolithic DMG do not require accurate measurement of
absolute dose for depth profiles in silicon, rather precise measurement of the Bragg peak
position is sufficient for range and beam energy reconstruction. The same is true for ra-
diation damage in the detector that can change the relative depth dose-response whilst
leaving the Bragg peak position unaffected.
3.4 Conclusions
The Serial Dose Magnifying Glass (sDMG) is a multistrip detector designed for high spa-
tial resolution dose profiling in silicon and subsecond temporal resolution. The detector
consists of two linear arrays of 128 n+ silicon strip diodes fabricated on a p-type silicon
substrate with a single axis of detection. Each strip diode has an effective sensitive vol-
ume of approximately 2 mm × 50 µm × 100 µm at a pitch of 200 µm.
This study demonstrates that the sDMG detector is a fast and powerful independent QA
tool for therapeutic 12C ion beams. The sDMG was characterised for energy verifica-
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tion by measurement of the Bragg peak profiles for a 290 MeV/u 12C ion beam with the
silicon detector embedded at various depths in a PMMA phantom. The depths of the
Bragg peak in the silicon detector measured experimentally at the HIMAC facility and
using Monte Carlo simulations were found to fall within ±0.2 mm for the two methods
and consequently the calculated energy of the beam incident on the detector was found to
agree within experimental error. The reconstructed residual energy of the beam incident
on the PMMA phantom was determined to be (280.8 ± 0.8) MeV/ u from the experiment
and (280.8 ± 0.8) MeV/u from the simulation. The energy of the beam incident on the
phantom was found to agree with the expected energy.
Chapter 4
Validation of scanning pencil beam
phase-space and evaluation of proton
range definitions with Geant4
4.1 Overview
The various definitions of proton range are described in Section 2.1.3; in this chapter a
Geant4 application is used to determine the relationship between the mean range, CSDA
range, projected range and characteristic points on the Bragg peak physical depth dose
profile such as the depth of the peak maximum, 90%, 80% etc distal falloff positions
(R100, R90, R80 respectively). For clinical use a definition of range based on physical dose
characteristics is more applicable and practical. As such, range is often defined from the
peak or distal falloff positions for quality assurance practises.
Proton range in water is most commonly considered due to water conventionally being
a substitute to human tissue. Water-equivalent plastics (such as perspex) however, are
often used as a practical alternative. Further, as silicon diode detectors are characterised
for proton range verification in the following chapters, range definitions were additionally
evaluated in persex and silicon.
Variable range definitions were evaluated for two proton sources, an idealised monoener-
getic proton beam and a clinical spot scanning proton beam as defined by the phase-space
information for the beam characteristics at the proton centre at Mayo Clinic, Rochester.
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4.2 Geant4 simulation with Mayo phase-space
4.2.1 Proton Beam Facility at Mayo Clinic Rochester
The proton therapy facility at the Mayo Clinic in Rochester Minnesota is equipped with
one horizontal fixed beam room and four clinical rooms with 180◦ rotating gantries all fed
by a single synchrotron. The spot-scanning proton beam with energy modulation has a
total of 97 proton energies available varying between 71.3 MeV and 228.8 MeV covering
ranges approximately between 40 and 320 mm in water. Energies were selected in order
to achieve a consistent range spacing between consecutive energy layers. The spot size
of the beam both at isocenter and at the depth of the Bragg peak vary with energy and is
elliptical in shape, precessing with gantry angle.
The spot scanning proton beam line has been closely modelled in Monte Carlo simu-
lations using TOPAS and an independent in-house GPU based Monte Carlo dose verifi-
cation system has been established and extensively verified.
4.2.2 Validation of phase-space simulation
Phase space information from the TOPAS simulation of the Mayo clinic proton beam (in-
cluding proton position, energy and momentum direction) were scored distal to the final
monitor chamber and vacuum exit window with a total of 100 000 protons scored for each
available proton energy. The phase space information for each spot was used as input for
Geant4 simulations containing detector geometries of 1 and 2 dimensional silicon diode
detector arrays developed at CMRP: the dose magnifying glass (DMG-256) and the DUO
detectors, respectively.
The Geant4 simulation implementing the phase space proton beam data was verified for
physical dose and more specifically proton range in water by simulating the depth dose
profiles for a single central axis spot scored in a water phantom placed at isocenter. Geant4
version 10.02.p02 was used for simulations with the physics lists implemented shown in
table 8.2. The water phantom was defined using G4 WATER from the NIST material
database with the mean excitation energy of the water set to 75 eV. Energy depositions
were scored in 10 µm bins relative to the incident beam direction and integrated over the
whole phantom in the lateral directions.
A multi-layer ionisation chamber (MLIC) with a 200 µm resolution in the depth direc-
tion was used to measure the depth dose profile of central axis beam spots over the full
range of energies. Figure 4.1 shows the relative depth dose profiles measured with the
MLIC and from the Geant4 simulation implementing the phase space files for a subset
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Table 4.1: Geant4 Physics models used in the simulation physics list.
Physics processes Geant4 models
Electromagnetic physics G4EmStandardPhysics option3
Decay physics G4DecayPhysics
Radioactive decay physics G4RadioactiveDecayPhysics





of energies. The R80 range corresponding to the 80% dose falloff position of the Bragg
peak are plotted as a function of proton energy in figure 4.2a. The R80 position was
found by linear interpolation between measurement points for both experiment and sim-
ulation and the difference in the measured ranges are shown in figure 4.2b. The Bragg
peak width measured in water from the proximal-80%-to-distal-80% (lP80−D80) and distal
80% to 20% falloff width (l80−20) are plotted in figure 4.3. A strong correlation between
simulation and experiment was observed for the Bragg peak depth profiles and measured
ranges.
4.3 Materials and Methods
A 40×40×40 cm3 phantom of the given material was positioned at isocenter in air. Two
proton beam sources were investigated:
• Generic monoenergetic proton beams. Primaries were generated within a 5 mm
diameter on the beams’ central axis at a distance of 42 cm from the upstream face
of the phantom (to match the position of the phase space scoring plane used in the
second case). No variation in the primaries kinetic energy or momentum direction
was modelled. The primary energies considered were equal to the mean kinetic
energy of primaries stored in the phase-space for each beam energy.
• The Mayo Clinic phase space beam described and benchmarked in section 4.2.2
was assessed for all available proton energies. The characteristics of this beam
including the energy spread, momentum direction and spot size all vary with energy.
Both cases were considered in order to rule out range differences due to the slight energy
spread inherent in clinical pencil beams when comparing different range definitions. Ta-
ble 4.2 shows each phantom material as defined in the simulation and the same physics
list is used as in section 4.2.2 shown in table 8.2. The energy deposition and proton flu-
ence was scored as a function of depth in the phantom. The depth dose profile was used
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Figure 4.1: Relative depth dose profiles in a water phantom at isocenter for a single
energy central axis beam spot. Solid lines indicate the profiles measured experimentally
with the MLIC and “×” markers indicate simulated profiles integrated over the whole
phantom.
Table 4.2: Phantom materials defined in the simulation using the NIST material
database. Note the mean ionisation energy, I, of water was changed from default value
of 78 eV.
Phantom material Geant4 NIST material name Density (g/cm3) I (eV)
Water G4 WATER 1.00 75.0
Silicon G4 Si 2.33 173.0
Perspex G4 PLEXIGLASS 1.19 74.0
to determine R100, R90 etc. ranges (Bragg peak maximum and 90% falloff respectively)
from the physical doses. The fluence depth profile was used to determine mean range by
recording the depth at which the proton fluence is reduced to 50%, I50. These were com-
pared with CSDA range for the given proton energy calculated from the PSTAR database
and the projected range from SRIM.
4.4 Results and Discussion
An example of the fluence and dose profiles used to evaluate the different range defini-
tions is depicted in figure 4.4 for the 71.3 MeV proton beam in a perspex phantom. The
projected ranges from the PSTAR and NIST databases as well as the CSDA range from
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Figure 4.2: (a) Proton range at the 80% falloff position of the Bragg peak for the
full range of energies measured with the multi-layer ionisation chamber (MLIC) (black
crosses) and from the Geant4 simulation using the phase space data (red open circles).
(b) The difference in R80 range measured in experiment and simulation as a function of
proton energy.
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Figure 4.3: Pristine Bragg peak widths measured with the MLIC and from simulation
for the proximal-80%-to-distal-80% width (lP80−D80) and the distal-80%-to-distal-20%
falloff width.
the PSTAR database are also plotted here.
Figures 4.5 and 4.6 show the range difference to the mean range in water for varying
proton energy using the generic monoenergetic proton source and the phase-space source
respectively. The CSDA and projected ranges from the PSTAR database were found to
overestimate the range compared to the physical dose Bragg peak and mean ranges. The
SRIM projected range was found to have closest agreement with the Bragg peak max-
imum depth (R100) while the mean range was found to be most closely correlated with
the 90% dose falloff position for lower energies and with R95 at the upper end of proton
energies assessed. These findings were consistent between both the monoenergetic source
and that with slight energy variation from the phase-space. Figure 4.7 shows the range
difference between the monoenergetic and the phase-space sources for different defini-
tions. The R100 was found to be most susceptible to variation in proton energy at the
source, particularly at higher energies, while the R90 and R80 ranges were found to vary
less that ±0.05 mm. For the phase-space source considered in this study the mean range
was found to be larger than the monoenergetic source with a greater difference observed
at higher proton energies. This reflects the increasing energy spread with particle energy
in the phase-space source.
Figures 4.8 and 4.9 show the range difference to the mean range in silicon for vary-
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Figure 4.4: Proton fluence and dose for a 71.3 MeV proton beam from the phase-space
source as a function of depth in a perspex phantom. The mean range (I50) determined
from the fluence distribution is marked as well as the CSDA and projected ranges from
the PSTAR database and projected range from SRIM database.
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Figure 4.5: Proton range difference (R - I50) in water for various range definitions and
dose falloff points for a generic monoenergetic proton source.
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Figure 4.6: Proton range difference (R - I50) in water for various range definitions and
dose falloff points for the clinical proton beam from phase-space.
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Figure 4.7: Difference in proton range determined from the monoenergetic and phase-
space sources (Rgen−Rph−sp) in water.
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Figure 4.8: Proton range difference (R - I50) in silicon for various range definitions and
dose falloff points for a generic monoenergetic proton source.
ing proton energies for the monoenergetic and phase-space sources respectively. For both
proton sources the R90 range has excellent agreement with the SRIM projected ranges and
has the closest agreement to the mean range at lower energies. Above approximately 160
MeV the 95% dose falloff has the best agreement with the mean range.
The differences in range observed for varying definitions are more closely correlated in
silicon due to the greater stopping power and density. Figure 4.10 shows the difference in
range in silicon between the monoenergetic and the phase-space proton sources, similarly
to water a higher discrepancy in the mean range is observed for the larger proton energies
while R90 and R80 are more consistent between the two sources and more robust to minor
energy variation in the beam spot.
The difference to the mean range for varying range definitions is depicted in figure 4.11
for the monoenegetic source and in figure 4.12 for the phase-space source in a perspex
phantom. Figure 4.13 shows the difference in range definitions between the two proton
sources. Similar trends were observed to the case in water however the SRIM projected
range was found to be shorter than the Bragg peak maximum depth in this case, particu-
larly for the monoenergetic source.
The width of the Bragg peak from the proximal to distal 80% dose points and the distal
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Figure 4.9: Proton range difference (R - I50) in silicon for various range definitions and
dose falloff points for the clinical proton beam from phase-space.
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Figure 4.10: Difference in proton range determined from the monoenergetic and phase-
space sources (Rgen−Rph−sp) in silicon.
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Figure 4.11: Proton range difference (R - I50) in perspex for various range definitions
and dose falloff points for a generic monoenergetic proton source.
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Figure 4.12: Proton range difference (R - I50) in perspex for various range definitions
and dose falloff points for the clinical proton beam from phase-space.
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Figure 4.13: Difference in proton range determined from the monoenergetic and phase-
space sources (Rgen−Rph−sp) in perspex.
falloff width from the 80% to the 20% dose points are shown in figure 4.14. As expected,
the peak widths increase with proton energy as a result increased multiple scattering re-
sulting in more pronounced range straggling. While the lP80−D80 is more sensitive to
variation in the primary proton energy spread, seen in larger discrepancies between the
monoenergetic source and clinical phase-space source, the lD80−D20 distal falloff width
was found to have closer agreement between the two cases. The Bragg peak physical
dose characteristics and mean range defined by the falloff in proton fluence was observed
to be more reproducible and less susceptible to energy variation with increasing material
density and relative stopping power.
4.5 Conclusion
A Geant4 Monte Carlo application was used to compare varying definitions of proton
range over clinically applicable energies for both a generic monoenergetic pencil beam
source and from the Mayo clinic phase-space library of pencil beams specific to their
center; water, perspex and silicon phantom materials were considered. The CSDA range
from the NIST database was found to consistently overestimate the proton range for all
materials and energies investigated. The 90% dose falloff position was found to have the
best agreement with the definition of mean proton range for energies up to approximately
160 MeV beyond which the mean range tends closer to the maximum dose position in
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Figure 4.14: Bragg peak width between proximal and distal 80% doses (lP80−D80) and
falloff width from the distal 80% and 20% doses (lD80−D20) in water, silicon and perspex
phantoms for the clinical phase-space source.
the Bragg peak. SRIM projected ranges for the mean proton energy correspond best with
the Bragg peak maximum for water and perspex however for silicon they very closely
reproduce the R90. The mean range and R100 were found to be least consistent between
the source types while R90 and R80 ranges and the distal falloff width were found to show
less variation with the introduction of slight energy fluctuations.
Based off the data presented here it is recommended that the R90 range be used to de-
fine proton range for monoenergetic beams in clinical PBS applications; this value was
found to best represent the mean particle range (as defined by the fluence) for varying
materials and is consistent with slight energy variation. For range measurements in sil-
icon, the mean incident proton energy can be accurately determined using the R90 and
corresponding SRIM projected range.
Chapter 5
Characterisation of the DMG dosimeter
to determine range in silicon for
therapeutic proton beams
5.1 Overview
Radiation therapy with charged particles is associated with sharp dose gradients both in
the lateral direction and with depth, particularly in the Bragg peak region. Further, ac-
tively scanned particle beams have small geometries and as such verification of the phys-
ical dose characteristics of the pencil beam and the spot position are crucial. It is due to
this that dosimeters with high spatial resolution and large dynamic range are required for
quality assurance practises in clinics. The DMG dosimeter is well suited for “single shot”
dose profiling as its array of small, well defined sensitive volumes with a sub-millimetre
pitch are readout individually and simultaneously. This allows for whole profiles to be
obtained with a single beam spill without the detector needing to be moved in depth or
within the field; making in a time effective tool.
In this chapter the response of the DMG is characterised for measurement of proton range
in a silicon with both Geant4 Monte Carlo simulation and from experimental measure-
ments with the DMG in the spot-scanning proton beam at Mayo Clinic in Rochester.
Three DMG detector housing configurations were assessed for both cases and a rigor-
ous analysis of the detector alignment and setup sensitivity for range measurement was
performed.
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5.2 Material and Methods
5.2.1 Monte Carlo Application
A geant4 application incorporating the DMG detector geometry for variable setup and
phantom geometries with an interchangeable proton source was used to investigate the
response of the detector for range determination in silicon. The application was divided
into three separate setups created to mimic phantom geometries available at the Mayo
clinic proton therapy centre for the experimental investigation. Geant4 version 10.04.p02
was used.
DMG detector model
The external dimensions of the modelled monolithic silicon wafer are 0.45 × 4.0 ×
51.4 mm3 consistent with the real detector. The 256 pixels have a pitch of 200 µm,
the implant area of each is 20 × 2000 µm2 on the surface of the wafer and the sensi-
tive volume used to score energy depositions extends a depth of 45 µm into the wafer.
The kapton carrier and electrical contacts for the pixels were also modelled to meet the
detector specifications. The DMG sensitive volumes
Proton source
Primaries were generated from one of three sources:
• Generic proton beam. Beam specifics controlled through user defined parameters.
The primary proton kinetic energy (with or without gaussian spread), starting plane,
field size and momentum spread were adjusted in order to observe effects of field
geometry on the DMG detector response.
• Phase space files for the spot-scanning proton beam at Mayo Clinic. Phase
space files, discussed and verified in section 4.2.2, were implemented with the ori-
gin of the simulation axes aligned with isocenter in the clinical setup. As such pri-
mary proton kinetic energy, lateral starting position and momentum direction were
read in from the phase space and shot from a plane 42 cm upstream of the isocenter
(scoring plane after the vacuum exit window). Although the phase space defined
proton beams were verified for range and therefore energy, the simulation defined
spot is circular, while the clinical beam is an ellipse that precesses with gantry angle.
A total of 100 000 primary protons were used for each clinically available proton
energy and these were recycled approximately 1000 times per profile measured.
• Aggregate proton source. The kinetic energy of primaries read from the phase
space files are implemented in conjunction with a user defined beam size and mo-
mentum spread. The position of primaries and momentum direction were generated
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at random. This proton source allowed the affect of the beam shape and size on the
DMG energy deposition profile to be investigated and compared to experimental
measurements.
A horizontal beam trajectory (90◦ gantry angle) was used for experimental measurements
due to ease of setup and hence also used for the simulated proton beams described above.
Simulation parameters
The physics lists used to define particle interactions with matter are the same as those
shown in table 8.2. The maximum step length allowed within the sensitive volumes and
silicon wafer of the DMG was set to 2 µm to ensure accurate energy deposition scor-
ing. The simulation was optimised by implementing cuts per region to help minimise
computational time while maintaining dosimetric accuracy in regions of interest. This
function limits the production and tracking of photons, electrons and positrons based on
their projected range. The threshold for the production of these particles was applied in-
crementally to volumes surrounding the detector such as phantom materials.
The phase space scoring plane (described in the previous section) is positioned down-
stream of the treatment nozzle in air and the simulated world volume was made large
enough to accommodate the proton trajectory from that point. The DMG detector simu-
lated in conjunction with different phantom configurations was modelled to replicate the
corresponding experimental setup however the patient couch used to support the detector,
its base and electronics in experiment was excluded as this was outside of the scanning
beam path. The Geant4 NIST materials database was used to define detector and phantom
materials.
5.2.2 DMG configurations
Different detector configurations were investigated to measure proton range in silicon.
The “in air” configuration was considered in order to determine the response of the detec-
tor in isolation and a custom built perspex phantom encapsulating the detector with inserts
to position energy degraders proximal to the detector. This phantom provided mechanical
rigidity for the flexible kapton carrier that the DMG wafer is mounted on and allowed for
accurate, quick and reproducible setup. The two setups were evaluated and compared for
range in silicon measurements for proton energies up to ~110 MeV with range in silicon
less than the length of the DMG detector. The latter setup is also assessed for range ver-
ification of higher energy protons with range in silicon exceeding the length of the DMG
by positioning brass degradation blocks upstream of the detector.
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For all experimental measurements the DMG was setup on the patient couch in the treat-
ment rooms positioned at isocenter on the central beam axis. This allowed 6 degrees of
freedom to align the detector with the incident proton beam and relative to isocenter with
aid of the external laser system in the treatment room. The couch can be translated with
an accuracy of 0.1 mm and the pitch, yaw and roll angles set to the nearest 0.1◦. Further a
digital level was used to assure the DMG was as orientated correctly on the patient couch
for measurement.
In air
In order to simplify detector geometry and investigate the response of the detector for pro-
tons traversing the DMG (and kapton base) only, without interference from surrounding
phantom materials, an “in air” setup was used. For the Geant4 simulation this is eas-
ily achieved by suspending the detector in air at isocenter. For the experimental setup
however the DMG was positioned on foam blocks on the patient couch. The foam has a
very low density and has little perturbation of the beam while still providing the rigidity
required for accurate alignment of the detector. As such the foam blocks provided the
closest approximation to the detector suspended in air.
Figure 5.1 shows the DMG detector setup on the patient couch at Mayo clinic for the
“in air” configuration.
Open-air, perspex base phantom
A custom built phantom, shown in figure 5.2, made from perspex was used to house the
DMG detector. The phantom consists of a recess approximately 1 cm high, with the width
of the kapton material holding the fan-out array for connection to the DAQ. The recess
extends beyond the length of the DMG carrier so that the silicon wafer is surrounded by
air above and on either side while still resting on a Perspex base. The phantom is open on
the proximal side of the detector with slots to insert up to 12 brass pieces each 5 mm thick.
This design allows for the energy of the proton beam to be degraded before incidence on
the detector and for the range for high energy protons, with range in silicon exceeding
the length of the DMG, to be determined. The phantom provides support of the detector
and electronics and allows the DMG to be setup on the patient couch in a reproducible
manner.
5.2.3 Range from DMG Bragg profile
The various definitions of proton range are discussed in section 2.1.3. Further, in chapter
4, it was demonstrated that the R90 range is correlated most closely with 50% falloff in
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Figure 5.1: Experimental setup for the DMG “in air” configuration. The blue arrow
indicates the incident direction of the spot scanned proton beam on the DMG wafer
aligned at isocenter.
proton fluence and projected ranges from the SRIM database using the mean proton ki-
netic energy from the phase-space, compared with the Bragg peak maximum and other
distal falloff points on the Bragg profile. Despite this, the shape of the Bragg profile
measured with the DMG varies to conventional detectors due to its geometry and as such
multiple points on the DMG recorded profile were considered. For range measurements
with the DMG the R100 range was taken from the depth of the channel with the maximum
dose response in the Bragg peak region and the R90 and R80 ranges were found from linear
interpolation of channel responses to find the 90% and 80% falloff positions respectively.
The R100 values presented therefore have a maximum resolution of 200 µm equal to the
pitch spacing between consecutive sensitive volumes.
For proton energies with ranges that exceed the length of the DMG, the perspex base
phantom was trialled with brass range shifting blocks placed upstream of the detector.
For this case the silicon-equivalent-thickness (SET) of the brass blocks was determined
in order to translate the recorded Bragg peak position in the DMG to the absolute range
in silicon only. The SET was calculated using equation 5.1 where RSi(T ) is the Bragg
peak depth recorded in the silicon DMG for range shifting brass thickness T for a given
proton beam energy. The range difference was computed under consistent conditions ie.
experiment or simulation with proximal or distal brass stacking independently.
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Figure 5.2: Experimental setup for the DMG in a custom built perspex phantom config-
uration: (a) angled and (b) top-down view of perspex phantom with brass blocks inserted
for beam degradation, (c) phantom setup on patient couch for acquisition (blue arrow
indicating incident direction of spot scanning proton beam) and (d) close-up of DMG




By converting the brass range shifter to the silicon-equivalent-thickness the absolute
proton range in silicon is determined from the measured peak position in the DMG RDMG,
the SET and the brass thickness T according to equation 5.2.
RSi−Absolute = RDMG+SET ×T (5.2)
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5.2.4 Alignment and setup sensitivity analysis
Spot scanned proton beams generally have Gaussian shaped fluence across the spot and
are more prone to scattering and beam divergence than heavier ions used for therapy;
this leads to a significant reduction in particle fluence along the central axis with depth.
The combination of small beam geometries with small volume detectors, such as with
the DMG dosimeter, results in increased sensitivity to setup and alignment for obtaining
depth dose profiles due to varying proton fluence. This section aims to evaluate the toler-
ance to setup errors resulting in misalignment of the DMG detector and the sensitivity of
the determined range in silicon for the Mayo clinic proton scanning beam.
The “in air” simulated DMG configuration was used to evaluate the sensitivity of the
measured range to setup errors including lateral and vertical offsets from the central axis
and angular misalignment of the detector in the yaw and pitch directions. The DMG was
first positioned in the ideal orientation with the front of the detector at isocenter and its
axis of detection aligned with the central axis and incident beam direction. The Bragg
profile measured with the DMG detector was used to determine the particle range in sili-
con for proton energies 71.3 MeV and 102.1 MeV. These energies where selected as their
ranges in silicon result in the Bragg peak being positioned in the front and back half of
the detector respectively. As such the alignment sensitivity could be assessed for different
proton path lengths in the silicon detector.
Bragg profiles were obtained at the same energies with the DMG misaligned as depicted
in figure 5.3. The middle of the DMG wafer was fixed on the central axis and rotated
about the horizontal axis for the pitch and the vertical axis for the yaw misalignments.
The pitch was varied between -0.5◦ and 2◦ where the positive direction of rotation indi-
cates the proximal end of the detector moving down and the distal end moving up relative
to the beams-eye view. It should be noted that in the positive pitch direction the beam only
traverses air before the detector however in the negative direction the beam first crosses
the thin kapton carrier that the silicon wafer of the DMG is mounted on. Yaw angles from
0◦ to 6◦ were considered (rotating to one side only due to detector symmetry). The affect
of translational offset of the detector was assessed by holding the DMG parallel to the
CAX and translating it up to 6 mm in the horizontal and vertical directions.
The determined range and Bragg profile shapes were compared to the ideal case for each
misalignment direction assessed.
CHAPTER 5. DMG FOR PROTON RANGE IN SILICON 64
Figure 5.3: Schematic of DMG detector with (a) lateral and (b) vertical offset from
the central beam axis, angular misaligment in the (c) pitch and (d) yaw directions. The
blue arrow indicates the incident direction and central axis of the proton beam spot;
schematics show a bird’s-eye view of the detector except for the bottom one showing a
side on view.
5.3 Results and Discussion
5.3.1 Detector response for varying proton energies
The DMG silicon wafer is approximately 52 mm along the axis of detection and thus, in
the edge-on orientation investigated in this chapter, the Bragg peak portion of the depth
dose curve can be measured for protons with range in silicon less than this without prior
beam moderation. In this case both the “in air” and open-air, perspex base phantom con-
figurations are applicable and are compared.
The perspex base phantom with brass blocks, inserted upstream of the detector for energy
degradation, was investigated for energies greater than ~110 MeV with range in silicon
exceeding the DMG length. Further as the Bragg peak becomes more difficult to resolve
with increasing depth in the detector, this arrangement was trialled to shift the Bragg peak
to the proximal end of the detector.
Comparison between phantom and DMG depth dose
Relative depth dose profiles for a single monoenergtic spot delivered at isocenter scored
in a 40 × 40 × 40 cm3 solid silicon phantom and with the DMG for the “in air” config-
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Figure 5.4: Simulated depth dose profiles in a solid silicon phantom and that scored in
the DMG detector for the “in air” configuration.
uration are shown in figure 5.4. Here the profiles are normalised to the maximum energy
deposition in a given profile. The response in the proximal end of the simulated DMG
depth profile is large and in most cases greater than the energy deposited at the Bragg
peak. This is attributed to multiple scattering of protons resulting in an increasing spot
size with distance from the source. As such the proton flux decreases along the central
axis of the beam and therefore the number of protons traversing the silicon wafer of the
DMG diminishes with depth in the detector. This characteristic of the depth dose profile
measured in silicon with the DMG is accentuated with increasing proton range as demon-
strated by the relative entrance to Bragg peak response with increasing nominal proton
energy. Energy deposition profiles scored in the phantom are integrated laterally over
each slice of the phantom and hence are not affected by spot divergence.
The consistent dose tail beyond the Bragg peak for profiles scored in the DMG is caused
by protons scattering from the air surrounding the DMG into the senstive volumes of the
detector. Due to the significantly lower stopping power of air these protons have a much
greater range and contribute to the response along the entire length of the DMG.
The difference in the range determined from simulated depth dose profiles in the sili-
con phantom and in the DMG are presented in figure 5.5. The R100 range from DMG
profiles is consistently greater than in the phantom while falloff points R90 and R80 are
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Figure 5.5: Difference in simulated proton ranges from depth dose profiles in a solid
silicon phantom and with the DMG, the difference in R90 and SRIM projected range (+)
is also plotted.
smaller with increasing discrepancy in range values with increasing proton energy and
path length in the silicon detector. This is attributed to loss of peak resolution with in-
creasing range in the detector. The R90 range is shown to have the closest agreement to
the ranges determined in the phantom.
Range in silicon < DMG length
The relative response profiles measured with the DMG “in air” for varying proton ener-
gies from experiment and simulation are depicted in figures 5.6 and 5.7 respectively. The
difference in the ranges for the two are plotted for varying proton energy in figure 5.8. A
maximum deviation of± 0.2 mm was found between experimental and simulated profiles
measured with the DMG up to 105 MeV. The response at the Bragg peak was seen to be
more pronounced compared to that at the entrance for the experimental data, likely due to
the difference in the spot shape which is elliptical in reality but circular in the phase-space
used for the simulation. A similar dose tail beyond the Bragg peak was observed between
the two cases. It should be noted that data is normalised to the response at the entrance
however for the experimental profiles the first channels were excluded due to skew equal-
isation factors effecting these channels.
Figures 5.9 and 5.10 show the relative response profiles measured with the DMG in the
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Figure 5.6: Relative depth profiles measured with the DMG detector in the “in air”
configuration for varying proton energies.
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Figure 5.7: Relative depth profiles from simulation of the DMG detector in the “in air”
configuration for varying proton energies.
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Figure 5.8: Difference in ranges measured with the DMG in experiment and simulation
for the “in air” configuration.
open-air perspex base phantom from experiment and simulation respectively; the range
differences between the two are presented in figure 5.11. Recorded ranges were consis-
tent within± 0.2 mm for R100 and± 0.1 mm for R90 between experiment and simulation.
The simulated profiles feature a bump proximal to the Bragg peak that is not observed
in experimental data. It is assumed that this is due to the kapton carrier of the detector
sitting inset and flush with the perspex base in the simulation. In reality a slight airgap is
anticipated to exist between the two. As such a greater scatter contribution from protons
in the perspex based are expected in the simulation that contribute to the peak.
Figure 5.12 shows the differences in ranges determined from experimental DMG profiles
in the “in air” and open-air perspex base phantom. The Bragg peak maximum fell at the
same channel for the two setups for all bar one energy (with 1 channel difference) and
R90 ranges were well within 0.1 mm. The major differences seen in the profiles were in
the increased dose tail and secondary peak formation (perspex peak) observed with the
perspex base phantom. Despite variable scattering conditions and slight variations in the
profile shapes obtained the determined ranges were found to be independent of the setup
configurations.
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Figure 5.9: Relative depth profiles measured with the DMG detector in the open-air,
perspex base phantom for varying proton energies.
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Figure 5.10: Relative depth profiles from simulation of the DMG detector in the open-
air, perspex base phantom for varying proton energies.
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Figure 5.11: Difference in ranges measured with the DMG in experiment and simulation
for the open-air, perspex base phantom.
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Figure 5.12: Difference in experimentally measured ranges with DMG “in air” and in
the open-air, persex base phantom.
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Range in silicon >= DMG length
In the previous section the DMG was found to accurately determine proton range in sili-
con for energies up to approximately 105 MeV, however peak resolution becomes difficult
to resolve with increasing proton range in the detector and higher clinically applicable en-
ergies cannot be measured. As such the open-air, perspex-base phantom was investigated
with range shifting brass blocks placed in front of the phantom. This would allow for
the Bragg peak to be shifted to shallower depths in the DMG in order to maintain a more
pronounced peak and to determine range for higher energy protons.
The phantom allows for up to 65 mm of brass to be stacked in inserts before the de-
tector; the upstream position of the stacked brass was found to affect the shape of the
profile obtained. As such two stacking configurations were assessed: the proximal posi-
tion, where blocks were placed in the most upstream positions available, and in the distal
position, closest to the DMG detector. For reference see figure 5.2(a) and (b) where the
brass is stacked in the distal position. For clinical applications range shifters are gener-
ally positioned as close to the patient surface as possible so that the spot size can be kept
smaller allowing shaper penumbra to the treatment field delivered. Despite this, the small
volume of the detector allows only for protons with momentum direction almost parallel
to the CAX to contribute to the Bragg peak. Protons with greater divergence angles, how-
ever, will contribute to signal proximal to the peak but scatter outside the detector prior to
their end of range. As such proximal brass stacking could be advantageous to allow beam
divergence prior to the detector thereby minimising contribution from protons that will be
directed outside the silicon wafer. Therein lies the rationale for assessing both stacking
configurations.
Figure 5.13 shows the DMG response profiles both from experiment and simulation for
proton energies 102.1 MeV, 126.0 MeV, 150.3 MeV, 175.6 MeV and 200.4 MeV with
varying brass thicknesses before the detector. While shifting the brass from proximal to
distal stacking positions resulted in varying shape of the obtained profile and most com-
monly a reduction in the relative peak height, the recorded Bragg peak positions were
found have a maximum difference of 0.4 mm for R100 and 0.3 mm for R90 for a given en-
ergy and thickness. The maximum difference between simulated and experimental R100
and R90 ranges were 0.6 mm and 0.5 mm respectively; relatively poor correlation between
the profile shapes were observed.
The SET values calculated from the difference in peak position measured in the DMG
for varying thicknesses of brass (see equation 5.1) plotted as a function of proton energy
in figure 5.14. The range difference measured in silicon was found to be dependent on the
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Figure 5.13: Relative depth profiles measured with the DMG in the open-air, perspex
base phantom with varying brass thicknesses for energy degradation for (a) 102.1 MeV
(b) 126.0 MeV (c) 150.3 MeV (d) 175.6 MeV and (e) 200.4 MeV proton beams.
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Figure 5.14: Silicon-equivalent-thickness (SET) of brass calculated using the differ-
ences in R100 and R90 ranges measured at varying brass thicknesses and incident proton
energies.
point on the Bragg profile used for the range. The range difference and hence equivalent
silicon thickness for the 90% falloff was greater than when using the peak maximum over
the energies assessed. No clear dependence of the SET on initial proton energy was ob-
served. The mean SET over all energies assessed was 2.97 ± 0.03 when using R100 and
3.06 ± 0.04 when using R90. This calculated value falls close to the ratio of the densities
of the two materials.
The absolute range in silicon was determined using equation 5.2, for each block thick-
ness and primary proton energy and compared to the SRIM projected ranges in silicon.
The range difference between the SRIM projected range and the absolute range in silicon
calculated using the SET from R100 and R90 are plotted in figure 5.15. The SET calcu-
lated using the R90 position of the Bragg peak over estimates the true value, seen in the
increasing range discrepancy with increasing brass thickness used (for increasing proton
energy). While the R100 calculated SET results in better agreement between SRIM pro-
jected range and the calculated absolute range in silicon, range discrepancies are still are
on the order of±1 mm. Such discrepancies are inadequate for quality assurance purposes
and as such this method of range determination using brass degradation in combination
with the DMG was found to be ineffectual.
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Figure 5.15: Mean difference in SRIM projected range and the absolute range in silicon
calculated from the DMG Bragg profile and the silicon-equivalent-thickness (from R100
and R90) of brass upstream.
5.3.2 Detector response for varying incident field sizes & shapes
Field size
Figure 5.16 shows the DMG response for varying incident field sizes compared with the
phase-space pencil beam. For the square fields the aggregate proton source was used
whereby the proton energy is read in from the phase-space and the starting position on
the phase-space plane is randomly generated within the prescribed field size. The beam
fluence for each case was held constant with varying field size. The measured range
is unaffected by variation in the field size, for the cases considered the R100 range was
the same; R90 and R80 ranges varied less than ±0.03 mm, no more significant that the
statistical uncertainty in the simulated profiles.
Spot ellipticity
The DMG response to varying spot ellipticity is displayed in figure 5.17. The phase-space
beam spot ellipticity is varied here by squeezing or stretching the spot in the lateral or
vertical direction by scaling the respective starting coordinate on the phase-space starting
plane by the factor shown. The measured range is unaffected by variation in the spot
ellipticity, for the cases considered the R100 range was the same; R90 and R80 ranges varied
less than ±0.02 mm, no more significant that the statistical uncertainty in the simulated
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Figure 5.16: Relative dose response profiles measured with the DMG detector for the
phase-space pencil beam and for varying field sizes for a 71.3 MeV proton beam centred
on isocenter.
profiles. The DMG response profile is seen to be more sensitive to the dispersion of
protons in the vertical direction than the horizontal direction.
5.3.3 Alignment setup and sensitivity analysis
The relative energy deposition profiles measured with the DMG at varying lateral offsets
for proton energies 71.3 MeV and 102.1 MeV are shown in figures 5.18a and 5.19a re-
spectively. The DMG measured response for an ideal detector alignment is depicted by
the black line and all data is normalised to the sensitive volume with the maximum energy
deposition in the ideal case. The range difference to the ideal case for varying lateral off-
sets are plotted in figure 5.18b for the 71.3 MeV beam and in figure 5.19b for 102.1 MeV
protons. The R90 and R80 ranges were relatively stable within a ±0.05 mm deviation for
all offsets with the lower energy and up to a lateral offset of 5 mm for the 102.1 MeV spot
which is well beyond the expected setup uncertainty. The R100 ranges varied no more than
one sensitive volume pitch spacing.
Figure 5.20 shows the energy deposition in the first sensitive volume of the DMG and
at the Bragg peak position as a function of detector offset from the central axis for both
energies considered. This figure illustrates the Gaussian shape of the beam spot and com-
pares the energy deposition at the maximum position (the entrance pixel) to that at the
CHAPTER 5. DMG FOR PROTON RANGE IN SILICON 76
Depth in Silicon (mm)

























Figure 5.17: Relative dose response profiles measured with the DMG detector for the
phase-space pencil beam with varying ellipticity for a 71.3 MeV proton beam centred on
isocenter.
Bragg peak. As the lateral offset of the detector is increased the variation in proton flux
along the length of the DMG is less severe, the entrance region of the profile flattens out
and the ratio of energy deposited at the entrance to Bragg peak approaches unity.
For vertical shifts in the detector position, DMG recorded profiles and range differences
are shown in figures 5.21 and 5.22 for the 71.3 MeV and 102.1 MeV beams respectively.
For the lower energy case the maximum R90 deviation was again within ±0.05 mm how-
ever greater range differences were observed for the greater energy spot;±0.2 mm up to a
4 mm vertical offset. The range was generally overestimated for inferior shifts and under-
estimated for shifts in the superior direction. R100 was robust within 1 sensitive volume
spacing for vertical offsets up to 6 mm.
The DMG response profiles for protons with energies of 71.3 MeV and 102.1 MeV with
introduced pitch angular misalignments are plotted in figures 5.23 and 5.24 respectively.
For this misalignment scenario the relative intensity of the Bragg peak increases with the
magnitude of the angular setup error up to around 1◦. Consequently the “dose tail” be-
yond the Bragg peak increases as more of the detector is presented to protons travelling
uninhibited through air above the detector before incidence. This large contribtion to sig-
nal beyond the Bragg peak prevents distal falloff points from being determined. For the
102.1 MeV case and greater detector pitch angles the peak becomes indistinguishable.
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Figure 5.18: (a) Relative dose response profiles measured with the DMG detector and
(b) corresponding range difference to ideal setup for varying lateral offsets from the beam
central axis for a single 71.3 MeV proton beam spot delivered at isocenter.
While R100 range values fell within ±0.2 mm for pitch angles up to 2◦ and 1.5◦ for the
lower and higher range beams assessed, respectively, a strong dependence on the R90 with
pitch is observed. R90 range differences to the ideal case were beyond 1 sensitive volume
spacing for pitches greater than 1◦ for the lower energy beam however were in excess of
0.6 mm for angles greater than 0.5◦ for the higher energy spot.
Figure 5.25 shows the DMG profiles for introduced yaw misalignments and the deter-
mined range differences for the 71.3 MeV beam; figure 5.26 shows the same for the 102.1
MeV case. This angular misalignment was much less sensitive than for the varying pitch
scenario however peak resolution was again seen to decrease with increasing setup error.
At 71.3 MeV, R90 and R100 were stable within ± 0.2 mm up to 4.5◦ and 6◦ respectively
and both up to 3◦ for 102.1 MeV. For yaw angles greater than 3◦ the peak couldn’t be
clearly resolved.
5.4 Conclusion
The DMG was characterised for determination of proton range in silicon for single mo-
noenergetic pencil beam spots. The small volume silicon multichannel detector features
well defined sub-millimetre sensitive volumes that are read out in parallel allowing ion
beam ranges to be determined at a high spatial resolution in the delivery of a single beam
spill.
The R90 range measured with the DMG was shown to have strong agreement to that
in a solid silicon phantom and to the SRIM projected ranges in silicon for energies up
to approximately 105 MeV. Reproducible range values were obtained between experi-
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Figure 5.19: (a) Relative dose response profiles measured with the DMG detector and
(b) corresponding range difference to ideal setup for varying lateral offsets from the beam
central axis for a single 102.1 MeV proton beam spot delivered at isocenter.
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1 71.3 MeV - Entrance
71.3 MeV - Bragg peak
102.1 MeV - Entrance
102.1 MeV - Bragg peak
Figure 5.20: Relative response measured in the first DMG channel and at the Bragg peak
channel for varying lateral offsets for both 71.3 MeV and 102.1 MeV proton beams.
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Figure 5.21: (a) Relative dose response profiles measured with the DMG detector and
(b) corresponding range difference to ideal setup for varying vertical offsets from the
beam central axis for a single 71.3 MeV proton beam spot delivered at isocenter.
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Figure 5.22: (a) Relative dose response profiles measured with the DMG detector and
(b) corresponding range difference to ideal setup for varying vertical offsets from the
beam central axis for a single 102.1 MeV proton beam spot delivered at isocenter.
mental and simulated setups both for an “in air” configuration and when using the DMG
in conjunction with an open-air perspex base phantom with a maximum deviation in the
measured range of±0.2 mm, equal to the spacing between consecutive sensitive volumes.
The Bragg peak resolution and accuracy of the determined ranges deteriorated with inci-
dent proton energy and hence range in the silicon wafer.
Measured ranges were found to be consistent for independent setups, the DMG deter-
mined ranges were found to be robust within reasonable angular and translational setup
errors and unaffected by the spot shape or incident field size. The R90 range is recom-
mended to define the proton range from the measured Bragg peak due to best agreement
with expected proton ranges in silicon.
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Figure 5.23: (a) Relative dose response profiles measured with the DMG detector and
(b) corresponding range difference to ideal setup for varying pitch misalignment angles
with respect to the beam central axis for a single 71.3 MeV proton beam spot delivered
at isocenter. Here the positive direction refers to the proximal end moving down and the
distal end of the detector moving up in the beams-eye view.
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Figure 5.24: (a) Relative dose response profiles measured with the DMG detector and
(b) corresponding range difference to ideal setup for varying pitch misalignment angles
with respect to the beam central axis for a single 102.1 MeV proton beam spot delivered
at isocenter.
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Figure 5.25: (a) Relative dose response profiles measured with the DMG detector and
(b) corresponding range difference to ideal setup for varying yaw misalignment angles
with respect to the beam central axis for a single 71.3 MeV proton beam spot delivered
at isocenter.
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Figure 5.26: (a) Relative dose response profiles measured with the DMG detector and
(b) corresponding range difference to ideal setup for varying yaw misalignment angles
with respect to the beam central axis for a single 102.1 MeV proton beam spot delivered
at isocenter.
The perspex phantom with range shifting brass blocks was trialled for range determina-
tion for proton energies exceeding 105 MeV and equivalent ranges in silicon were found
to be inconsistent with expected values. It was concluded that this method for range mea-
surement for higher energy protons was too inconsistent and unsatisfactory for quality
assurance practises. Alternate range measurement methods using the DMG for the full
range of clinical energies is evaluated in the following chapters.
Chapter 6
Design and evaluation of DMG angled
phantom system to determine range in
perspex
6.1 Overview
In the previous chapter, the edge-on configuration of the high resolution DMG detector
was assessed for range verification of spot scanning proton beams in silicon. This ar-
rangement was found to be limited to proton energies up to approximately 100 MeV and
exhibited a loss of peak resolution and range determination accuracy with increased pro-
ton range in the silicon detector. In order to address the shortcomings of this method and
to diversify the applicability of the DMG to range measurements over the full range of
clinically available energies, an alternate method of range measurement is employed in
this chapter. Here, the DMG is used to measure range in perspex, a tissue equivalent and
readily used material in clinics.
The Geant4 Monte Carlo application of the DMG detector, described previously, was
adapted to design and optimise an angular perspex phantom to house the DMG so that
pixels vary in depth in the perspex material. Such a setup allows the relative energy de-
position profile to be measured as a function of depth in perspex. The phantom design
presents a compromise between maximising the angle from the DMGs axis of detection
to the normal of the beam direction, and hence the depths in perspex sampled, and having
the profile shifted proximally due to protons traversing multiple silicon sensitive volumes.
Flat treatment plans were generated and delivered to the DMG detector in the angled
phantom setup to measure the Bragg peak profile and determine the proton range. The
phantom design was fabricated and tested for the spot scanning proton beam at Mayo
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Clinic for a number of proton energies and detector depths. The accuracy of the range
measurements from the experimental investigation of the detector is assessed and a sig-
nal processing method is presented for the prolonged acquisitions as the pencil beam is
scanned over the detector.
6.2 Optimisation of phantom design
The Geant4 application described in 5.2.1 was adapted to find the optimum detector and
phantom setup for measuring proton range in perspex using the DMG detector. The depth
response profiles simulated with the DMG at varying depths and angles relative to the
normal of the incident beam direction were compared to those scored in a perspex phan-
tom alone. Shifts in the Bragg profile with changing angle were compared by assessing
the differences in the measured range.
In order to measure the relative dose at varying proton path lengths with this setup a flat
proton field in the beams-eye view projection of the DMG is required. This was achieved
using the aggregate beam source (see section 5.2.1) and a 60 mm × 5 mm rectangular
field. Multiple beam energies over those clinically available were assessed with varying
peak position relative to the DMG position. From this data the maximum angle that could
accurately reproduce the expected Bragg peak position was chosen.
The simulated DMG response profiles for varying detector angles are plotted with the
relative energy deposition profile scored in the solid perspex phantom in figure 6.2a for
flat proton fields at the low end of clinically available energies. The range differences de-
termined from these profiles are plotted as a function of detector angle to the beam normal
in figure 6.2b. Similarly, the DMG profiles and range differences for the upper limit of
clinical proton energies are plotted in figure 6.3.
An elevated dose response is observed in the entrance channel when comparing the DMG
profiles to those measured in perspex. The falloff region of the Bragg peak however shows
closer agreement between the two. These trends are due to variation in the stopping power
ratio (SPR) of silicon to perspex as plotted in figure 6.1. The SPR is relatively constant
around 1.62 for energies above ~70 MeV resulting in higher doses deposited in the sili-
con wafer for protons entering the phantom. As the protons loose kinetic energy the SPR
approaches unity, explaining the strong agreement in the Bragg peak and falloff region.
For lower proton energies the Bragg peak maximum (R100) measured with the DMG
was proximally shifted compared to the expected position in perspex; this discrepancy
was seen to increase with the DMG angle. Distal falloff positions were found to be more
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Figure 6.1: Silicon to perspex stopping power ratio (SPR) over clinically relevant proton
energies. Data plotted here was taken from the NIST PSTAR database [42].
robust to variation in the DMG angle with little-to-no change for angles up to 60◦. At a
detector angle of 70◦ to the normal of the beam CAX an obvious elevation in the rela-
tive dose in the entrance and a proximal shift in the peak and distal falloff positions were
seen. At this angle protons begin to traverse multiple sensitive volumes of the detector
and the increased path length in silicon results in a diminished range causing the peak
shift. The Bragg peak profiles scored with the DMG detector at the upper end of clinical
energies is seen to have a distal shift compared with those scored in the perspex phantom
alone. Despite this, the falloff positions were seen to have less than ±0.2 mm difference
to the expected ranges. The difference in R100 positions up to approximately 0.4 mm is
attributed to a lack of smoothness in the DMG curves due to poor statistics, further, this
point limited to the pitch in the detector channels. No clear angular dependence was seen
besides a greater spread in the ranges determined at a detector angle of 70◦.
The simulated profiles and respective ranges were seen to be reproducible for a given
proton energy at different DMG depths in perspex as depicted in figure 6.4 for a 88.5
MeV field. This is anticipated for the aggregate source used here as protons are gen-
erated within the given field size and are relatively forward directed. For the scanning
proton beam however, where the pencil beam is scanned over the field by deflecting the
beam with X and Y scanning magnets, the spot trajectory is not quite perpendicular to
the face of the phantom. As such, the path length of protons incident on the detector
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(particularly at the extremities of the field) will be greater than the perpendicular depth
of a given channel in perspex. Figure 6.5 shows the simulated Bragg profiles and range
differences for the same proton energy however using the scanning proton beam model
as the proton source. A DMG angle of 60◦ was considered at depths where the Bragg
peak fell at the extremities of the detector, the falloff positions showed less than±0.1 mm
difference to the expected range. With smaller detector depths in perspex, the Bragg peak
falls closer to the rear of the detector and a slight distal shift in the peak falloff is observed.
From the simulation results presented here, it was concluded that a detector angle of
60◦ from the normal to the beam CAX (or 30◦ to the beam CAX itself) be used for the
fabrication of the DMG angled phantom. This angle allows for maximum range sampling
without compromising the measured range due to incident protons crossing multiple sen-
sitive volumes or excess silicon along their trajectory resulting in a proximal peak shift.
The phantom design is presented in the following section.
The geometry modelled for the DMG detector defines individual sensitive volumes to
have a width of 20 µm and a depth of 45 µm. As the size of the diode collection re-
gion may vary and is anticipated to be slightly larger than that modelled, the impact of
changing SV size on the measured profiles for the angled setup was assessed. With in-
creasing SV size the likelihood of protons traversing and contributing to signal in multiple
channels increases. The simulated DMG response for varying SV widths and depths are
shown in figure 6.6 as well as the measured range differences to the Bragg profile sim-
ulated in perspex alone. The SV width was found to have no impact on the measured
profile and while the distal falloff positions were seen to vary slightly with increasing
sensitive volume depth, the discrepancies were less than ±0.1 mm and the R100 position
was unaffected. Increasing both the collection region width and depth showed the same
trend. To ensure that the increasing discrepancy with increasing SV depth wasn’t due to
the DMG angle being excessively large, the variable SV depth cases was assessed for a
DMG angle of 55◦ (shown in the bottom row of figure 6.6) and showed similar results.
6.3 Phantom design
Figure 6.7 shows CAD drawings of the angled perspex phantom design featuring a tight
fit recess for the DMG detector in its perspex sheath at an angle of 60◦ to the upstream
face of the phantom. The recess was positioned so that the middle of the detector is at a
depth of 35 mm in perspex both from the front and top face of the phantom including the
thickness of the DMG sheath along the line of incidence. This depth was chosen to allow
for measurements starting at less than 10 mm in perspex. The consistency in DMG depth
from the top and front faces allows the setup to be easily adapted for range measurements
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90R71.3 MeV - 
80R71.3 MeV - 
70R71.3 MeV - 
100R88.5 MeV - 
90R88.5 MeV - 
80R88.5 MeV - 
70R88.5 MeV - 
DMG center at 40 mm
(b)
Figure 6.2: (a) Simulated depth dose profiles in a solid perspex phantom and those
scored with the DMG positioned at 40 mm in a perspex phantom at varying angles to the
beam normal direction for flat 71.3 MeV and 88.5 MeV proton fields. (b) Range differ-
ences between the DMG profiles and those scored in the phantom for varying detector
angles.
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0.4 100R221.3 MeV - 
90R221.3 MeV - 
80R221.3 MeV - 
70R221.3 MeV - 
100R228.8 MeV - 
90R228.8 MeV - 
80R228.8 MeV - 
70R228.8 MeV - 
DMG center at 270 mm
(b)
Figure 6.3: (a) Simulated depth dose profiles in a solid perspex phantom and those
scored with the DMG positioned at 270 mm in a perspex phantom at varying angles
to the beam normal direction for flat 221.3 MeV and 228.8 MeV proton fields. (b)
Range differences between the DMG profiles and those scored in the phantom for varying
detector angles.
CHAPTER 6. DMG FOR PROTON RANGE IN PERSPEX 87
Depth in Perspex (mm)




































88.5 MeV proton field
































100R40 mm - 
90R40 mm - 
80R40 mm - 
70R40 mm - 
100R50 mm - 
90R50 mm - 
80R50 mm - 
70R50 mm - 
100R60 mm - 
90R60 mm - 
80R60 mm - 
70R60 mm - 
88.5 MeV proton field
(b)
Figure 6.4: (a) Simulated depth dose profiles in a solid perspex phantom and those
scored with the DMG positioned at different depths in a perspex phantom at varying an-
gles to the beam normal direction for a flat 88.5 MeV proton field. (b) Range differences
between the DMG profiles and those scored in the phantom for varying detector angles.
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(b)
Figure 6.5: (a) Simulated depth dose profiles in a solid perspex phantom and those
scored with the DMG positioned at different depths in perspex for an 88.5 MeV spot-
scanned pencil beam proton field. (b) Range differences between the DMG profiles and
those scored in the phantom for varying detector depths in perspex.
with vertical gantry angles; while just over half the depths are sampled for vertical com-
pared to horizontal beam delivery, the pixel spacing in depth results in a higher spatial
resolution.
A built-in wedge was used to support the fanout array of the detector for connection
to the DAQ; this prevented torsion along the length of the detector sheath and maintains a
rigid alignment of the detector setup. External reference markers were placed at the edges
of the phantom to allow ease of setup and alignment to the external laser system in the
treatment room indicating the isocenter position.
The phantom, fabricated by the Department of Engineering at Mayo Clinic in Rochester,
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Figure 6.6: Simulated energy deposition profiles with varying sensitive volume (SV) (a)
width, (c) depth and (e) a combination of the two for a 71.3 MeV proton beam with the
DMG centered at 40 mm in persex and angled at 60◦. The differences in range to that
scored in a perspex phantom only are shown in (b), (d) and (f) respectively. Profiles for
the sample beam energy and detector depth but at 55◦ for varying SV depth is shown in
(g) and the corresponding range differences in (h).
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Figure 6.7: CAD design drawings of the custom perspex angled phantom used for the
experimental investigation for DMG range determination in perspex.
is shown in figure 6.8. A solid perspex block was machined to sit on top and flush with
the DMG sheath so that proton fields traverse a homogeneous material before incidence
on the detector. The base and wedge that the detector and solid perspex top sit on are
hollow and 3D printed, reducing the weight, cost and manufacture time to produce the
setup. As the printed material is either out of the primary field or downstream of the de-
tector, the hollow structure and different material composition isn’t anticipated to affect
the field or range measurements. The figure shows the compact range measurement sys-
tem positioned on the patient treatment couch and aligned with the middle of the DMG at
isocenter. Due to the physical length of the DMG detector the setup is restricted to sam-
pling depth response profiles over approximately 44 mm in perspex for horizontal beam
delivery. Proton range can be measured for all clinically available energies by stacking
perspex blocks, which are readily available for clinical use, upstream of the phantom.
6.4 Field design and verification
For experimental application of this technique a flat proton fluence and dose field is re-
quired in the Bragg peak region and the lead-up to. For actively scanned pencil beams,
this involves tuning of the spot size and/or spacing in the delivered plan so that the sum-
mation of the Gaussian dose distribution from each spot produces a flat dose field at the
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Figure 6.8: Images of the custom built angled perspex phantom with DMG positioned
in the recess.
desired depth. The spot FWHM increases with penetration depth due to multiple coulomb
scattering and for the scanning pencil beam at Mayo Clinic the initial spot size varies
with energy so that a consistent spot spacing produces a homogeneous dose field at the
depth of the Bragg peak. For the purpose of this study 13 treatment plans were gener-
ated in EclipseTM for Proton (Varian Medical Systems, Palo Alto, California) in a perspex
phantom at energies ranging between the lowest (71.3 MeV) and highest (228.8 MeV)
clinically available. The planning treatment volume (PTV) was set to an area of 7.5× 2.5
cm2 at a depth corresponding to the Bragg peak range for the energy in question. Treat-
ment plans were generated for a gantry angle of 90◦ (horizontal beam delivery) with the
long axis of the field in the vertical direction to match the orientation of the DMG in the
angled phantom. The field was made considerably larger than the projection of the DMG
from the beams-eye view so that the setup was robust and less susceptible to translational
misalignments influencing the measured range. A larger field size helps to ensure that the
detector is outside of the penumbral region, however also increases the delivery time and
hence noise acquisition by the detector. Figure 6.9 shows the dose distribution in perspex
for the 71.3 MeV proton plan.
The field flatness was assessed for a subset of the treatment plans delivered from the
dose distributions profiles from the treatment planning system (TPS), from Monte Carlo
simulations using the Geant4 application and using film. Flatness is defined in equation
6.1 where Dmax and Dmin are the maximum and minimum dose inside 80% of the core
field size along a profile. The flatness was calculated for profiles along the vertical and
horizontal mid lines of the field. The PTV dimensions were used to define the core field
size so the minimum and maximum dose within the central 6 cm and 2 cm of the field,





CHAPTER 6. DMG FOR PROTON RANGE IN PERSPEX 91
Figure 6.9: Colour-wash view of dose delivered for the 71.3 MeV rectangular field from
the eclipse treatment planning software.
Gamma analysis [109] methods are often implemented for comparison of dose distri-
butions for example from measurement and simulation; a 3%/3 mm pass rate is often
adopted for example in IMRT QA dosimetry with a recommended pass rate of 90% [110,
111]. This is a quantitate analysis method for comparing dose distributions considering
both the dose difference and the distance to agreement and determines the rate of agree-
ment based on the criteria used for example dose difference between two data points fall
within 3% in a 3 mm distance. In this study the relative lateral dose profiles normalised to
the maximum dose from the TPS and from the Geant4 simulation were compared using
gamma analysis with a 3%/3mm passing criteria. Global calculation was used and a 10%
low dose cut-off was applied.
6.4.1 Film
Film irradiations were performed, primarily for visual inspection of dose consistency on
a plane normal to the beam CAX. Gafchromic EBT3 film was positioned between solid
perspex blocks at a depth close to the Bragg peak and centred on the CAX. A dose of 200
cGy was delivered at the film depth. The typical OD to dose calibration curve is relatively
linear for doses around 200 cGy and with minute variations in absorbed dose (as is in
this case), it is a fair assumption that the OD profile is proportional to the absorbed dose
profile for a relative dose comparison. Films were scanned using an EPSON 11000XL
flatbed scanner at a 72 dpi resolution. Film strips were placed in a single row at the centre
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of the scanner bed and a flat glass plane was used to press the film flat against the surface
of the scanner. Three preliminary scans were taken before the scan used for analysis to
eliminate warm-up effects of the scanner. FilmQA Pro Software (Ashland Inc., Wayne,
NJ, USA) was used to collect the OD profiles along the mid-line of the treatment field in
vertical and horizontal directions.
6.4.2 Monte Carlo simulation
The Geant4 application using phase-space information for the scanning pencil beam was
used to simulate the proton field delivered from the treatment plans. Here the proton
energy and spot positions were taken from the treatment plan beam delivery files. The
generated treatment plans had equal weighting of spots within a given plan. A total of
106 primaries were simulated per spot and fields ranged from a total of 167 up to 209
spots. Energy depositions within a perspex phantom were scored for planes normal to the
beam CAX in 1 mm3 bins from which 2D dose plots at varying depths and 1D vertical
and lateral beam profiles were obtained.
6.4.3 Results
Figure 6.10 shows the 1D lateral dose profiles from the treatment planning system and
from MC simulation at the Bragg peak depth as well as 2D dose profiles at the entrance
of the phantom and at the Bragg peak from MC simulation for a number of plans. The
lateral dose profiles from the TPS and from MC were found to show good agreement; the
results from the Gamma analysis criteria between the two are shown in table 6.1. The field
flatness at the entrance of the phantom decreases with increasing proton energy however
at the Bragg peak depth all fields show a homogeneous flat field.
Table 6.2 shows the calculated field flatness for profiles taken from the middle of the
long and short axes of the field for the three data sets: TPS, MC and film. The TPS
uses an analytical pencil beam model to calculate dose distributions and results in a very
smooth and flat field, the flatness variation less than 1% for all fields on both axes reflects
this. Film and Monte Carlo results showed greater variation in the field flatness however
the former are susceptible to large uncertainties and the Monte Carlo flatness would im-
prove with increased statistics (ie. more primaries run per spot). As the simulated field
showed sufficient flatness (within recommended 2% [23]) further statistics were rendered
unnecessary. The long axis was found to be less flat due to being made up of a larger num-
ber of spots. The field flatness calculated over a region of interest (ROI) from simulated
profiles is plotted in figure 6.11 as a function of total range in perspex. The ROI flatness
was calculated using the minimum and maximum dose values within the central 6 × 2
cm2 of the field to give an indication of the whole field flatness. Higher energy fields with
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smaller initial beam spots result in poor field flatness in the entrance channel however all
plans simulated here resulted in a consistently flat field in the lead up to and at the end of
range. The change in the flatness with depth is due to multiple scattering of protons from
individual spots that combine to produce as flatter field with increasing depth.
Table 6.1: Comparison between TPS and Monte Carlo dose profiles in a perspex phan-
tom at the Bragg peak depth using 3%/3mm Gamma index analysis.
Proton Energy Long axis profile Short axis profile
(MeV) Passing Rate (%) Mean γ Passing Rate (%) Mean γ
71.3 96.6 0.306 100.0 0.310
85.3 91.7 0.307 100.0 0.275
109.1 86.9 0.511 100.0 0.304
119.7 83.4 0.657 100.0 0.332
139.1 96.9 0.363 99.1 0.366
148.1 99.4 0.260 100.0 0.296
175.6 97.8 0.259 100.0 0.269
209.7 74.4 0.836 91.1 0.408
Table 6.2: Field flatness for varying proton fields evaluated from lateral dose profiles
taken from the treatment planning system (TPS), from irradiated EBT3 film and from the
Geant4 Monte Carlo (MC) application. Uncertainties for field flatness evaluated from
film measurements are estimated within ±5% and within ±2% for simulation values.
Proton Energy Depth in TPS flatness (%) Film flatness (%) MC flatness (%)
(MeV) perspex (mm) long axis short axis long axis short axis long axis short axis ROI
71.3 30.3 0.10 0.59 1.13 0.85 0.72 0.49 2.05
85.3 47.6 0.17 0.15 1.60 0.96 0.56 0.57 2.35
109.1 75.3 0.11 0.04 1.43 1.32 0.98 0.80 2.41
119.7 89.0 0.01 0.05 2.34 1.36 1.21 0.75 2.73
139.1 116.8 0.05 0.10 1.48 0.67 1.15 1.18 3.54
148.1 130.6 0.29 0.16 1.35 1.09 0.94 0.75 2.60
175.6 175.6 0.24 0.61 1.03 0.78 0.63 0.56 2.49
209.7 237.9 0.47 0.39 0.74 0.50 0.92 0.69 2.55
6.5 Range measurements
6.5.1 Experimental setup
The experimental setup for measuring proton range in perspex with the DMG detector
and angled perspex phantom is depicted in figure 6.12. The detector and phantom were
fixed on the patient couch and aligned so that the upstream face of the phantom was posi-
tioned at isocenter using the in-room laser system and a digital level as a guide. A single
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Figure 6.10: 1D dose profiles of the treatment plan from TPS and Monte Carlo (left).
2D dose profiles from the Geant4 simulated plans in a perspex phantom at the entrance
(middle) and Bragg peak (right), these are normalised to the maximum dose in each plot.
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Figure 6.11: Field flatness from Geant4 dose profiles over a 6 × 2 cm2 ROI for varying
depths and proton energy plans.
monoenergetic treatment plan (evaluated in the previous section) was delivered across the
detector for each acquisition. The monitor units for the plan were scaled to deliver ap-
proximately 2 Gy at the Bragg peak. The plans were fixed so that the monitor units for
a given spot position were delivered in full before switching positions (ie. no rescanning
allowed) to minimise delivery time and hence detector noise collection. Plan delivery
times fluctuated from around 15 - 30 seconds between fields due to varying spot numbers
and monitor units delivered per spot. The detector acquisition time was set accordingly to
capture the response for the entire plan delivery. The integration time, gain and frequency
settings were held constant for all data taken and were selected to maximise the signal
collected while avoiding saturation.
With increasing proton energy and hence range, the detector depth within the phan-
tom was increased by placing perspex blocks before the angled phantom as seen in the
right hand image of figure 6.12. The treatment plan for each proton energy was delivered
to the detector at a number of depths. For shallow detector positions the Bragg peak is
measured at the distal end of the detector and closer to the top of the field edge and the
reverse for deeper detector positions. For spots at the extremities of the field the incident
angle of the protons relative to the CAX increases and the difference between the path
length and the perpendicular distance traversed increases. As such the range of each pro-
ton energy was measured at varying detector depths to ensure it was unaffected by the
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Figure 6.12: Experimental setup of the DMG detector and angled perspex phantom
positioned on the patient couch and aligned using the in-room laser system. The detector
depth is shifted by placing perspex blocks used for QA upstream of the angled phantom
(see image on the right hand side). The blue arrow indicates the incident proton beam
direction.
peak position relative to the detector and the field.
6.5.2 Perspex/water equivalent thickness conversion
The perspex blocks used to shift the detector depth are commonly used in the clinic as
a substitute for water for QA and other measurements; hence their thickness is labelled
in terms of a water-equivalent-thickness (WET). In order to translate the WET thickness
to absolute range in perspex and visa versa a conversion factor was calculated. The ratio
of physical thickness of perspex to the WET label was determined to be (0.865 ± 0.002)
by measuring individual block thicknesses with callipers. The conversion factor was also
calculated by dividing the shift in Bragg peak position by the difference in the WET thick-
nesses place before the detector. This ratio was assessed over the range of energies for
shifts in R100, R90 and R80. Figure 6.13 shows the mean conversion factors calculated
for a given energy and point on the Bragg peak considered; the mean conversion factor
from this data was found to be (0.865 ± 0.005). The R100 ranges show greater variation
as these are limited to the sensitive volume spacing, R90 and R80 however are found from
linear interpolation between channel responses.
6.5.3 Noise processing
The proposed mode of operation for measuring proton range in perspex with the DMG
detector in this chapter requires the pencil beam to be scanned over the detector to pro-
duce a flat field. This results in added complication for signal processing compared with a
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Figure 6.13: WET to perspex conversion factor calculated from the average range differ-
ence measured with the DMG and angled perspex phantom for varying WET thicknesses
of perspex. Error bars represent one standard deviation of the mean. The black dashed
line indicates the average conversion factor from all data.
single spot delivery to all channels simultaneously. While the field delivery is still rather
quick (less than 30 seconds) noise accumulation throughout the acquisition can distort the
measured profiles and be more difficult to remove as “beam-on” time is less well defined
with different channels being irradiated at different times. This section addresses how in-
dividual channel noise is removed from the integral signal used to determine proton range.
The AFE boards used for readout in the DAQ can be a major source of the noise due
to damage, poor connection or otherwise. An example of the noise recorded with the
DMG detector over a 20 s acquisition with no stimulus is shown in figure 6.14. The DMG
uses 2 AFE boards to readout all 256 channels, this figure highlights the difference be-
tween a well tuned AFE board for the first 128 channels and a noisy one in the rear 128
channels. The count rate of the noise accumulated in a given channel is nearly constant
over time, as seen in image (b) of the figure where the cumulative counts is plotted over
time.
The linearity of noise collected over time was exploited by finding the mean count rate due
to noise for a given channel over the first 1.2 seconds of the acquisition, before the first
spot is delivered. The mean noise count rate was used to project the total counts due to
noise over the entire acquisition period and subtracted from the integral counts measured
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Figure 6.14: (a) Integral of counts collected due to detector noise over a 20 s acquisition
with no external stimulus. (b) Cumulative counts collected over time for a number of
individual channels. (c) Counts recorded over time for different detector channels.
on a channel-by-channel basis. Figure 6.15 shows the integrated Bragg profile measured
with the DMG for the 85.3 MeV proton plan before and after noise subtraction. The pro-
file shown here was obtained with the same detector settings and AFE boards as in figure
6.14 for a 25 s acquisition. Similarly, this figure shows the cumulative counts from the
raw signal and counts measured as a function of time for a subset of channels. The noise
subtracted profile is very similar to the integrated profile for the first half of the detector,
due to much less noise in these channels however a substantial improvement to the Bragg
profile is seen in the last 128 channels. The time profiles shown across the bottom of the
figure feature a spike in the counts as the beam is switched on and the intensity varies as
the spot proximity to the given channel changes. The counts due to noise are seen to be
minimal compared to the true signal from dose deposited by the proton beam as seen in
the time output for channel 210, however over a prolonged period noise counts become
significant particularly in low dose cases such as for channel 250 which falls beyond the
Bragg peak.
This noise subtraction method was applied to all the measured profiles using the frame-
by-frame output file from the DAQ GUI and a c++ application to calculate and subtract
noise from the integral profile.
CHAPTER 6. DMG FOR PROTON RANGE IN PERSPEX 99
channel number














85.3 MeV proton field
(a)
Time (s)




























85.3 MeV proton field
(b)
Time (s)
























































Figure 6.15: (a) Integral of counts collected during delivery of the 85.3 MeV proton
plan before and after noise subtraction. (b) Cumulative counts collected over time for
a number of individual channels. (c) Counts recorded over time for different detector
channels.
6.5.4 Results
The difference between the SRIM projected range in perspex and the simulated R100, R90
and R80 ranges from Bragg peak profiles scored in a perspex phantom alone and those
in the DMG angled phantom setup are shown in figure 6.16. As seen in chapter 4, the
SRIM projected ranges in perspex correlate best with the R100 range definition scored in
the phantom however tends to overestimate R100 for lower clinical energies and underes-
timate it at higher energies. Despite this, there was a maximum variation of ±0.3 mm
for R100 between the two. The depth of the Bragg peak maximum scored with the DMG
detector was seen to fall proximal to both the SRIM projected ranges and those scored in a
perspex phantom alone, particularly at lower proton energies. The distal falloff positions
of the peak however are closely correlated between simulated phantom and DMG profiles
with less than ±0.07 mm difference in the corresponding R90 and R80 values.
A sample of the Bragg peak depth dose-response profile measured with the angled phan-
tom DMG system for each energy assessed is plotted as a function of depth in perspex
in figure 6.17. Several acquisitions were taken for each proton plan and detector depth
from which the mean measured ranges were calculated. The measured proton range was
found to be independent of the DMG depth in perspex for the detector depths considered
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(with Bragg peaks falling within the range sampled by the detector, mainly within the
central 220 channels). The difference between the SRIM projected range and the mean
ranges from experiment are plotted in figure 6.18. Similar to simulated results presented
in figure 6.16, the R100 ranges showed strong agreement with SRIM ranges. A maximum
difference of±0.21 mm was observed with most measured R100 values falling within one
standard deviation of the SRIM projected range. Figure 6.19 shows the differences in
the range between experimentally determined ranges and those from simulation of the
treatment plan in a perspex phantom alone. The R100 range was found to agree within
±0.2 mm for energies up to 148.1 MeV (of the energies considered). R90 and R80 were
found to show greater variation between simulated ranges in perspex and the experimen-
tally measured ranges, however values still fell within ±0.32 mm over the full range of
clinical energies. The Bragg peak position measured with the detector setup generally
shifts from a proximal to a distal offset compared to the simulated Bragg peak position as
the proton energy increase.
In chapter 4 it was shown that the SRIM projected range in perspex falls closest to the
R100 range while the mean range (defined as the 50% falloff in proton fluence) agrees
best with R95/R90 over the clinically relevant energies considered. The Bragg peak curve
measured with the DMG and angular phantom showed the closest correlation between
R100 and SRIM projected ranges over the span of energies assessed. As such for recon-
struction of incident proton energies from the measured range, the DMG measured Bragg
peak maximum and the SRIM database are recommended. For mean range determination
R90 values measured with the DMG are accurate within an uncertainty of ±0.3 mm. R80,
a commonly used point on the Bragg curve as clinical definition of range can also be
measured with uncertainty less than ±0.35 mm.
6.6 Conclusion
Monte Carlo simulations were performed with a Geant4 application modelling the DMG
detector in order to optimise the design of an angled perspex phantom for the DMG to
measure proton range over all clinically available energies in perspex. The optimum de-
tector angle was found to be 60◦ to the normal of the beam central axis. Simulation results
presented in this chapter show that Bragg curves scored with the angled DMG setup accu-
rately reproduce the depth-dose curve scored in perspex alone and the range for a number
of dose points on the curve at both low and high clinical energy cases.
The angled perspex phantom was fabricated by the Department of Engineering at Mayo
Clinic, Rochester and was experimentally tested for proton range verification for the pen-
cil scanning beam at the Mayo Clinic proton facility. Monoenergetic, flat-field treatment
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Figure 6.16: Proton range differences between the SRIM projected range in perspex
and those from Bragg curves simulated in a perspex phantom and with the DMG in the
angled phantom.
Depth in Perspex (mm)































Figure 6.17: Relative depth dose-response profiles measured using the DMG detector in
the angled perspex phantom. The Bragg peak was measured over the whole spectrum of
clinical energies by adding more perspex materials in front of the angled phantom.
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Figure 6.18: Differences between SRIM projected ranges and ranges determined from
the Bragg curve measured with the DMG detector and angled phantom setup. Error bars
indicate one standard deviation of the mean range from experimental measurements.
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Figure 6.19: Differences in ranges from simulated plans in a perspex phantom and those
measured with the DMG detector and angled phantom setup. Error bars indicate one
standard deviation of the mean range from experimental measurements.
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plans were generated using the EclipseTM for Proton treatment planning system over the
whole range of clinically available energies and verified for field flatness. The DMG and
angled phantom system was used to measure depth dose-response profiles for each treat-
ment plan at various detector depths. The measured R100 range was found to consistently
reproduce SRIM projected ranges in perspex over all energies with less that ±0.21 mm
variation. The mean DMG measured ranges were accurate within ±0.5 mm for R100, R90
and R80 ranges compared with ranges simulated in perpex with there Geant4 application
over the whole range of clinical energies.
The DMG angled phantom system was shown to be well suited for measuring proton
range in perspex with sub-millimetre accuracy for an active scanning proton pencil beam.
This system presents a practical and efficient solution to measure proton range with re-
duced size, setup time and cost compared to commercially available devices. The system
is additionally suitable for range measurements at proton therapy facilities with passively
scattered beamlines. The setup has the potential for application in particle therapy with
heavier ions and could be investigated in future work.
Chapter 7
Combined detector arrays for pencil
beam scanning profiles and range
determination
7.1 Overview
Dosimetry makes up a large proportion of daily QA for proton therapy systems. The
AAPM taskgroup 224 [23] recommends that, for PBS delivery, proton range and spot
position are checked daily with tolerances of±1 mm and±2/1 mm (absolute/relative) re-
spectively. The DMG was demonstrated to be an accurate and reproducible tool for daily
range verification to determine range in silicon for energies up to ~105 MeV (chapter 5)
and for range in perspex over the full range of clinical energies (chapter 6). Combined
systems that are capable of performing multiple checks at once or with a single setup are
favourable in the clinical environment to optimise the daily QA process and maximise
efficiency.
In this chapter the angled phantom DMG setup, that was assessed for range verification
in the previous chapter, is used in conjunction with the Duo detector to create a com-
bined detector system for simultaneous range and spot position measurements. The Duo
is a monolithic silicon detector with two orthogonal arrays of diodes with 200 µm pitch;
further details about the detector are given in section 2.4.1. The high resolution of this
detector along two axes makes it well suited for small fields such as those used in proton
PBS delivery. The entire thickness of the Duo including perspex casing, air void, silicon
wafer and PCB is less than 1 cm. Positioned with the plane of the detector orthogonal
to the beam central axis, the Duo is suitable as a transmission device. In the combined
detector setup proposed here, the Duo is positioned directly upstream of the DMG angled
phantom setup. The perspex equivalent thickness of the Duo is determined by measuring
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the shift in the Bragg profile with and without the detector in place. The mean equiva-
lent thickness is used to determine absolute proton range in perspex with the combined
system and was used to benchmark the accuracy of range measurements against those
without the Duo and against simulated proton ranges in perspex. For these measurements
a monoenergetic, rectangular proton field was delivered to the combined detector system.
A method to measure proton range with a single spot delivery is also evaluated whereby
the spot profile measured with the Duo is used to correct for variable proton fluence across
the spot.
7.2 Materials and Methods
7.2.1 Experimental setup
The experimental setup using the Duo for spot-shape and position monitoring and the
DMG for depth profiling is depicted in figure 7.1. The angled perspex phantom, designed
and evaluated in chapter 6 for proton range measurement using a scanned flat-field, was
used to house the DMG. The DMG phantom was aligned with the upstream face normal
to the incident beam direction and the centre of the silicon wafer positioned at ioscenter on
the patient couch using the in-room laser system and a digital level for guidance. The Duo
detector was fixed directly upstream of the DMG phantom with its two orthogonal arrays
aligned with the vertical and horizontal planes of the isocenter lasers. With increasing
proton energy and hence range, perspex blocks were stacked immediately upstream of
the Duo so that the Bragg peak was shifted to fall close to the centre of the DMG. The
experimental setup was evaluated for two modes of range measurement: (1) with a flat
rectangular field and (2) with a single central axis beam spot delivery. These two modes
are discussed below.
Figure 7.1: Experimental setup using Duo and DMG detectors in combination for spot
size/position and range measurement respectively. The spot position and FWHM as
measured with the DUO is used to scale the DMG response by the variable proton fluence
across the beam spot.
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7.2.2 Flat, rectangular field delivery
The method described in chapter 6, using a monoenergetic rectangular flat field, to mea-
sure proton range was implemented here however with the Duo detector placed upstream.
The perspex equivalent thickness of the Duo detector was measured by delivering the
same rectangular field to the DMG angled phantom with and without the Duo in place.
The proton beam traverses a number of materials while travelling through the Duo in-
cluding its perspex casing, silicon wafer, PCB carrier and embedded electronic wires. As
such the equivalent thickness was assessed for multiple energies to ensure no large energy
dependence was observed. This equivalent thickness was used to compare the absolute
range measured in perspex with the Duo to those without and to simulated ranges in per-
spex.
The distal falloff widths for DMG depth dose-response profiles measured with and with-
out the Duo in place were compared for a number of proton energies. The R80 and R20
ranges in perspex were found from linear interpolation between individual sensitive vol-
ume responses to find the respective depths of the 80% and 20% dose falloff positions.
The distal falloff width, l80−20, was defined as the difference between the R20 and R80.
The falloff width was assessed to determine whether placing the Duo upstream compro-
mises or changes the peak falloff shape. The size and position of spots delivered on the
central beam axis and along the horizontal and vertical axes within the field are measured
with the Duo simultaneously to the range with the DMG.
7.2.3 Single central axis spot delivery
The feasibility of using a single central axis spot for range measurement with the angled
phantom was assessed with the DMG and Duo combined setup. A single spot measure-
ment could be advantageous to reduce the time for a single acquisition. Further, a single
spot range determination method could be used to determine the equivalent thickness of
heterogeneous materials (both in lateral and longitudinal directions) placed upstream of
the combined detector system. This method however presents several challenges as the
proton fluence in a single spot has a Gaussian profile. The proximal and distal ends of
the depth dose-response profile measured with the DMG will therefore show decreased
signal due to reduced fluence at the spot edges. Further, the small size of a single proton
spot results in only a subset of the DMG pixels contributing to the sampled ranges. The
relative depth of the DMG in perspex then is much more sensitive to a single spot deliv-
ery. The schematic depicted in figure 7.2 demonstrates the increased detector placement
sensitivity (see the orange series that doesn’t capture the Bragg peak) and the effects of
variable fluence on the relative detector response.
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Phantom
Figure 7.2: A schematic of relative depth dose measurements for a flat field delivery
(left) both along the CAX and for collinear points at an angular offset. The same setup
for a single PBS spot with Gaussian proton fluence is shown on the right; measurements
at the field edge underestimate the relative dose.
The Duo detector placed upstream of the DMG angled phantom was used to measure the
spot profile and position. A method to correct the DMG measured depth dose-response
profile for variable proton fluence across the spot was assessed. A Gaussian curve was
fit to the spot profile measured with the arm of the Duo parallel to the DMG axis. This
profile was assumed to be analogous to the proton fluence incident on the DMG. The rel-
ative response of a given DMG sensitive volume was scaled by the corresponding fluence
measured at the same off axis position. While multiple coulomb scattering and divergence
of the proton spot will occur in the perspex between the Duo and DMG, particularly for
distal DMG sensitive volumes, the Duo measured spot profile was considered the best
approximation for fluence correction.
7.3 Results and Discussion
7.3.1 Flat, rectangular field delivery
The measured shift in the Bragg peak peak maxima, 90% and 80% falloff positions with
and without the Duo upstream of the DMG are plotted in figure 7.3. As the R100 ranges
are determined from the depth of the channel with the maximum response, these values
are limited to the sensitive volume spacing and are hence susceptible to greater variation
as reflected by the larger uncertainties. The range shift was relatively stable across the
energies assessed and as such a single value was used to translate the Duo thickness to
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Figure 7.3: The measured shift in the Bragg peak position when the Duo is paced up-
stream of the DMG angled phantom. The black, dashed line represents the mean range
shift and error bars indicate the combined uncertainty from one standard deviation of the
mean range measured in each case.
perspex equivalent thickness. The mean perspex equivalent thickness of the DMG was
calculated to be (8.69 ± 0.22) mm from the average shift in the Bragg peak for all three
dose points considered. This equivalent thickness was used to calculate absolute ranges
in perspex for measurements with the combined detector system.
Figure 7.4a shows the difference in the absolute measured range with the combined de-
tector setup (including the perspex equivalent thickness of the Duo) and the DMG angled
phantom setup only. The range values measured with the two experimental setups were
within ±0.5 mm with the exception of one point. The difference between the absolute
measured range with the combined setup and simulated proton ranges for the delivered
treatment plans in perspex (see chapter 6 regarding simulation specifics) are plotted in
figure 7.4b. The measured ranges were found to agree within ±0.5 mm of simulated
ranges for energies up to 191.3 MeV and within ±0.8 mm over the entire energy range.
The combined setup showed similar trends to the DMG angled phantom (see figure 6.19),
with an tendency to underestimate the proton range low lower energies and visa-versa for
the higher energies. The results presented in figure 7.4 demonstrates that a single mean
equivalent thickness value for the Duo in the combined detector setup is suitable to repro-
duce proton range values with sufficient accuracy.
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Figure 7.4: Range differences between the mean absolute range measured with the com-
bined detector system and those from (a) the angled DMG phantom only and (b) from
simulated treatment plans in a perspex phantom.
The distal falloff widths with and without the Duo in place calculated for multiple pro-
Proton energy (MeV)
















 - DMG only80-20l
 - DMG + DUO80-20l
Figure 7.5: Bragg peak distal falloff width measured between the 80% and 20% falloff
positions measured with the DMG and angled phantom with and without the Duo de-
tector placed directly upstream. Error bars indicate the combined uncertainty from one
standard deviation of the mean R80 and R20 for each energy.
ton energies are plotted in figure 7.5. No substantial variation was observed between the
two datasets. As such the combined detector system with a flat, rectangular field delivery
can be used to measure proton range and spot position/profiles simultaneously with little
compromise on the range measurement accuracy
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7.3.2 Single central axis spot delivery
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SS - 24.2 mm
Figure 7.6: Depth dose-response profiles measured with the combined setup for
97.8 MeV protons for a flat, rectangular field delivery and for single spot (SS) deliveries
with the combined detector at varying depths in perspex (as indicated in the legend).
The depth dose-response profiles measured with the DMG in the combined detector
setup for a single spot delivery at various depths in perspex are plotted in figure 7.6 along
with the response from a rectangular field delivery. The measured profile shape is highly
dependent on the depth of the detector setup in perspex. For shallower depths more of the
spot is sampled and a greater contribution to the signal is seen in the region proximal to the
peak. With increasing depth only the penumbra and leading edge of the spot is sampled
resulting in a narrower peak profile being recorded. While the proximal side of the profile
is seen to vary the most, the recorded distal falloff position is relatively independent of
the detector depth. The drop in proton fluence with depth at the end of range is steep and
somewhat negates the effects of variable fluence with lateral displacement across the spot.
Examples of spot profiles measured with the Duo detector in the combined detector setup
are plotted in figure 7.7. Both vertical and lateral profiles are depicted and are labelled
parallel and perpendicular, respectively, relative to the axis on which the DMG measures
range. Inconsistencies in the profiles seen here are likely due to variable relative pixel re-
sponse and noise between the measured proton spot profiles and the equalisation factors
applied.
Figure 7.8 compares depth dose-response profiles measured with the DMG in the com-
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Figure 7.7: Lateral spot profiles measured with the Duo detector for various proton
energies for parallel and perpendicular directions relative to the DMG axis.
bined detector setup with a rectangular field delivery to a single spot delivery. Here the
single spot response is also scaled by a Gaussian fit of the lateral dose profile measured
with the Duo detector. The proximal and distal edges of the scaled profile are amplified
due to the small Duo response at the spot edges. Examples plotted in 7.8a and 7.8b show
instances where the scaling has little effect on the peak and falloff depths. Plots shown
in figures 7.8c and 7.8d however result in large under- and over-estimation of the range
from scaled profiles, respectively. The scaling method was found to be unreliable and
overly sensitive when implemented in practise. The scaling method also introduced fur-
ther uncertainties to the measurement process. Figure 7.9 shows the differences in the
mean measured ranges with the DMG angled phantom only (with flat field delivery) and
to those measured with a single spot (SS) delivery using the combined detector setup
(denoted at CS in the figure). The absolute ranges for the combined detector setup were
calculated using the perspex equivalent thickness of the Duo. The difference in mean
measured ranges were found to fall within ±1 mm both without and with fluence scaling.
Figure 7.10 shows the difference in simulated ranges in perspex to the mean measured
ranges with the combined detector setup for a single spot irradiation both without (a) and
with (b) scaling of the spot fluence. The mean measured ranges in both cases were found
to fall within ±0.8 mm of simulated ranges. No improvement in the determined ranges
were observed with fluence scaling.
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Duo - Spot profile
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(a) 71.3 MeV
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(b) 85.3 MeV
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(c) 139.1 MeV
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(d) 209.7 MeV
Figure 7.8: Depth dose-response profiles for flat field delivery (grey), raw single spot
delivery (black) and fluence scaled single spot response (red) using Gaussian fit to Duo
measured spot profile (blue).
Proton Energy (MeV)




























(a) no fluence scaling
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(b) with fluence scaling
Figure 7.9: Range differences between those measured with the angled DMG phantom
only and the range measured with the combined detector system (a) without and (b) with
fluence scaling.
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(a) no fluence scaling
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(b) with fluence scaling
Figure 7.10: Difference in ranges from simulation in perspex to mean ranges measured
with combined detector system for single spot delivery both (a) without and (b) with
fluence scaling.
7.4 Conclusion
In this chapter the DMG angled phantom setup was adapted to measure both proton range
and verify spot position and size. This was achieved using the 2D Duo detector placed
directly upstream of the DMG angled phantom. The feasibility of using the Duo detec-
tor as a transmission device was assessed by evaluating the perspex equivalent thickness
from the shift in the peak position with and without the detector in place. The equivalent
thickness of the Duo was found to be relatively stable over the full range of energies and
the mean value was determined to be (8.69 ± 0.22) mm. The Bragg peak distal falloff
width was found to relatively unaffected when the Duo was placed upstream.
The range measured with the combined detector setup for a flat field delivery was found to
fall within±0.5 mm for the majority of cases compared to those measured with the DMG
angled phantom only and to those simulated in a perspex phantom. A single central axis
spot delivery was also assessed for range measurements. This method is much more sen-
sitive to the DMG depth. The shape of the measured depth dose-response profile was also
found to be susceptible to detector depth due to variable proton fluence across the spot. A
method to correct for variable spot fluence was trialled by scaling the DMG response by
a Gaussian fit of the Duo measured spot profile. The fluence scaling method was found to
be unreliable and in many cases did not improve the measured range accuracy. The range
measured with a single spot delivery was found to fall within ±1 mm of those measured
with a flat field delivery and from simulated ranges in perspex.
The combined system was found to accurately determine proton range and to simulta-
neously measure lateral spot profiles for a flat field delivery. A single spot central axis
range measurement is possible with this setup however results in reduced range measure-
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ment accuracy and greater sensitivity to measurement position.
Chapter 8
Monte Carlo model and out-of-field
measurements of the passively scattered
proton beamline at iThemba using
Geant4
The phase-space files generated from the Geant4 Monte Carlo model of the iThemba pro-
ton beam-line presented in this chapter are implemented for simulations results published
in the journal Physics in Medicine and Biology:
A. Parisi, S. Chiriotti, M. De Saint-Hubert, O. Van Hoey, C. Vandevoorde, P. Beukes,
E. A. De Kock, J. Symons, J. N. Camero, J. Slabbert, P.Megret, E. Debrot, D. Bolst, A.
Rosenfeld and F. Vanhavere, A novel methodology to assess linear energy transfer and
relative biological effectiveness in proton therapy using pairs of differently doped ther-
moluminescent detectors, Physics in Medicine and Biology, 2019, 64 [112]
8.1 Overview
Proton therapy is a rapidly developing treatment modality for oncology patients due to
the advantageous physical dose characteristics as well heightened biological effective-
ness compared with conventional photon based therapies. Radiation therapy with protons
allows for considerable normal tissue sparing, particularly for critical structures nearby
targeted tissues, making it favorable pediatric patients. Despite this, stray radiation and
secondary particle production in proton therapy contribute to low out-of-field doses to nor-
mal tissue. With improved patient outcomes and many patients living greater life spans
following radiation therapy, the risks of radiation induced secondary cancers is becoming
an increasing concern [113, 114]. It is therefore important to assess and characterise out-
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of-field doses delivered during treatment.
Out-of-field doses in proton therapy are primarily due to neutrons that are produced in
nuclear reactions with beam-line components and within the patient. Neutrons are of par-
ticular interest as they have been widely established to have a high potential for induction
of late effects and carcinogenesis even in low doses due to their increased biological effec-
tiveness [113]. Beam contamination and secondary particle production is more common
in passive scattering proton beam delivery systems compared with newer active pencil-
beam scanning (PBS) technologies being implemented in state-of-the-art proton therapy
facilities [114–116]. This is due to the presence of scattering materials, range modulators
and collimating devices in a passive scattering beam-line in addition to monitor unit cham-
bers used in PBS. The out-of-field radiation quality and dose equivalent has been shown
to strongly depend on the presence of a range shifter [117], range modulation width [118,
119], beam energy and field size [120].
The complex radiation fields produced in proton therapy require characterisation and
evaluation of the spectra of particles produced and their radiation quality for treatment
planning, radiation protective purposes and quality assurance. Monte Carlo techniques
are the gold standard for dose calculation and are a powerful tool for radiation therapy.
Further, Monte Carlo simulations can also provide a wealth of information such as parti-
cle species production and distribution, particle LET and they are often used for detector
characterisation and other particle therapy research. Such simulations however require
validation against experimental data.
In this chapter the passive double-scattering clinical proton beam line at the iThemba labs
in Cape Town, South Africa is modelled using the Monte Carlo toolkit Geant4 and two
different proton fields were verified against experimental measurements. The first field
considered was for a cylindrical target volume 3 cm in diameter and 3 cm long - close to
the typical size of a head and neck target. The out-of-field radiation quality of this field
was assessed by measuring the microdosimetric spectra using a SOI microdosimeter at
various positions and orientations both in experiment and using the Geant4 simulation of
the beamline and experimental setup. The dose equivalent was determined at the out-of-
field measurement positions from the radiation quality and absorbed dose. The simulation
was also used to analyse the composition of the radiation field at the measurement posi-
tions.
The second radiation field simulated using the Geant4 application of the beam-line setup
had a broader SOBP of 50 mm and a diameter of 10 cm. This simulated field was shown
to comply with experimental measurements of the physical dose and was used to asses
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the variable proton RBE in the distal falloff of the SOBP where the LET increases greatly.
The results of which are presented in chapter 9.
8.2 Materials and methods
8.2.1 iThemba Proton Beamline setup
The proton beamline at the iThemba labs is a passively scattered system fed by a separator-
selector cyclotron. The accelerator produces protons at an energy of 200 MeV at the
start of the treatment nozzle which consists of several scattering and flattening filters to
produce of homogeneous broad-beam. Numerous collimating devices, a double wedge
energy degrader and a range modulation (RM) wheel are used to define the field size,
maximum range and to produce a spread out Bragg peak of a fixed width. The beam-
line was modelled in Geant4 and the visualisation of the simulated treatment nozzle is
depicted in figure 8.1. Each beamline component was closely modelled according to its
materials, their thicknesses and positions along the beamline axis according to specifica-
tions provided in documentation [121] of the nozzle.
A reference “shoot through” beam is used to determine the number of thiolyte range
Figure 8.1: Layout of the iThemba proton beamline treatment nozzel modelled in
Geant4.
trimmer plates that are placed in the beam path. For this reference beam the double
wedge energy degrader is fully retracted out of the beam and replaced with a lead scatter-
ing plate. The trimmer plates are stacked so that the 50% dose falloff in the Bragg peak
is positioned at a depth (R50) of 240 mm in water using the reference setup and remain
in place for following irradiations. This reference setup was also tested in the simulation
and the same number of trimming plates was found to produce the correct R50.
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The energy degrader system is made up of two synthetic graphite wedges mounted back-
to-back that slide into the beam to shift the R50 range as required. For the simulation the
position of the wedges was determined by checking that the R50 range in water fell at the
prescribed depth. A spread out Bragg peak (SOBP) is formed using the range modulation
system consisting of a modulator wheel driven by a belt and pully systems connected to
a DC motor. A series of perspex RM wheels are available with variable thicknesses to
achieve SOBP with widths between 20 and 110 mm. Figure 8.2 shows an example of
the modulator wheels. In order to simplify the geometry and avoid dynamic parts in the
simulation, the average dwell time at each blade thickness of the RM wheel was used
to determine the ratio of the primary protons shot for each perspex thickness placed in
position of the RM wheel.
An occluding ring and central beam stop, used to flatten the field, is positioned up-
Figure 8.2: Schematic of a two blade range-modulator wheel from [121] (left) and image
of 31 mm range-modulator wheel used for experiments (right).
stream of a series of collimators of deceasing aperture size followed by a monitor unit
chamber. A patient specific collimator can also be placed immediately before the patient
or phantom used.
8.2.2 Radiation fields and dosimetry
Two proton SOBP fields produced at the iThemba labs were considered in this study, the
dimensions of each are given in table 8.1. Field 1 was used in order to assess out-of-field
dose for passive proton therapy delivery due to stray radiation and secondary particles
such as neutrons. Dose to normal tissue outside of the prescribed target volume may
increase the risk of secondary malignancies and is of particular concern for paediatric pa-
tients with heightened sensitivity and susceptibility to radiation-induced secondary can-
cers. As such the field dimensions used for this study were chosen to replicate a brain
treatment site considering out-of-field positions within a radius of 75 mm representative
of a 5 year old child’s head size. The radiation quality outside the primary field was eval-
uated by measuring the microdosimetric spectra at various out-of-field positions using
a SOI microdosimeter (see section 2.4.2). Field 2 was used for a proton RBE study to
investigate the variable relative biological effectiveness (RBE) in the distal falloff of the
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SOBP where the proton LET is seen to increase greatly. The results for the RBE study
using field 2 are presented in chapter 9.
For both cases the treatment field size was defined using a 5 cm thick brass collimator
with circular aperture and diameter given in table 8.1. The collimator was placed at the
patient specific collimator site just before the phantom as shown in figure 8.3.
Table 8.1: Radiation fields produced at iThemba assessed in experiment and simulation.
Field 1 Field 2
(out-of-field measurements) (in-field measurements)
R50 proton beam range (mm) 100 120
SOBP witdth (mm) 31 50
Field diameter (cm) 3 10
Reference dosimetry
Percentage depth dose (PDD) profiles of each field were measured along the central beam
axis in a water phantom using a MarkusTM ionisation chamber (model 30-329) with a
0.055 cm3 sensitive volume. The simulated depth dose profiles in water were compared
to those measured experimentally to validate the simulation setup.
Out-of-field Microdosimetry
In order to assess the radiation quality outside the primary radiation field the microdosi-
metric spectra was measured using the SOI Bridge microdosimeter discussed in section
2.4.2. The microdosimeter was placed at three lateral out-of-field positions 25 mm, 50
mm and 75 mm from the central beam axis and at a depth of 85 mm corresponding to
the middle of the SOBP. These measurement positions were labelled A, B and C respec-
tively and are depicted in figure 8.3. The detector was used in two orientations for the
lateral measurement positions: face-on and edge-on as shown in figure 8.4. The Bridge
microdosimeter consists of arrays of 3D parallelepiped sensitive volumes connected by
bridging structures on a single plane and since radiation incident lateral to the primary
field is not necessarily forward directed or mono-directional, this may lead to a single
particle traversing more than one sensitive volume and thus effecting the recorded results.
As such the measured spectra with the two orientations were compared. Measurement
position D was at a depth of 130 mm in water (30 mm beyond the R50 range of the SOBP)
on the central axis of the beam where the Bridge microdosimeter was placed in the face-
on orientation.
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Figure 8.3: Left: Top-down illustration of the out-of-field water phantom setup. The
Bridge microdosimeter was placed at lateral positions A, B and C at the depth of the
middle of the SOBP and at position D on the central beam axis beyond the distal falloff
of the SOBP. Right: 3D Bridge microdosimeter in waterproof MicroPlus probe setup in
the water phantom. The blue arrow indicates the direction of the proton beam incident
on the phantom.
The microdosimetric spectra measured with the 3D Bridge microdosimeter was used
to calculate the frequency-mean (yF ) and dose-mean (yD) lineal energies as given using
equations 8.1 and 8.2 respectively.
yF =
∫





y2 f (y) dy∫
y f (y) dy
(8.2)
8.2.3 Determination of average quality factor and dose equivalent
A radiation quality factor is a quantity used to weight absorbed doses according to their
biological effectiveness. The average radiation quality factor is used to characterise the
effects of low doses of ionising radiation and to calculate out-of-field dose equivalent
values. The average quality factor and its relation to lineal energy provides information
about the types and quantity radiation at a point. The average radiation quality factor Qavg
was calculated from equation 8.3 and the lineal energy spectra measured with the Bridge
microdosimeter. The quality factor Q is given as a function of lineal energy, y, as shown
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Figure 8.4: Microplus probe with 3D Bridge microdosimeter inserted in face-on and




1 y < 10 keV/µm
0.32y−2.2 10 keV/µm≤ y≤ 100 keV/µm
300y−0.5 y > 100 keV/µm
(8.4)
The dose equivalent, H, describes the low-dose effects of radiation and is regularly applied
in radiation protection. H is given in equation 8.5 with units Sv and in such applications
typically quoted in mSv/Gy delivered in-field during treatment.
H = QavgD (8.5)
Where D is the absorbed dose in tissue which was determined from simulated depth dose
profile and lateral dose profile at the centre of the SOBP (85 mm WET) where the lateral
out-of field measurements were taken. The simulated dose at the centre of the treatment
field was used to calculate the absorbed treatment dose that the dose equivalent was scaled
by.
8.2.4 Simulation parameters
The iThemba beam-line was modelling using Geant4 version 10.02.p02 and particles were
tracked from the downstream face of the vacuum exit window. Primary protons were
produced with an energy of 200 MeV within a 5 mm diameter spot size and momentum
direction along the central beam axis. No spread was included in the initial proton energy
or momentum direction due to the significant distance between the source and target and
the multitude of beam scattering and energy modulating and devices that result in a highly
modulated and scattered beam at the position of the phantom. The physics lists used to
describe particle interactions with matter are displayed in table 8.2.
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Table 8.2: Geant4 Physics models used in the simulation physics list.
Physics processes Geant4 models
Electromagnetic physics G4EmStandardPhysics option3
Decay physics G4DecayPhysics
Radioactive decay physics G4RadioactiveDecayPhysics





Geant4 cuts per region were set in order to optimise the simulation by preventing the pro-
duction and tracking of secondary γ’s, electrons and positrons with insufficient range to
reach the phantom or detector. The minimum required cut for production was decreased
with increasing proximity to scoring volumes. In order to improve the dosimetric accu-
racy of measurements the step length within the detector and surrounding volumes was
limited to 1/10 of the smallest detector dimension.
The depth dose profiles for the shoot through beam and for both of the radiation fields
considered were measured in a water phantom with 0.1 mm resolution in the depth di-
rection. For the simulated setup of the out-of-field measurements taken with the Bridge
microdosimeter however the perspex shell of the water phantom used in experiment, con-
taining a thin entrance window at the proximal end of the tank, was modelled. The di-
mensions and materials of the Bridge microdosimeter and waterproof microplus probe
encasing it were closely modelled in the simulation geometry.
Phase-space production and validation
To further optimise the simulation for repeated delivery of the same field for varying de-
tector positions, phase-space files were produced at the end of the beam-line for each
field setup. The phase-space information was scored in a plane between the patient col-
limator and the phantom. The species, position, kinetic energy and momentum direction
was recorded for all particles incident on the scoring plane. This allowed the compu-
tational time for the simulated microdosimetric setup to be greatly reduced by avoiding
repeated tracking of particles through the entire treatment nozzle and apparatus. For field
1 a total of 1010 primary protons were tracked from the start of the beam-line up to the
phase-space scoring plane, this resulted in approximately 107 protons scored prior to the
phantom in addition to other secondary particles produced; neutrons, photons and elec-
trons being among the most abundant. The larger field size for field 2 resulted in the
transmission of more primary protons and as such fewer primary protons, 109 in total,
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were tracked and from which just over 1.3×107 were scored at the phase-space plane. To
ensure adequate statistics and reproducibility of the phase-space information for each of
the radiation fields simulations run using the phase-space information were benchmarked
against the full simulation from the depth dose measurements in water.
The phase-space files were recycled for the out-of-field measurements with the Bridge
microdosimeter until adequate statistics were obtained.
8.3 Results and discussion
8.3.1 Reference dosimetry and evaluation of Geant4 beam-line sim-
ulation
A series of percentage depth dose measurements taken using the MarkusTM chamber
in a water phantom and the corresponding simulated profiles for both radiation fields
are shown in figure 8.5. An obvious inconsistency among the experimentally measured
PDD’s here is attributed to instability of the beam source due to malfunctioning of the
switching and focusing magnets up-stream of the treatment nozzle. Despite this the rel-
ative dose at the centre of the SOBP and in the distal falloff are seen to be relatively
reproducible and show good agreement with the simulated dose profiles. These positions
are significant as measurements performed using Field 1 are at off-axis positions at the
center of the SOBP and beyond the distal falloff and for Field 2 in the distal falloff of the
field.
The variation in the spectrum of kinetic energies of protons at various positions along the
WED (mm)






















































Figure 8.5: Percentage depth dose profiles as a function of water equivalent depth
(WED) from experiment and Geant4 simulation.
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treatment nozzle for Field 1 are shown in figure 8.6. The inset figure magnifies the proton
kinetic energy spectra towards the end of the treatment nozzle where the relative fluence
decreases dramatically due to the central beam stop and various collimators. This plot
shows the energy modulation and degradation of the beam as it traverses various nozzle
components. The nominal and mean energies for this field with R50 = 100 mm are ~113
MeV and ~105 MeV respectively. For this treatment field the RM wheel has 5 different
perspex blade thicknesses, this is reflected by the 5 local maxima in the inset plot of the
proton kinetic energies.
A beams-eye view of the proton fluence at various positions along the treatment noz-
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Figure 8.6: Proton energy spectra following various beam-line components for Field 1
with 108 primaries from Geant4 simulation.
zle from the simulation of Field 1 are depicted in figure 8.7. The figure demonstrates
the increased field size and homogeneity with distance along the treatment nozzle as the
tight 5 mm spot size is scattered to create a collimated, broad-beam field at the patient or
phantom position. The z-axis colour scale here is adjusted to avoid saturation in a given
image however the reduction in proton fluence from the start of the treatment nozzle to
the phantom position at the end is seen to be approximately 10000 times.
Figures 8.6 and 8.7 demonstrate that a substantial proportion of the protons tracked from
the exit of the vacuum window do not reach the end of the treatment nozzle and by im-
plementing a two-stage phase space simulation a substantial amount of CPU time can be
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saved for simulations concerned with the radiation field produced inside the phantom.
Verification of phase-space files simulation
The two-stage phase-space simulation was benchmarked against the full simulation using
percentage depth dose profiles measured in water as shown in figure 8.8. The percentage
difference (PD) between the full simulation and the phase-space setup is also plotted in
this figure. The maximum percentage difference was found to be below ±2% for depths
up to the R50 falloff point for Field 1 and within ±5% for Field 2. Beyond the R50 falloff
the percentage error increases due to significantly lower doses at these points causing an
inherent increase in the statistical uncertainty.
The kinetic energy spectra of the most abundant particles scored in the phase-space files
for both fields are displayed in figure 8.9. The flux is presented per primary proton tracked
from the beginning of the treatment nozzle and scored in the phase-space after the final
patient collimator and just before the face of the phantom. It is clear that the radiation
fields produced by the treatment nozzle are complex and contain a variety of secondary
particles in addition to the primary protons intended for treatment. While electrons and
photons produced are considered to be less biologically effective than the primary protons
and than secondary neutrons produced, these particles have the potential to increase skin
dose and out-out field doses respectively due to electrons short range in tissue at the given
energies up 0.3 MeV and due to photon scatter.
As Field 2 has a larger diameter thus allowing greater transmission of protons through
the patient specific collimator (as well as less shielding of electrons) the resulting fluence
of these particles is approximately 10× that for Field 1. The effect of the smaller aper-
ture on the patient collimator for Field 1 results in significantly more primary beam loss,
a greater number of photons and particularly neutrons produced. Further, as the patient
collimator is the final beam-line element before the patient, the larger number of these
secondaries produced will have a direct impact on the quality of the field delivered and
the potential for dose to non-targeted tissues. Herein lies a perfect example of one of the
advantages of PBS delivery techniques especially for small fields.
8.3.2 Assessment of radiation field and composition
The fluence per treatment dose delivered (at the centre of the target volume), mean kinetic
energy and relative contribution to dose for the most abundant particle species incident at
each measurement position are plotted in figures 8.10, 8.11 and 8.12 respectively.
The fluence of all particles is seen to decrease with increasing lateral distance from the
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Figure 8.7: A beam’s eye view of simulated proton fluence for Field 1 (31 mm SOBP, 3
cm diameter) following beam-line components as labelled. Fluence plots are in order of
position in the beam-line from left-to-right and top-to-bottom.
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Figure 8.8: Comparison between full and two-stage phase-space simulation percentage
depth dose profiles in water for Field 1 (31 mm SOBP) and Field 2 (50 mm SOBP) and
the percentage difference (PD) between the two simulation methods.
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Field 1: 31 mm SOBP
Field 2: 50 mm SOBP
proton energy spectra
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Field 1: 31 mm SOBP
Field 2: 50 mm SOBP
photon energy spectra
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Field 1: 31 mm SOBP
Field 2: 50 mm SOBP
electron energy spectra
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Field 1: 31 mm SOBP
Field 2: 50 mm SOBP
neutron energy spectra
Figure 8.9: Energy spectra of most abundant particles scored in phase space files for
both radiation fields simulated.
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field edge and for many cases position D (beyond the Bragg peak) has a greater num-
ber of incident particles than positions B and C. The mean neutron energy is in the fast
neutron range and the energy spectra of neutrons at all four positions was seen to peak
around 2 MeV. The primary mode of interaction of fast neutrons with tissue or water at
these energies is through hydrogen elastic scattering producing secondary protons with
approximately half the neutron kinetic energy followed by elastic scattering with target
nuclei resulting in oxygen, carbon and nitrogen ions [123]. This is reflected by the rela-
tive fluence of these particles incident and consequently the contribution of these particles
to the overall dose at the out-of-field measurement positions. As such low energy, high
LET charged particles that are largely responsible for the dose deposited out-of-field are
a result of the neutron field produced from nuclear interactions between primary protons
and beam-line components or the phantom. Although the dose is substantially lower than
within the primary field, the biological effectiveness and radiation quality makes it signif-
icant and an important consideration for healthy tissue exposure and resultant late effects.
The fraction of energy deposited by neutrons and photons, seen in figure 8.12, is small as





























Figure 8.10: Yield of various particle species incident at out-of-field measurement posi-
tions
8.3.3 Out-of-field microdosimetry measurements
The microdosimetric lineal energy spectra, yd(y), measured both in experiment and in
simulation using the 3D Bridge microdosimeter orientated face-on at all 4 out-of-field
positions are shown in figure 8.13. The contribution from different particles to the simu-
lated spectra is also shown. As these measurements are performed outside of the primary
field the dose is substantially lower than that in the target volume and so the statistics
for these measurements are low despite maximising the dose-rate delivered and the ac-





































Figure 8.11: Mean kinetic energy of different radiation types incident at out-of-field
measurement positions from simulation of Field 1 in a water phantom. The error bars







































Figure 8.12: Fraction of total dose deposited in water scoring volume at each measure-
ment position according to radiation type.
quisition time in an attempt to register more events for experimental measurements. Low
statistics also became a barrier with increasing distance from the primary field in the
simulation. To combat this, a greater number of particles were fired (by recycling the
phase-space files more times) with increasing distance from the field. This exercise how-
ever is rather computationally expensive due to the low statistics outside the primary field.
At position A the majority of the radiation field is made up of scattered primary pro-
tons and the spectra for the experimental and simulated data appear to peak at similar
lineal energies and bear the same shape. As the off-axis distance is increased (for posi-
tions B and C), the proportion of primary protons reaching the detector is seen to decrease
while secondary protons begin to dominate. At position D, distal to the target volume, no
primary protons contribute to the spectra as this position exceeds their range. Heavier
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Table 8.3: Microdosimetric quantities calculated from experimental and simulated spec-
tra measured using the Microplus probe in water with face-on orientation.
Position Distance from Depth in yF (keV/µm) yD (keV/µm)
CAX (mm) water (mm) Exp Sim Exp Sim
Ref 0 85 - 2.51 ± 0.01 - 4.46 ± 0.08
A 25 85 3.07 ± 0.02 2.99 ± 0.02 11.45 ± 0.58 6.138 ± 0.79
B 50 85 3.49 ± 0.05 2.78 ± 0.22 19.67 ± 1.72 11.03 ± 3.85
C 75 85 3.59 ± 0.07 2.84 ± 0.40 23.71 ± 2.31 21.72 ± 14.01
D 0 130 3.78 ± 0.06 2.89 ± 0.27 21.90 ± 1.67 24.73 ± 12.21
and higher LET α particles are a primary contributor to events on the high lineal energy
end of the spectra. This reflects the spectra of secondary particles produced by neutron
interactions with the phantom and detector materials as discussed in the previous section.
A non-significant contribution from heavier ions such as carbon, nitrogen and oxygen was
observed here however. This is likely due to the denser perspex material in the detector
sheath in combination with the lower average kinetic energy and greater mass of these
ions resulting in higher stopping power and insufficient range to reach the detector.
The simulated spectra for positions B and C underestimate the number of high-lineal
energy events and overestimate the low energy contribution. Simultaneous event regis-
tration could potentially account for the spikes in the experimental yd(y) spectra at lineal
energies around 1-2 keV/µm and the lack of lower lineal energy events recorded. Further,
for energies below 1 keV/µm, detector sensitivity and noise become an issue in practise.
The simulation however allows all energy depositions to be scored.
Table 8.3 shows the frequency-mean and dose-mean lineal energies calculated from the
measured and simulated spectra for the face-on orientation. Uncertainty values for the
simulation data were found from the standard error of the mean for 10 independent sim-
ulations while those from experimental measurements were propagated from the error in
the counts per bin of lineal energy frequency distribution. An in-field reference position
was also considered on the central axis at the centre of the SOBP in simulation (see “Ref”
in table 8.3 and figure 8.3). The calculated yD value at this reference position was found
to be consistent with those presented in literature for clinical proton beams measured with
both the Bridge microdosimeter and TEPCs [96, 97, 124, 125].
The yd(y) spectra for lateral out-of-field positions (A-C) with the Bridge microdosimeter
in the edge-on orientation are shown in figure 8.14 for experimental and simulated data.
The contribution of secondary particles to the spectra at position A is much greater in
the edge-on orientation and a larger spread in the recorded lineal energies, with a greater
proportion of higher lineal energy events, is seen compared with the face-on orientation.
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Position A: 25mm from central beam axis, 85 mm depth
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Position B: 50mm from central beam axis, 85 mm depth
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Position C: 75mm from central beam axis, 85 mm depth
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Position D: 0mm from central beam axis, 130 mm depth
Figure 8.13: Microdosimetric spectra acquired with the Bridge microdosimeter orien-
tated face-on in experiment (grey) and simulation. The total spectra measured in simula-
tion is shown in black as well as the contribution of dominant particles.
The resulting microdosimetric quantities calculated for the detector positioned edge-on
are displayed in table 8.4, the shift to higher lineal energies in the spectra here is reflected
in the greater yD. Figure 8.15 shows experimental and simulated spectra for both orienta-
tions plotted together for each measurement position. The greatest discrepancy between
the detector orientations is observed nearest to the field edge. This is attributed to particles
closer to the field being more forward directed. In such cases the edge-on orientation is
less appropriate as multiple sensitive volumes are able to be traversed by a single particle
and the definition of the particle chord length in the sensitive volume becomes ill-defined.
Figure 8.16 shows the calculated frequency and dose mean lineal-energies plotted as
a function of distance from the central beam axis. Frequency-mean lineal energies in-
creased with distance before reaching a plateau in the face-on orientation however were
found to decrease monotonically for the edge-on orientation. The dose-mean lineal en-
ergy increases with distance from the central beam axis for all data sets. Simulated values
were found to render lower yD values for experiment compared to simulated data and the
face-on orientation was found to give lower values than the edge-on orientation.
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Position A: 25mm from central beam axis, 85 mm depth
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Position B: 50mm from central beam axis, 85 mm depth
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Position C: 75mm from central beam axis, 85 mm depth
Figure 8.14: Microdosimetric spectra acquired with the Bridge microdosimeter orien-
tated edge-on in experiment (grey) and simulation. The total spectra measured in simu-
lation is shown in black as well as the contribution of dominant particles
Table 8.4: Microdosimetric quantities calculated from experimental and simulated spec-
tra measured using the Microplus probe in water with edge-on orientation.
Position Distance from Depth in yF (keV/µm) yD (keV/µm)
CAX (mm) water (mm) Exp Sim Exp Sim
A 25 85 5.32 ± 0.04 4.15 ± 0.40 18.27 ± 0.75 14.83 ± 4.38
B 50 85 4.42 ± 0.07 3.12 ± 0.28 22.90 ± 1.90 14.99 ± 3.45
C 75 85 4.12 ± 0.10 2.91 ± 0.61 27.01 ± 3.03 33.58 ± 22.23
8.3.4 Quality factor and dose equivalent
The average radiation quality factors calculated using the ICRP 60 recommendation and
the lineal energy spectra measured with the Bridge microdosimeter at each position and
the corresponding dose equivalent per treatment dose delivered at the centre of the field
is presented in table 8.5. Figure 8.17 plots these values for positions A-C as a function of
lateral distance from the beam central axis. Both data sets showed a heightened quality
factor obtained edge-on, compared to the face-on orientation however the dependence on
detector orientation was seen to decrease with increasing distance from the field edge for
experimental data. This follows the trends observed in the lineal energy spectra and dose-
mean lineal energies.
The quality factor was seen to increase with distance from the field for experimentally
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Position A: 25 mm from central beam axis, 85 mm depth
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Position B: 50 mm from central beam axis, 85 mm depth
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Position C: 75 mm from central beam axis, 85 mm depth
Figure 8.15: Comparison of micrdosimetric spectra measured with the Bridge micro-
dosimeter for face-on and edge-on orientations in experiment and simulation.
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Figure 8.16: Frequency- (yF ) and dose-mean lineal energies (yD) calculated from mi-
crodosimetric spectra measured with the Bridge microdosimeter in experiment and sim-
ulation for face-on and edge-on orientations.
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Table 8.5: Average quality factor calculated using the ICRP 60 recommendation and
dose equivalent for different out-of-field positions.
Face-on Edge-on
Position Qavg H/DT (mSv/Gy) Qavg H/DT (mSv/Gy)
Exp Sim Exp Sim Exp Sim Exp Sim
A 2.52 ± 0.09 1.46 ± 0.11 24.45 ± 0.85 14.14 ± 1.03 3.83 ± 0.12 3.49 ± 1.28 37.26 ± 1.21 33.90 ± 12.41
B 4.17 ± 0.26 2.71 ± 0.95 0.96 ± 0.06 0.62 ± 0.22 4.80 ± 0.29 3.69 ± 1.05 1.10 ± 0.07 0.85 ± 0.24
C 5.16 ± 0.39 4.49 ± 1.95 0.22 ± 0.02 0.19 ± 0.08 5.41 ± 0.44 7.56 ± 4.02 0.23 ± 0.02 0.32 ± 0.17
D 4.81 ± 0.28 4.75 ± 1.22 25.42 ± 1.48 25.13 ± 6.46 - - - -
measured data while that from the simulation was found to be inconclusive. Yonai et al
[126] and Wroe et al [127] both demonstrated increasing average quality factor with lat-
eral distance in phantom from the treatment volume up to 25 and 50 cm respectively from
the beam axis for comparable passive scattering proton therapy field sizes. These studies
both used measured lineal energy spectra to calculate the quality factors, Yonai using a
TEPC and both ICRP 40 and 60 recommendations while Wroe used SOI microdosimeters
and ICRP 40. The average quality factor, found by Yonai, using the same ICRP recom-
mendations as used in this study found an average quality factor of 5.1 at a distance of
105 mm from the field edge which is consistent with the values reported here for position
C. Both of these studies demonstrated greater quality factor values calculated downstream
of their target than for comparable lateral offsets from the field edge.
The dose equivalent was found to rapidly diminish with distance from the field edge due
to the reduction in the absorbed dose. The dose equivalent determined for positions A and
C are considerably large compared with values reported in literature most with maximum
values of usually no more than 5 mSv/Gy [117–119, 126] with the exception of Binns
[128] et al. As the measurement positions in this study have a much closer proximity to
the field edge, the absorbed doses are approximately 1-2 orders or magnitude higher at
positions A and D than those reported elsewhere. In Binns’ study [128] microdosimetric
measurements using a TEPC in air were performed at the iThemba beamline (the same
as in this study) and reported a dose equivalent value of 80 mSv/Gy at a lateral offset of
13 cm from the field edge. Despite this, measurements in air have been found to ren-
der conservative neutron dose values [120] by approximately a factor of 2 and the dose
equivalent values were also shown to increase with proton energy (Binns’ study using 200
MeV protons).
8.4 Conclusion
The passive double-scattering proton therapy treatment nozzle at the iThemba Labs in
Cape Town, South Africa, was modelled using the Monte Carlo toolkit Geant4. Each
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Figure 8.17: Average radiation quality factor (Qavg) calculated from microdosimetric
spectra measured with the Bridge microdosimeter and corresponding dose equivalent per
absorbed treatment dose (H/DT ) in experiment and simulation for face-on and edge-on
orientations.
proton field delivered has variable beam-line set-up to change the beam size and energy
spread. The simulated beam-line was validated for two fields of interest 1) a 3 cm diame-
ter, 31 mm length target at a maximum range of 100 mm in water and 2) a 10 cm diameter,
100 mm SOBP with maximum range of 120 mm in water.
Field 1 was evaluated for out-of-field radiation quality using the 3D Bridge microdosime-
ter. The field size is representative of a typical head-and-neck target and the micodosi-
metric spectra was measured at the 3 positions lateral to the centre of the SOBP and one
beyond the Bragg peak all within a radius of 75 mm - dimensions similar to a paediatric
patients head. The dose-mean lineal energy and radiation quality was found to increase
with lateral distance from the field edge while the dose equivalent was found to rapidly
drop with distance from the field edge. The radiation quality was found to greater distal
to the target volume in the beam direction than laterally from the centre of the SOBP.
It is important to characterise radiation dose and quality outside of the primary field in
order to evaluate the risk of radiation induced complications and malignancies. The sec-
ondary field produced during therapy is highly dependant on field parameters and delivery
methods and as such clinics should do this on an individual basis. Small, reliable and ver-
satile detectors such as the Bridge microdosimeter are well suited for such applications
however require further characterisation for sparse radiation like that in the out-of-field
environment.
Chapter 9
SOI microdosimetry and modified
MKM for evaluation of relative
biological effectiveness for a passive
proton therapy radiation field
The results presented in this chapter have been publish in the journal Physics in Medicine
and Biology:
E. Debrot, L. T. Tran, L. Chartier, D. Bolst, S. Guatelli, C. Vandevoorde, E. A. de Kock, P.
Beukes, J. Symons, J. Nieto-Camero, D. A. Prokopovich, S. Chiriotti Alvarez, A. Parisi,
M. De Saint-Hubert, F. Vanhavere, J. Slabbert and A. B. Rozenfeld,“SOI microdosimetry
and modified MKM for evaluation of relative biological effectiveness for a passive proton
therapy radiation field”, Physics in Medicine and Biology, 2018, 63.
9.1 Overview
With more patients receiving external beam radiation therapy with protons, it becomes
increasingly important to refine the clinical understanding of the relative biological effec-
tiveness (RBE) for dose delivered during treatment. Treatment planning systems used in
clinics typically implement a constant RBE of 1.1 for proton fields irrespective of their
highly heterogeneous linear energy transfer (LET). Quality assurance tools that can mea-
sure beam characteristics and quantify or be indicative of biological outcomes become
necessary in the transition towards more sophisticated RBE weighted treatment planning
and for verification of the Monte Carlo and analytical based models they use.
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It has been well documented that a strong correlation exists between LET and RBE due
to greater localisation of radiation induced DNA damage. As a result, RBE models that
relate dose deposited due to high LET particles to that with conventional x-ray therapies
for the same biological effect have been developed and introduced for clinical treatment
planning in carbon ion therapy; namely, the Local Effect Model (LEM) [54, 57] and the
modified Microdosimetric Kinetic Model (MKM) [52, 53, 129]. Despite the increasing
LET of protons along their track and the demonstrated heterogeneity of RBE in proton
fields that results from this [7, 57, 96–98, 124, 130, 131], a constant RBE of 1.1 has
been adopted for proton therapy treatment planning systems used clinically throughout
the world.
The MKM method is based on the measurement of microdosimetric spectra typically
using tissue-equivalent proportional counters (TEPC), however the development of small
volume semiconductor detectors have shown promise for ion beam quality assurance and
microdosimetry. In this study the RBE for the Chinese hamster ovary (CHO-K1) cell
line in a passively delivered clinical proton spread out Bragg peak (SOBP) from a passive
delivery system is determined both in-vitro and using a silicon-on-insulator (SOI) micro-
dosimetry method paired with the modified Microdosimetric Kinetic model. The silicon
3D Bridge microdosimeter [94] is used in this investigation to measure the lineal energy
spectra of the proton beam and is used as an input for the modified MKM [53]. Mea-
surements were concentrated at the distal end of the SOBP where changes in the proton
LET/RBE are expected to be most pronounced and a high resolution of measurements
can be obtained due to the advantages of the wall-less design and small sensitive volume
of the 3D Bridge microdosimeter used.
9.2 Materials and Methods
9.2.1 Radiation field and reference dosimetry
Both radiobiological and microdosimetric measurements (see sections 9.2.4 and 9.2.5 re-
spectively) were conducted in the passive clinical proton beam-line at the iThemba labs
in South Africa. The beam-line employs a number of scattering and flattening filters to
produce a broad beam and a range modulation wheel paired with a double-wedge energy
degrader to produce a spread out Bragg peak (SOBP) at the desired depth. A 200 MeV
proton beam is fed from the separator-sector cyclotron to the treatment nozzle. For this
investigation a 50 mm SOBP with R50 (50% distall falloff) range of 120 mm in water and
a 10 cm diameter field was delivered. The primary beam energy was degraded to approx-
imately 127 MeV at the surface of the phantom for the protons with maximum range in
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the SOBP.
The physical depth-dose profile of the proton SOBP was measured along the central axis
of the beam using a MarkusTM ionisation chamber (model 30-329) with 0.055 cm3 sen-
sitive volume size in a water phantom and is shown in figure 9.1. Physical dose mea-
surements were used as reference dosimetry for the radiobiology and microdosimetry
components and for RBE calculations for a prescribed dose, D, with protons (RBED) of
2Gy at the middle of the SOBP.
9.2.2 Modified MKM for cell survival estimation
The modified MKM [53] relates the surviving fraction of cells, S, to the average num-
ber of lethal lesions in the nucleus, L, and to the dose-mean lineal energy corrected for
saturation, y∗, in the LQ model as follows:
S = exp
(−L)= exp(−αD−βD2)= exp[− (α0+ βρpir2d y∗)D−βD2
]
(9.1)
Where α0 is the slope in the limit of LET → 0, β is the quadratic coefficient of the
LQ model and its value is independent of radiation type, D is the absorbed dose and the
saturation corrected dose-mean lineal energy y∗ is given by equation 9.2. The linear term
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(9.2)
Here f (y) is the probably density function of y and y0 is the saturation correction param-





Where ρ and rd are the density and radius of the domain respectively and Rn is the radius
of the nucleus.
The lineal energy spectra was measured in experiment using the 3D Bridge microdosime-
ter (see section 9.2.5) from which the αMKM values were calculated as in equation 9.1.
Parameters α0 and rd were determined from the y-intercept and slope, respectively, of the
linear least squares fitting of α values determined from in-vitro irradiations as a function
of the calculated yD from the measured lineal energy spectra. Since in the limit LET→ 0,
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y∗ ∼= yD then:
αMKM ∼= α0+ βρpir2d
yD (9.4)
Where yD denotes the dose-mean lineal energy.
9.2.3 RBE calculation
The RBE for a 10% cell survival (RBE10) and for a given proton dose Dp (RBED) were
calculated using equations 9.5 and 9.6 respectively. RBE is defined as the ratio of the
dose delivered with the reference radiation to that with protons for the same cell survival
S. Here the dose for a given cell survival is derived from equation 9.1.
RBE10 =
2βre f D10,re f√
α2p−4βre f ln(0.1)−αp
(9.5)
Where D10,re f is the dose of reference radiation resulting in a 10% cell survival given
from the LQ model for cell survival (
√
α2re f −4βre f ln(0.1)−αre f )/2βre f , αre f and αp are




α2re f −4βpln(Sp)−αre f
2βpDp
(9.6)
RBED values were determined for a dose of 2 Gy delivered at the maximum dose po-
sition in the proton SOBP. Two reference curves were considered, a Co60 photon curve
measured at the iThemba Labs with LQ parameters αCo = 0.173± 0.031 Gy−1, βCo =
0.039±0.003 Gy−2 and D10,Co = 5.77 Gy and a 250kVp x-ray reference curve taken from
Weyrather et al [132], with LQ parameters αx = 0.228±0.020 Gy−1, βx = 0.020±0.002
Gy−2, and D10,x = 6.45 Gy. The Co60 curve was used as this was able to be measured at
the same time and under the same conditions as the proton curves; however as this showed
some deviation in its slope compared to the measured proton survival curves and those
reported in literature, the latter reference curve was also considered as it has a consistent
β value with the proton data measured in this experiment.
9.2.4 In-vitro cell irradiation
In this investigation particular emphasis is placed on the RBE at the distal end and in the
falloff region of the SOBP. As this region of the treatment field often lies within healthy
tissue distal to the tumour volume but still within the planned treatment volume, the Chi-
nese hamster ovary (CHO-K1) cell line, that has a similar response to healthy tissue, was
used for irradiation. Clonogenic survival assay was performed in order to determine the
RBE at varying positions within the proton SOBP.
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CHO-K1 cells, donated from the Medical University of Southern Africa (MEDUNSA)
(passage number 16), were cultured in Roswell Park Memorial Institute (RPMI) medium
supplemented with 10% fetal calf serum (FCS) and 1% pen/strep in culture flasks. Af-
ter trypsinization, exact cell numbers were seeded in 60 mm Petri-dishes for irradiation
aiming for 200 surviving colonies per Petri-dish according to a previously established di-
lution scheme. Samples were positioned within a Perspex plate with a Petri-dish cut-out
designed to hold the samples at varying depths (see table 9.1) in a Perspex phantom with a
positioning accuracy of 0.1 mm. Samples were incubated for 6 days following irradiation
after which they were stained with 0.5% Crystal violet and counted. Colonies containing
50 or more cells were considered viable and scored. The average plating efficiency was
observed to be 82%.
The resultant survival curves were fit using the linear-quadratic model for cell survival
and in-vitro RBE10 and RBED values were calculated from equations 9.5 and 9.6 respec-
tively.
9.2.5 Microdosimetric Measurement with 3D Bridge Microdosime-
ter and MicroPlus probe
The 3D Bridge microdosimeter is a SOI microdosimeter comprised of an array of 3D sil-
icon sensitive volumes over a combined area of 4.1× 3.6 mm2. Individual 3D sensitive
volumes have an area of 30× 30 µm2, similar to that of a cell, and a thickness of 10 µm
connected in 6 odd and even arrays. For this study one array of sensitive volumes was
used for readout in order to avoid pileup. The Bridge microdosimeter is described in fur-
ther detail in by Tran [94] and Rosenfeld [93]. The SOI microdosimeter has previously
been used for microdosimetric characterisation of clinical 12C ion therapy beams [94, 98]
and for RBE calculation using the modified MKM [53]. Recently the microdosimeter has
also been applied in proton beam studies in both clinical passive double scattering (DS)
systems by Tran [97] and in pencil beam scanning (PBS) delivery by Anderson [96] and
Howard [124] in order to measure yD and in the latter study to compare this with in-vitro
RBE measurements.
The Bridge is advantageous for microdosimetry applications in particle therapy due to
its small sensitive volume size allowing for measurements to be taken with high spatial
resolution along the incident particle direction and their array formation results in a com-
bined spectra indicative of the radiation quality received by a group of cells rather than
in a singular volume. Furthermore the SOI microdosimeter requires very little operating
voltages and do not require gas flow as the gold standard TEPC does.
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In this investigation the lineal energy spectra was measured at a number of water equiv-
alent depths (WEDs) in a Perspex phantom with a high resolution of measurements at
the distal end of the SOBP and at WED positions corresponding to the in-vitro measure-
ments using the 3D Bridge microdosimeter. The detector was mounted in a polymethyl
methacrylate (PMMA) waterproof sheath named the MicroPlusTM probe developed at the
Centre for Medical Radiation Physics and positioned in a Perspex plate cut-out in the
phantom again with a positioning accuracy of 0.1 mm.
A tissue correction factor of 0.58 was applied to the recorded energy spectra to relate
the average chord length measured in silicon to that in tissue in accordance to the meth-
ods of Bolst [133] applied to protons at therapeutic energies [97]. The average chord
length 〈l〉 in silicon was considered to be 10 µm also based on the findings of Bolst [98,
133] that showed that the average path length of ions traversing a sensitive volume is
best approximated by the sensitive volume thickness in the incident beam direction. This
study showed that due to the high directionality of ion beams used for therapy, Cauchy’s
formula is not appropriate to determine 〈l〉 as it is for an isotropic source.
9.2.6 Monte Carlo Simulation
The iThemba proton beam line was modelled using the Monte Carlo toolkit Geant4 [101]
from the point at which the protons emerge from the vacuum window from the accelera-
tor. Primary protons were tracked from a 5 mm diameter source on the downstream face
of the vacuum exit window with initial energy 200 MeV and momentum along the beam
direction. The source was modelled to be monoenergetic with momentum direction along
the beam direction only. The passive beam line was closely modelled whereby the pri-
mary beam undergoes considerable scattering and variable energy degradation resulting in
an energy and momentum direction spread of the beam incident on the phantom surface.
Geant4 version 10.02.p02 was used in this investigation, the electromagnetic interactions
were modelled using G4EmStandardPhysics option3, the neutron High Precision (HP)
model was implemented for neutron interactions up to 20 MeV. G4IonINCLXXPhysics
and HadronElasticPhysicsHP were used for hadron fragmentation and elastic scattering
processes, respectively.
The program was benchmarked against percentage depth dose (PDD) ion chamber mea-
surements in a water tank for the physical dose characteristics of the SOBP used and
strong agreement was observed particularly in the distal falloff region, see figure 9.1. The
3D Bridge microdosimeter and MicroPlus probe were simulated and the microdosimetric
spectra was scored at the same WEDs as in experiment.
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Figure 9.1: Percentage depth dose profile of the proton radiation field with 50 mm SOBP
and R50 range of 120 mm in water measured in experiment with an ion chamber and from
the Geant4 simulation.
9.3 Results and discussion
9.3.1 In-vitro RBE with CHO cell line
Figure 9.2 shows the measured CHO cell survival curves for different positions in the
SOBP and in the distal falloff. Table 9.1 shows the calculated α and β values for each
curve obtained from a least square fitting. The proton cell survival curves were first fit
without parameter restrictions and resulted in a relatively constant β with an average
value of 0.021± 0.006 Gy−2 at the 95% confidence level. This justified the use of a fixed
beta value of 0.02 Gy−2, equal to that of the 250kVp x-ray reference radiation, for the
curve fitting without significant increase in the associated parameter uncertainties. This
supports a fundamental assumption of the MKM that the quadratic term is independent
of the radiation type. The α value was found to increase with depth in the SOBP with
the exception of the 20% distal falloff position which was subject to greater uncertainties.
RBE10 values were found to range from 1.07 - 1.58 and RBED varied between 1.11 -
1.93 with values increasing with penetration depth and thus proton LET along the SOBP.
Calculated RBE values are shown in table 9.2. As such the static value of 1.1 was found
to underestimate the RBE for both endpoints in the SOBP region and most significantly
in the distal falloff. The RBE values are plotted with RBE values calculated from the
SOI-microdosimetry-MKM method in figure 9.6 as a function of WED.
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Figure 9.2: CHO cell survival curves for 250 kVp x-ray reference radiation (black)
[132], Co60 reference radiation (dashed) and at varying depths along the SOBP with
particular interest in the distal fall-off region whereby the percentage shown is rounded
to the nearest 10% of the maximum dose delivered in the SOBP at the distal fall-off
(see table 9.1 for exact values). Error bars indicate 2σ in the survival recorded between
triplicate samples.
9.3.2 Microdosimetry Measurements
The microdosimetric yd(y) spectra plotted as a function of lineal energy y is shown in fig-
ure 9.3. The spectra has been converted from that measured in silicon with the 3D Bridge
microdosimeter to tissue for both experimental measurements and from simulation. The
peak of the spectra is seen to shift to larger lineal energies with increasing depth in the
Table 9.1: LQ parameters for in-vitro cell survival curves under free fitting conditions
and with a fixed β = 0.020 Gy−2 (equal to the 250kVp x-ray reference radiation) at
different positions across proton SOBP.
Free fit Fixed β fit
WED (mm) PDD (%) α (Gy−1) β (Gy−2) α (Gy−1) β (Gy−2)
30.006 74.88 0.314 ± 0.058 0.011 ± 0.006 0.260 ± 0.008 0.020 ± 0.002
94.432 101.10 0.328 ± 0.030 0.018 ± 0.003 0.316 ± 0.004 0.020 ± 0.002
117.310 83.44 0.390 ± 0.059 0.017 ± 0.006 0.370 ± 0.007 0.020 ± 0.002
119.360 57.18 0.431 ± 0.060 0.026 ± 0.006 0.469 ± 0.008 0.020 ± 0.002
120.476 39.76 0.418 ± 0.059 0.030 ± 0.006 0.483 ± 0.008 0.020 ± 0.002
122.056 18.98 0.461 ± 0.123 0.020 ± 0.013 0.461 ± 0.016 0.020 ± 0.002
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Table 9.2: Calculated RBE at different positions across proton SOBP using LQ parame-
ters from the fixed β fit to experimental data. RBED is calculated for 2 Gy at the SOBP.
250kVp x-ray Reference Co60 Reference
WED (mm) PDD (%) RBE10 RBED RBE10 RBED
30.006 74.88 1.07 ± 0.02 1.11 ± 0.08 0.95 ± 0.02 1.19 ± 0.12
94.432 101.10 1.19 ± 0.01 1.28 ± 0.08 1.06 ± 0.01 1.30 ± 0.11
117.310 83.44 1.31 ± 0.02 1.46 ± 0.10 1.17 ± 0.01 1.49 ± 0.13
119.360 57.18 1.55 ± 0.02 1.82 ± 0.12 1.38 ± 0.02 1.91 ± 0.17
120.476 39.76 1.58 ± 0.02 1.93 ± 0.14 1.41 ± 0.02 2.09 ± 0.21
122.056 18.98 1.53 ± 0.04 1.93 ± 0.16 1.37 ± 0.03 2.27 ± 0.30
SOBP reflecting increasing particle LET with depth.
The simulated spectra was found to peak at lower lineal energies than those measured
experimentally, particularly for more proximal positions. A small secondary peak is ob-
served at the high lineal energy end of the spectra for the 20% SOBP falloff position and
is particularly pronounced for the simulated profile. Further analysis of the simulated
spectra revealed that this high lineal energy peak is attributed to primary protons with in-
sufficient kinetic energy to traverse the thickness of the detector. These high LET protons
result in high lineal energy events being recorded as they stop in the sensitive volume
(stoppers). These stopper events are suppressed in the calculation of y∗ and RBE due to
the saturation correction parameter that reduces the weight of high lineal energy events.
In light of this and due to the small subset of the spectra where the stopper peak is seen,
no further effort was made to account for this peak.
The frequency-mean, yF , and dose-mean, yD lineal energies calculated from the mea-
sured microdosimetric spectra in experiment and simulation are plotted as a function of
WED in figure 9.4. Greater mean y values obtained for experiment, in the proximal and
plateau region of the SOBP, reflect the slight shift of the spectra towards higher lineal
energies compared to simulation.
A larger contribution from stoppers for simulated spectra however result in greater mean
y values for simulation in the distal falloff. It is anticipated these stoppers are more promi-
nent in simulated spectra due to an ideal charge collection efficiency that doesn’t occur in
experiment and due to limitations on WED uncertainties.
A clear increase in the lineal energy is observed in the distal end and in the falloff of
the SOBP with yD values calculated between 3.16 and 10.17 keV/µm in experiment and
from 2.73 to 10.36 keV/µm from simulation. These values were found to be consistent
with those in literature for therapeutic proton fields measured with a TEPC [53, 125] and
with the Bridge microdosimeter [96, 97, 124].
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Figure 9.3: Microdosimetric spectra measured with the 3D Bridge microdsimeter in
the proton SOBP at the maximum, 80%, 60%, 40% and 20% falloff values for ex-
periment (solid lines) and from the Geant4 simulation (dashed lines). The distribu-
tion represents the product of the lineal energy with the dose distribution given by
d(y) = y f (y)/
∫
y f (y)dy against the logarithm of lineal energy, log(y).
9.3.3 Modified MKM parameters
The α values measured in-vitro are plotted against the calculated experimental yD values
in figure 9.5. Note a fixed β value of 0.020 Gy−2 was maintained. A linear least square
fitting of this data revealed α0 = 0.201± 0.050 Gy−1 in the limit of LET→ 0 and rd =
0.192± 0.040 µm was determined from the slope (see equation 9.4). The radius of the
nucleus was assumed to be Rn = 3.3 µm determined from the average CHO cell radius
and its ratio with nuclear size as measured by [134]. The saturation correction factor was
calculated from these parameters and equation 9.3 to be y0 = 87.71 keV/µm. The linear
relationship assumed between α and yD is reasonable for the range of data presented here
up to ~10 keV/µm.
9.3.4 RBE calculations
The saturation corrected dose-mean lineal energy, y∗, and the αMKM parameters were cal-
culated for each measurement position with the MKM input parameters determined in
section 9.3.3. From these the RBE10 and RBED were calculated for both 250kVp x-ray
and Co60 reference radiation and are plotted in figure 9.6(a) and (b) respectively as a
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Figure 9.4: Frequency-mean, yF , dose-mean, yD and saturation corrected, y∗, lineal
energies calculated from microdosimetric spectra measured in the proton SOBP with the
3D Bridge Microdosimeter in experiment and simualtion.
Figure 9.5: Measured α values for CHO as a function of dose-mean lineal energy, yD,
calculated from microdosimetric spectra measured with the 3D bridge microdosimeter at
WEDs listed in table 9.1.
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function of WED. RBE10 values were found to increase from 1.1 to 1.56 while RBED
values varied between 1.15 and 1.98 for the x-ray reference radiation. For Co60 reference
radiation RBE10 varied from 0.98 to 1.39 and from 1.21-2.32 for RBED. RBE10 values
less than 1.1 in the proximal part of the SOBP for the Co60 reference are attributed to the
greater β for this curve.
RBE values calculated from simulated microdosimetric spectra were found to follow the
same trend as the mean y, with lower values in the regions proximal to and in the plateau of
the SOBP however were slightly elevated at the distal falloff in comparison to experiment.
The RBE calculated from the SOI-microdosimetry-MKM method were found to agree
to those from in-vitro data within experimental uncertainty and fell within a percentage
difference < 8% for corresponding WEDs for both endpoints.
9.4 Conclusions
The RBE was determined for a clinical proton SOBP field at varying depths both in-vitro
and for an experimental SOI-microdosimetry-MKM approach for the CHO-K1 cell line.
The RBE10 values were found to vary from 1.07-1.58 and RBED between 1.11-1.98 for a
250 kVp x-ray reference radiation and from 0.95-1.41 for RBE10 and 1.19-2.34 for RBED
for Co60 reference radiation. A percentage difference < 8% was found between the in-
vitro and microdosimetry approaches for both endpoints assessed.
The 3D Bridge microdosimeter was used to measure the lineal energy spectra within the
proton SOBP with a high spatial resolution along the incident beam direction. Modified
MKM input parameters for CHO-K1 cells were determined from the measured yD and
in-vitro α parameters for the cell line used and were found to accurately reproduce the
cell survival from measured spectra.
The SOI-microdosimetry-MKM method presented here for determination of cell survival
after irradiation with protons at therapeutic energies was demonstrated to be effective.
It was shown that the 3D Bridge microdosimeter can be used for fast determination of
beam quality and the measured spectra can be used for accurate RBE prediction. The 3D
Bridge microdosimeter has potential to be used as a QA tool for RBE verification of bio-
logically optimised treatment plans. This study has again demonstrated a large variation
in the biological effectiveness of a therapeutic proton beam and highlighted the need for
its consideration in the treatment planning process.
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Figure 9.6: RBE values calculated from in-vitro CHO cell survival curves (see figure
9.2) and calculated using the modified MKM with CHO fit parameters and measured
lineal energy spectra with the 3D Bridge microdosimeter (figure 9.4) for 10% survival
(RBE10) and for 2 Gy delivered at the middle of the SOBP (RBED).
Chapter 10
Investigating variable RBE in a carbon
ion minibeam field with microdosimetry
and Geant4
The results presented in this chapter have been published in the journal Radiation Protec-
tion Dosimetry:
E. Debrot, D. Bolst, B. James, L. Tran, S. Guatelli, M. Petasecca, D. A. Prokopovich,
M. Reinhard, N. Matsufuji, M. Jackson, M. Lerch and A. B. Rosenfeld, “Investigating
Variable RBE in a 12C Minibeam Field With Microdosimetry and Geant4”, Radiation
Protection Dosimetry, 2018, 1-7. [135]
10.1 Overview
External ion beam radiation therapies, with protons and 12C ions in particular, are modal-
ities that have experienced rapid growth in recent decades for the treatment of malignant
tumours. This can be attributed to the advantageous physical and biological character-
istics of using ions for therapy in comparison to conventional treatments using photons.
The Bragg curve that features sharp dose gradients with the highest dose being deposited
at the distal end of the ion range and the relatively small lateral scattering of the ions
makes it possible to achieve a highly conformal dose delivery. This allows sparing of
healthy tissues surrounding the target volume. Further, the variable LET along ion beam
tracks results in an increased relative biological effectiveness (RBE) that is particularly
pronounced in the Bragg peak.
Despite the high ratio of peak to entrance dose for 12C ions, the dose in the entrance
channel of the beam, proximal to the target volume, is one of the greatest contributors to
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dose in healthy tissue both in passive scattering and active scanning beam delivery sys-
tems. In order to achieve a higher therapeutic ratio for 12C ion therapy, the biologically
effective dose to healthy tissue in the entrance channel needs to be reduced.
Microbeam studies with synchrotron produced high-intensity photons have demonstrated
increased healthy tissue tolerance to spatially fractionated doses compared with tumorous
tissues [136]. Minibeam radiation therapy (MBRT) with 12C ions is proposed to incorpo-
rate the benefits of 12C therapy with the added healthy tissue sparing effects due spatial
fractionation proximal to the target. 12C minibeams (~0.5mm), spread laterally with pen-
etration depth in a medium or patient. As such, an array of 12C minibeams produces a
complex radiation field whereby spatial fractionation is achieved in the entrance channel
of the beam and an increasingly homogeneous field is produced with penetration depth as
the minibeams spread to form a solid radiation field. MBRT fields could potentially be
used for spatial fractionation in the entrance channel of the beam, proximal to the target,
while maintaining a homogeneous field in the target volume.
In order to characterise the MBRT field produced and the variable relative biological
effectiveness as a function of the lateral position in the minibeam structures at varying
depths, small volume, high spatial resolution microdosimeters are required in order to
determine the spatial fractionation of the biological dose and potential benefits of MBRT.
In this chapter an experimental and simulation-based study was performed on a 12C ion
minibeam radiation therapy (MBRT) field produced with a clinical 12C broad beam and
a brass multi-slit collimator (MSC). The microdosimetric properties of the variable ra-
diation field produced were measured using the 3D SOI Bridge microdosimeter and a
single sensitive volume microdosimeter (SSMD), both developed at CMRP. The micro-
dosimetric spectra at varying positions throughout the MBRT field and the corresponding
dose-mean lineal energies and RBE for 10% cell survival (RBE10) were calculated using
the modified Microdosimetric Kinetic Model (MKM).
10.2 Materials and Methods
10.2.1 Bridge and SSMD SOI microdosimeters
Two SOI microdosimeters, were used in the experimental measurements presented in this
work; the 3D Bridge microdosimeter [95] and a single sensitive volume microdosimeter
(SSMD).
The Bridge microdosimeter is made up of an array of silicon sensitive volumes over a
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Figure 10.1: Bridge microdosimeter and scanning electron microscope image of sensi-
tive volumes (right).
combined area of 4.1 × 3.6 mm2 with a thickness ~10 µm. Individual sensitive volumes
have an area of 30 × 30 µm2 with connecting bridge volumes 10 × 20 µm2. The Bridge
microdosimeter is described in further detail in by Tran et al. [95] and Rosenfeld [93] and
is shown in figure 10.1. The Bridge microdosimeter has previously been used for RBE
studies with 12C ions and was shown to produce comparable results to measurements with
a tissue-equivalent proportional counter (TEPC) [95].
The SSMD is operated using a single sensitive volume with an area of 10× 250 µm2 and
thickness ~10 µm. This small single volume detector allows for microdosimetric mea-
surements to be taken with a high spatial resolution.
While the TEPC is the gold standard detector for microdosimetry such a large detec-
tor geometry is not suited to the small, highly variable fields used in MBRT. The SOI
microdosimeters used in this work are advantageous for MBRT due to their small sensi-
tive volume size and unlike TEPC’s, these detectors operate at low voltages and do not
require a gas flow ensemble.
10.2.2 Minibeam production and experimental setup
Experimental measurements were carried out at the Heavy Ion Medical Accelerator in
Chiba (HIMAC) using Biological beamline that is a passive beam using the wobbler-
scatterer method. A mono-energetic 290 MeV/u 12C ion broad beam and a custom brass
multi-slit collimator (MSC) were used to generate a minibeam radiation field. The col-
limator has an area of 15 × 15 cm2 and is 45 mm thick with 21 slits 0.5 mm × 25 mm
at a centre-to-centre spacing of 1 mm. The collimator was positioned with the slits in
a vertical orientation ~10 cm after the XY brass collimators of the beamline. The XY
collimators were positioned so that a field size of 28 × 40 mm2 was incident on the MSC
in order to completely cover the slits whilst avoid beam loss in and activation of the MSC
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Figure 10.2: MSC and experimental setup.
(as it is composed of 2.5% lead, much higher than the beamline collimators). Figure 10.2
shows the MSC and the experimental setup. Gafchromic film was placed before and after
the MSC at various depths in a PMMA phantom in order to check the coarse alignment
of the detector and observe the minibeam structures emerging.
The Bridge and SSMD SOI microdosimeters were connected to the readout electron-
ics µ-plus probe in a PMMA waterproof sheath attached to a 2D motion stage and water
phantom (see figure 10.2). This allowed for the detectors to be moved throughout the
MBRT field remotely with step sizes down to 100 µm both laterally and in depth within
the water phantom.
10.2.3 Comparison between broad beam and MBRT fields
The Bridge microdosimeter was used to measure the microdosimetric spectra at varying
depths in the water phantom both with and without the MSC in place. For the MBRT case
(where the MSC was used), the detector was positioned at the centre of the MBRT field
and as the active area of the Bridge microdosimeter covers an area of 4.1 × 3.6 mm2,
the contribution from multiple peak and valley regions of the minibeams were acquired
together in an ‘average’ spectra. A comparison between the measured spectra for the
broad beam and MBRT fields was made from the microdosimetric spectra measured and
the corresponding RBE10 values calculated using the modified MKM (see the following
section on MKM) [53, 94, 95, 137].
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Figure 10.3: MSC and SSMD setup, the SSMD detector is represented by the solid box
that was positioned at various lateral positions in the field. The dashed boxes represent
the simulated SSMD-sized water volumes with two scoring orientations.
10.2.4 Lateral profiling of MBRT field
The SSMD detector was used to measure the microdosimetric spectra in the peak and val-
ley regions of the MBRT field at varying depths in the water phantom. The detector was
orientated with its 250 µm side perpendicular to the minibeams as shown in figure 10.3
and was moved laterally through the field in order to measure the changing dose-mean
lineal energy and calculate the corresponding RBE10.
This setup was also simulated with the Geant4 application where water volumes with
the same dimensions as the SSMD detector were placed in the MBRT field. The 10
× 250 µm2 area was placed in two orientations, with the 250 µm2 edge parallel to the
scanning direction (the orientation used in the experimental measurements) and with the
10 µm2 side parallel to the scanning direction. This was done in order to observe the effect
of minibeam ‘smearing’ due to the long edge of the detector crossing the peak edge and
valley in some positions in the experimental setup.
10.2.5 Monte Carlo simulations
The HIMAC Biological beamline and experimental setup including detailed detector ge-
ometry were modelled in a Monte Carlo simulation using Geant4 version 10.2p02. The
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application used was adapted from that described by Bolst et al [137]. The electromag-
netic interactions were modelled using G4StandardOption3, the neutron High Precision
(HP) model was used to describe neutron interactions up to an energy of 20 MeV. The Bi-
nary Intranuclear Cascade (BIC) model and the G4HadronicElasticPhysicsHP were used
for hadron fragmentation processes and elastic scattering, respectively.
The Bridge microdosimeter response was modelled for different misalignment angles of
the brass MSC in order to gain insight into the experimental response and misalignment
during setup. The impact of collimator misalignment on the radiation quality throughout
the MBRT field was investigated and the ideal case was modelled for the two detectors
and the respective measurements taken.
10.2.6 RBE10 calculation with modified MKM
The lineal energy, y, is a fundamental microdosimetric quantity and is defined as the en-
ergy deposited in a single event per average chord length in a micrometre sized sensitive
volume. The dose-mean lineal energy, yD is given in equation 10.1, where f (y) represents






The modified microdosimetric kinetic model (MKM) uses the spectra of lineal energies
deposited in a sensitive volume in order to approximate the cell survival and is assumed
to be independent of the radiation type. The MKM uses the linear quadratic (LQ) model
of cell survival where the alpha value is calculated using equation 10.2. The saturation-
corrected dose mean lineal energy, y∗, (see equation 10.3) is used here accounts for cell







(1− exp(−y2/y20)) f (y)dy∫
y f (y)dy
(10.3)
For RBE calculations presented in this work the following parameters from Kase et al.
[53] for the HSG cell line were used: α0 = 0.13 Gy−1, β = 0.05 Gy−2, the domain radius
CHAPTER 10. INVESTIGATING VARIABLE RBE IN A 12C MINIBEAM FIELD155
rd = 0.42 µm, the cell density ρ = 1 g/cm3 and the saturation correction factor y0 = 150
keV/µm. The relative biological effectiveness for 10% cell survival, RBE10, values were
calculated according to equation 10.4 where 200kVp X-ray radiation was used as the ref-




The SOI microdosimeters used in this work are not tissue-equivalent and thus a correction
factor was applied in order to relate the average chord length through the silicon sensitive
volumes to that in water. A correction factor of 0.57 was applied to the chord length when
computing the lineal energy in accordance with the findings of Bolst et al [133].
10.3 Results and Discussion
10.3.1 Comparison between broad beam and MBRT fields
The microdosimetric spectra measured with the Bridge microdosimeter placed at the cen-
tre of the 12C broad beam and MBRT fields are shown in figure 10.4. This plot clearly
shows a shift to higher lineal energies with increasing depth in the water phantom leading
up to the Bragg peak. The microdosimetric spectra for the MBRT field with the MSC in
place show a decrease in the height of the peak as well as a greater contribution of high
energy deposition events. This is attributed to degradation of the primary beam energy
and thus increasing primary ion LET in the MSC. The production of secondary fragments
in the MSC also contributes to the high energy tail beyond the peak in the microdosimet-
ric spectra.
The RBE10 values calculated using the spectra measured with the Bridge microdosimeter
and equation 10.4 at varying depths in water are plotted in figure 10.5 for both experimen-
tal measurements and from the Geant4 simulation. The shift in the microdosimetric spec-
tra to higher lineal energies with the introduction of the MSC is reflected here in higher
RBE10 values; an average increase in the RBE10 of around 30% in the plateau region of
the Bragg curve was observed when the MSC was used.
The simulated spectra for perfect MSC alignment (with 0◦ rotation relative to the beam
axis) results in RBE10 values approximately 10% greater than for the broad beam case.
The disagreement between the spectra obtained for experiment and simulation for the
MBRT field was suspected to be due to misalignment of the MSC in the experimental
measurements. As such, the Geant4 application was used to further investigate the impact






















Figure 10.4: Comparison of microdosimetric spectra measured with the Bridge in a 12C
ion broad beam (dashed lines) and MBRT field (solid lines) at varying depths in a water
phantom.
of collimator misalignment on the radiation field and the resulting spectra. These findings
are presented in the following section.
10.3.2 Effect of collimator misalignment
Figure 10.6 compares the microdosimetric spectra measured in experiment (with and
without the MSC) at a depth of 20 mm in water and the simulated spectra from the Geant4
application at the same depth for varying MSC misalignment angles. The peak height and
sharpness decreases with increasing misalignment angle and a greater proportion of high
energy deposition events is seen to occur. This is expected as the thickness of brass tra-
versed by the primary beam increases with the angle of misalignment resulting in more
energy loss and fragmentation of primary ions. A simulated MSC angle of 0.7◦ was found
to give the best agreement to the microdosimetric spectra measured with the Bridge mi-
crodosimeter in experiment.
Figure 10.5 also depicts the calculated RBE10 values for the simulated MSC at a 0.7◦
misalignment and has good agreement with the experimental MSC values. The lateral
physical dose profile for perfect alignment of the collimator and for 0.7◦ misalignment is
shown in figure 10.7.
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Figure 10.5: RBE10 values calculated from microdosimetric spectra measured with the
Bridge microdosimeter detector from experiment and Geant4 simulation.
The valley dose is seen to increase with misalignment angle of the collimator. This is
expected as the proportion of the primary beam travelling through brass before emerging
from the collimator is higher with greater angles. The overall beam profile also becomes
less symmetric and a shift in the peak maxima is observed. Figure 10.8 shows a 2D plot
of the physical dose deposited in the water phantom for perfect MSC alignment and for
the 0.7◦ offset. The minibeam structures cannot be clearly resolved for the experimental
MSC misalignment that was used. Further with this 0.7◦ MSC misalignment the physical
dose delivered in the entrance region is a factor of ~10 higher than at the expected depth
of the Bragg peak.
The collimator alignment therefore is crucial to the MBRT to being a beneficial modality
if implemented clinically.
10.3.3 Local RBE10 across lateral profile in MBRT field
The yD values calculated from experimental measurements with the SSMD showed little
variation with lateral displacement in the MBRT field due to the collimator misalignment
causing the minibeams to be misformed (see figures 10.7 and 10.8).
Figure 10.9 shows the simulated microdosimetric spectra at various lateral displacements
from the centre of the MBRT field (centre minibeam) with perfect collimator alignment.




















Figure 10.6: Comparison of microdosimetric spectra measured at 20 mm depth in water
using the Bridge microdosimeter in a 12C ion with and without the MSC and for varying
simulated collimator angles relative to the incident beam direction.
 Lateral offset (mm)


















Figure 10.7: Simulated lateral dose profile of MBRT field at a depth of 20 mm in water
for 0◦ and 0.7◦ MSC alignment relative to the beam axis.
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Figure 10.8: Simulated relative physical dose scored in a water phantom for perfect
MSC alignment (left) and for a 0.7◦ mis- alignment (right) relative to the central beam
axis.
m)µy (keV/























Figure 10.9: Simulated microdosimetric spectra in SSMD-sized water volumes in 10 µm
orientation for different lateral positions in the MBRT field at a depth of 20 mm in water.
CHAPTER 10. INVESTIGATING VARIABLE RBE IN A 12C MINIBEAM FIELD160
Lateral Offset (mm)
















m orien.µ 10 10RBE
m orien.µ 250 10RBE
m orien.µ 10 
D
y
































Figure 10.10: RBE10 and y calculated for events scored in simulated water volumes as a
function of lateral displacement in MBRT field at a depth of 20 mm in water for 10 and
250 µm orientations. Physical dose at this depth is depicted by the solid black line and
the RBE10 weighted dose calculated from the 10 µm orientation RBE10 values is shown
in the broken black line.
Events were scored in the water volumes orientated with their 10 µm side parallel to the
lateral axis. Measurements at positions 0, 1, 2 mm etc correspond to the centre of the
minibeam and those at 0.5, 1.5, 2.5 mm etc. correspond to the valley region. The spectra
measured at the centre of the minibeams have a lower lineal energy peak than for the
valley positions as the valley dose is primarily from 12C ions that have traversed some of
the brass material and therefore have lower kinetic energy and higher LETs. Figure 10.10
depicts the calculated yD from the simulated water volumes in both the 10 µm and 250 µm
orientations and the corresponding RBE10 values calculated. This figure clearly depicts
an elevated dose-mean lineal energy and RBE10 in the valley regions between minibeams
resulting in a reduction of the peak-to-dose valley ratio in the biologically effective dose
compared to that of the physical dose. Despite this, the biologically effective dose de-
posited in these valley regions is still less than that for a broad-beam case in the entrance
channel of the beam. The RBE10 values calculated in the peak positions agree with those
for the broad beam case at the same depth, while the biological effectiveness in the valley
was found to slightly higher than the ‘average’ RBE10 values simulated with the Bridge
microdosimeter.
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10.4 Conclusions
A 12C ion MBRT field was produced at the HIMAC biological beamline using a broad
beam and a multi-slit collimator. The introduction of the MSC greatly affected the radia-
tion quality of the field and the calculated RBE10 values with ~30% increase in the plateau
region measured in experiments and ~10% increase in the simulation with the ideal setup
both measured using the Bridge microdosimeter. The simulation component was used to
determine that the experimental collimator misalignment was 0.7◦ from the incident beam
direction resulting in the higher RBE10 values observed. The simulated microdosimetric
spectra with SSMD-sized sensitive volumes showed elevated yD and thus RBE10 values
observed in the valley regions between the minibeams. Despite this, the low physical dose
in the valley region still allows for a lower biological dose delivered in the valley regions
compared with broad beam 12C ion therapy. The benefits of MBRT, however, are shown
to be heavily reliant on the alignment of the MSC and it is crucial that the biological dose
is considered for these complex fields.
Experimental validation of the simulation findings will be possible with the SOI micro-
dosimeters and precise MSC collimator alignment with a goniometer and moving stage
setup to ensure accurate alignment. The small sensitive volumes of these detectors make
them very well suited for micrometre resolution measurements in highly variable fields
with sharp dose gradients such as those in MBRT.
Chapter 11
Conclusion
This thesis presents the use of silicon diode detectors for applications in particle therapy.
The silicon detectors, subject of this thesis, were developed at the Centre for Medical
Radiation Physics at the University of Wollongong. Silicon, in comparison to gas de-
tectors, has a high sensitivity, due to both a greater density and less energy required for
the production of electron hole pairs. In light of this, silicon sensitive volumes are able
to be fabricated with sub-millimetre size and at high density for high spatial resolution
dosimetry. This is particularly advantageous for small fields and in high dose gradients;
both of which are featured in clinical particle therapy fields. Novel silicon array detectors
were characterised for beam profiling and QA purposes. In addition to greater demand for
precision of physical dose characteristics, particle beams used for therapy create highly
complex and mixed fields which result in variable biological effectiveness per unit of
absorbed dose. In this work silicon microdosimeters were investigated and used to char-
acterise radiation quality in particle therapy fields both within and outside the primary
field and for novel particle therapy techniques. The Monte Carlo toolkit Geant4 has been
used extensively throughout this work in order to characterise detector response and to
optimise measurement setups.
A summary of the core results of this thesis are stated below under each of the aims:
Aim 1: Assess the feasibility of using high resolution 1D silicon detector arrays for
carbon ion energy reconstruction for quality assurance.
Chapter 3 presents results from an experimental and simulation study of the serial Dose
Magnifying Glass (sDMG) in a passively scattered carbon ion therapy field. The relative
response profiles along the single axis measured with the sDMG detector were found to
have good agreement between experiment and simulation with the position of the Bragg
peak determined to fall within 0.2 mm or 1.1% of the range in the detector for the two
cases. The energy of the beam incident on the detector was found to vary less than 1%
between experiment and simulation. The beam energy incident on the phantom was deter-
mined to be (280.9 ± 0.8) MeV/u from the experimental and (280.9 ± 0.2) MeV/u from
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the simulated profiles. These values coincide with the expected energy of 281 MeV/u.
The sDMG detector was found to accurately determine the 12C beam energy and is suited
for fast energy and range verification quality assurance. It is proposed that the sDMG is
also applicable for verification of treatment planning systems that rely on particle range.
Aim 2: Use a Monte Carlo model to evaluate the relationship between the Bragg
peak physical depth-dose curve and common proton range definitions in different
media.
Phase-space files for the Mayo Clinic proton centre pencil beams were validated against
experimental beam profiles and ranges measured with a MLIC detector using a Geant4
simulation application in chapter 4. The mean range (defined as the 50% fluence falloff
position), Bragg peak maximum and distal dose falloff positions were obtained from the
Geant4 simulation and compared with CSDA ranges from NIST and SRIM projected
ranges. Both the phase-space source and a monoenergetic proton beam with the same
mean energy were assessed. The mean range was found to be most closely correlated
with the 90% dose falloff position for all three materials considered for energies up to
~160 MeV. For energies greater than this the mean range tended closer to the Bragg peak
maximum depth. As anticipated the CSDA range consistently overestimates the proton
range. The SRIM projected range however was found to show strong correlation with
the 90% dose falloff position in silicon and to the maximum peak position for water and
perspex.
Aim 3: Assess the accuracy and reproducibility of a revised 1D silicon diode ar-
ray detector for proton range measurements.
The DMG-256 detector (referred to as DMG) was investigated for range verification of
proton pencil beam scanning systems. In chapter 5 the DMG was investigated in an edge-
on configuration for determination of range in silicon using a single spot delivery. The
proton range was found to be accurately and reproducibly determined for energies up to
~105 MeV within ±0.2 mm between simulation and experimental implementation. A
Monte Carlo application was used to analyse the sensitivity of range measurements to
detector misalignment. The measured range was found to be robust to reasonable angular
and translational setup errors. The use of this setup to measure range for higher proton
energies with brass range shifting blocks was analysed and was found to have insufficient
accuracy.
The DMG was evaluated for range in perspex measurements in chapter 6. A Geant4
application was developed and used to optimise an angled phantom design for the DMG
detector. The optimum detector angle was found to be 60◦ to the normal of the beam
direction. This allowed for maximum range sampling without compromise on the range
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measurement accuracy due to protons traversing multiple silicon sensitive volumes. Flat
monoenergetic fields were delivered to the DMG angled phantom setup and were able to
measure Bragg peaks over the entire range of clinically available energies. The proton
range was accurately determined with this setup with an accuracy of ±0.5 mm.
Chapter 7 presented a further adaptation to the DMG angled phantom setup using the
2D Duo detector as a transmission spot size and position monitor. The effect of the Duo
detector on the range measurement system was assessed and proton ranges were again
able to be determined within a ±0.5 mm of those measured without the Duo and com-
pared with simulated ranges in perspex. A single central axis spot delivery was assessed
for this combined system however was more sensitive to detector depth and was found to
have decreased range measurement accuracy.
Aim 4: Explore the applications of silicon microdosimetry in particle therapy for
radiation protection purposes, calculation of relative biological effectiveness and in
novel particle therapy applications.
The silicon-on-insulator Bridge microdosimeter is implemented for microdosimetric mea-
surements for out-of-field radiation quality measurements and for in-field RBE estima-
tion in a therapeutic passively scattered proton beam in chapters 8 and 9 respectively. A
Geant4 Monte Carlo application was developed to model the experimental beamline. The
simulated physical dose distribution was validated against ionisation chamber measure-
ments for 2 reference fields with varying penetration depth, SOBP width and field size.
The simulation including the model of the Bridge microdosimeter was compared with
experimental measurements using the microdosimeter and to investigate the properties of
the radiation field produced.
The treatment field delivered for the study in chapter 8 was representative of a head
and neck treatment field for a paediatric patient. This investigation sort to analyse the
out-of-field radiation quality which is particularly important for development of radiation
induced toxicities within the surrounding healthy tissue in the brain. The dose-mean lineal
energy and radiation quality were found to increase with distance from the field boundary
with maximum experimental values of (23.7 ± 2.3) keV/µm and (5.2 ± 0.4), respectively
for a face-on detector orientation. The quality factor and dose equivalent were calculated
from the ICRP 60 definition using the measured lineal energy spectra with the Bridge
microdosimeter. The highest equivalent dose of the measurement points considered was
(25.4 ± 1.5) mSv/Gy and was downstream of the treatment field. Radiation quality was
found to be greater distal to the target volume than for the same lateral distance from the
field edge. Relatively good agreement was found between simulation and experimental
measurements for secondary radiation, out-of-field measurements.
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The Bridge microdosimeter was used to measure the lineal energy spectra in a clinical
proton treatment field and to predict RBE as a function of depth in chapter 9. A high res-
olution of points were able to be measured in the distal falloff of the treatment field where
the LET and hence RBE show a pronounced peak. The RBE for the CHO-K1 cell line was
determined in-vitro using clonogenic survival assay at the same measurement positions in
the treatment field. The resultant cell survival curves were used to generate input param-
eters for the MKM calculation. RBE10 values were found to fall within 1.07 and 1.58.
Close agreement between RBE values derived from in-vitro experiments and those for
the SOI-microdosimetry-MKM method showed good agreement. This study highlights
the necessity of RBE consideration in the treatment planning process rather than the in-
variant value of 1.1 that is currently adopted in clinics. Further the results demonstrate a
fast, high resolution method to predict RBE using experimental microdosimetry.
In chapter 10 the Bridge microdosimeter and a single sensitive volume microdosimeter
were used to characterise a 12C minibeam radiation field produced using a broad beam
and multi-slit collimator. Due to their small volumes these microdosimeters could be used
for measurement in the steep dose gradient field and were used to compare the charac-
teristics of a broad beam field to a minibeam one. A Geant4 application replicating the
experimental setup was used to compliment and explain experimental measurements and
MSC alignment setup sensitivity. The RBE10 calculated from experimental microdosi-
metric data showed a ~30% increase in the entrance region with the introduction of the
MSC compared to the broad beam case primarily due to elevated mean lineal energy in the
valley regions. The simulation revealed an experimental collimator misalignment of ap-
proximately 0.7◦ and showed an increase in average entrance RBE10 of ~10% compared
to a broad beam when there is perfect MSC alignment. This study highlights the impor-
tance for precision for particle minibeams field setups and demonstrates the applicability
small volume silicon microdosimeters for characterisation of small fields and potential
novel particle therapy modalities.
11.0.1 Future work
In this thesis two generations of the 1D silicon array detector “Dose Magnifying Glass”
were used for range verification systems in particle therapy. It is proposed that this de-
tector could be upscaled for measurements over a longer axis. It is possible to produce a
larger monolithic silicon wafer. Potentially a DMG with length up to ~30 cm used in the
same configuration as the prototype assessed in chapter 6 could measure particle range
over a large span of energies. With a longer detector axis, a single QA plan could be used
with high energy protons delivered to the distal detector volumes and lower energies to
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the proximal volumes without the need for range shifting perspex blocks placed upstream.
While CMRP array detectors have been thoroughly characterised for photon therapy and
have been applied for particle therapy applications here, further work into analysing the
energy and LET dependence of these detectors is required for use in particle therapy fields.
This will also allow a larger DMG detector, like that proposed above to be translated for
range verification for heavier ions such as carbon and oxygen beams with a much larger
LET.
The Duo detector was briefly introduced for spot size and position measurements in chap-
ter 7, primarily as a proof of principle for the combined detector setup. Further character-
isation of this detector should be performed to benchmark the detector response and mea-
sured profiles against film spot position/profile measurements for example. For the setup
described in chapter 7, the Duo was placed immediately upstream of the DMG angled
phantom; the Duo response when placed at the front of the entire phantom setup (where
proton energies are much more variable) and the equivalent thickness of the detector at
this point should be assessed. The Duo dose-per-pulse dependence and dose-linearity
has been previously investigated for photon therapy; an investigation of the Duo dose-
response characteristics for particle irradiation could be performed to allow output factor
measurements to additionally be performed with the Duo in the combined detector setup.
It is conceptualised that a novel, compact, high resolution, real time, all-in-one QA detec-
tor system for particle therapy applications could follow based off the systems presented
here.
Further development and optimisation of SOI microdosimeter designs are ongoing at
CMRP and these are continually being characterised for use various ion beam types and
for space applications.
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